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Licorice {Radix Glycyrrhizae) is one of the most widely used medicinal herbs 
since ancient time. Glycyrrhizin, a pentacyclic triterpenoid, is the major active 
constituent of licorice. Glycyrrhizin has been shown to be metabolized to its 
aglycone form, 1 Sp-glycyrrhetinic acid, after oral administration. Although the 
importance of glycyrrhizin and 1 Sp-glycyrrhetinic acid is becoming more prominent 
when their hepatoprotective, anti-inflammatory, anti-viral, immunomodulatory and 
cancer chemopreventive effects are unraveled, yet their direct anti-tumor activity and 
therapeutic potentials have not been fully explored. 
In the present study, the growth-inhibitory and differentiation-inducing effects of 
glycyrrhizin and 1 Sp-glycyrrhetinic acid on neuroblastoma cells were examined in 
vitro. Our results showed that both glycyrrhizin and 1 Sp-glycyrrhetinic acid 
exhibited anti-proliferative activity on murine (Neuro-2a, BU-1 clone) and human 
(SK-N-DZ and SH-SY5Y) neuroblastoma cell lines in a dose-dependent manner. 
Kinetic studies indicated that glycyrrhizin and 1 Sp-glycyrrhetinic acid also inhibited 
the proliferation of BU-1 cells time-dependently, with optimal inhibitory effect seen 
at 24 — 48 hours. Moreover, 1 Sp-glycyrrhetinic acid was found to be more potent 
than glycyrrhizin as the former exerted its anti-proliferative activity at micromolar 
concentrations whereas the latter was effective at millimolar ranges. In addition, the 
reversibility of the anti-proliferative effect of glycyrrhizin and 1 Sp-glycyrrhetinic acid 
was dependent on the drug concentration and duration of drug exposure. 
Interestingly, the growth-inhibitory effect of glycyrrhizin and ISP-glycyrrhetinic acid 
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on BU-1 cells could not be attributed directly to their cytotoxic and 
apoptosis-inducing effects as the percentage of viability was found to be over 90% 
and no DNA fragmentation could be detected after drug treatment. 
On the other hand, glycyrrhizin and ISp-glycyrrhetinic acid were found to be 
capable of inducing neuronal differentiation of the murine neuroblastoma BU-1 cells. 
Morphological and biochemical changes characterized by neurite outgrowth, increase 
in cell size and increased expression of the neuronal differentiation markers MAP2 
and neurofilament-200 were observed in drug-treated cells. Moreover, the 
differentiation induced by 18 (3-glycyrrhetinic acid in BU-1 cells was accompanied 
with a down-regulation of N-myc gene expression and an up-regulation in the 
expression of Bcl-2, NF-KB/p50 and c-fos genes. 
As shown by the cell cycle analysis, the anti-proliferative activity of glycyrrhizin 
and ISp-glycyrrhetinic acid is probably mediated through the G2/M phase arrest. 
The cell cycle arrest of the BU-1 cells induced by ISP-glycyrrhetinic acid may be 
brought about by the down-regulation of cell cycle regulatory proteins including 
cyclin A, cyclin B and cdc2. On the other hand, it was found that combinations of 
glycyrrhizin and 1 Sp-glycyrrhetinic acid or dXl-trans retinoic acid and 
ISp-glycyrrhetinic acid had resulted in synergism on the growth inhibition and 
differentiation of BU-1 cells. Although ISp-glycyrrhetinic acid failed to alter the 
mRNA expression of protein kinase C (PKC) isoforms, addition of PKC inhibitors 
effectively antagonized the ISP-glycyrrhetinic acid-induced differentiation of BU-1 
cells. These results suggest that the differentiation-inducing effect of 
ISp-glycyrrhetinic acid may be PKC-dependent. On the contrary, the 
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differentiation-inducing effect of ISP-glycyrrhetinic acid appears to be independent of 
protein kinase A (PKA) as the 18|3-glycyrrhetinic acid-induced differentiation of 
BU-1 cells could not be modulated by PKA inhibitors although the differentiation of 
BU-1 cells could be augmented by cAMP elevating agent or cAMP analogs. 
It is hoped that the above findings could provide better insights into the direct 
anti-tumor effects of glycyrrhizin and 1 Sp-glycyrrhetinic acid on neuroblastoma cells 
in vitro. Nevertheless, more thorough understanding of the molecular mechanisms 
and the signaling pathways by which glycyrrhizin and 18P-glycyrrhetinic acid could 
exert their actions on neuroblastoma cells are required before these natural products 
can be considered as therapeutic agents in neuroblastoma treatment. 


























加神經元分化標記如：微管蹄合蛋白1 (MAP2)及神經微絲-200 (neurofilament-200) 
的產生。再者，隨著18P-甘草次酸誘導的細胞分化而來的轉變是N-myc基因之 
表達被下調及Bcl -2�NF-KB/p50和c - fos之基因表達被上調。 
根據細胞週期分析結果，甘草甜素及18P-甘草次酸之抑制癌細胞增殖的機 
制可能是通過促使癌細胞週期停留在G2/M期來實現的�18P-甘草次酸誘發的細 
胞週期阻礙亦可能是透過細胞週期控制蛋白包括細胞週期蛋白(cyclin A, cyclin B) 
及細胞週期蛋白依賴性激梅(cdc2)表達的下調來實現。另一方面，我們發現甘草 
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Chapter 1 General Introduction 
1.1 Neuroblastoma — An Overview 
1.1.1 Epidemiology of Neuroblastoma 
Neuroblastoma is the most common extracranial childhood solid tumor that 
accounts for 8 to 10% of all childhood cancers (Gumey et al., 1997; Brodeur & Maris, 
2002). It accounts for about 50% cancer cases in children younger than two years 
old, 75% under age 4, 90% under age 10 and the mean age at diagnosis for 
neuroblastoma patients is about 22 months (Lanzkowsky, 2000; Cullen, 2003). 
Infants who are diagnosed under the age of one tend to have localized, 
good-prognosis tumor while children who are diagnosed over the age of one have 
poor outcome and usually have metastatic disease (Caron & Pearson, 1998). 
Approximately 50% of the infant patients and 70% of the older patients have 
disseminated disease at diagnosis (Reynolds & Seeger, 2001). 
Neuroblastoma usually occurs sporadically although 1 - 2% was reported to be 
familial cases (Brodeur & Maris, 2002). The etiology of neuroblastoma is unknown. 
Embryologically, neuroblastoma arises from primordial neural crest cells that 
normally give rise to sympathetic ganglia and adrenal medulla (Lanzkowsky, 2000). 
The primary tumor can arise at any point where there is tissue of the sympathetic 
nervous system and the majority of primary tumors arise in the adrenal glands. In 
general, the tumors exhibit three distinct clinical behaviors: (1) spontaneous 
regression, (2) differentiation into a benign form, and (3) life-threatening progression. 
The incidence of spontaneous regression in neuroblastoma is between 10- and 
100-fold greater than that for other human cancers (Westermann & Schwab, 2002). 
Moreover, a spectrum of maturation, differentiation, and clinical behavior are 
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reflected by three distinct histopathologic patterns: neuroblastoma, 
ganglioneuroblastoma and ganglioneuroma (Cullen, 2003). Most neuroblastomas 
are undifferentiated tumors consisting of small, round cells called neuroblasts. Some 
tumors that show partial histological differentiation are called ganglioneuroblastoma. 
Tumors with the most differentiated phenotype are called ganglioneuroma which 
consists of clusters of mature neurons surrounded by a dense stroma of Schwann cells 
(Brodeur, 2003). 
1.1.2 Clinical Presentations of Neuroblastoma 
Since neuroblastoma can arise from any site along the sympathetic system chain, 
the locations of primary tumors at the time of diagnosis are varied. About 25% of 
the primary tumors are found in the neck or the thorax, 70% in the abdomen and 5% 
in the pelvis (Caron & Pearson, 1998). Moreover, the frequency of adrenal tumors is 
slightly higher in children compared to infants and the latter have more thoracic and 
cervical primary tumors (Brodeur & Maris, 2002). The clinical manifestations of 
neuroblastoma are very diverse, depending on the site of the primary tumor and 
whether there is metastatic disease. Upper thoracic tumors can give rise to 
respiratory distress and infections, dysphagia and circulatory problems while lower 
thoracic tumors seldom produce symptoms (Voute et al., 1992). Among the children 
with abdominal tumors, the predominant clinical manifestation is an abdominal mass, 
but anorexia, vomiting, abdominal pain, distension and weight loss are also common 
symptoms (Lanzkowsky, 2000; Haase & LaQuaglia, 2003). Pelvic tumors may be 
associated with chronic constipation or urinary tract obstruction with or without 
infection. In children with paraspinal neuroblastoma, the tumor can grow through 
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the intervertebral foramina and cause extradural spinal cord compression (Haase & 
LaQuaglia, 2003). Compression of the spinal cord leads to localized back pain and 
tenderness, immobility, weakness of lower extremities, scoliosis, bladder and anal 
sphincter dysfunction etc. (Voute et al., 1992; Lanzkowsky, 2000). In infants, 
compression may cause a change in the frequency of voiding and urinary tract 
infections. Moreover, the most common motor manifestation in older children is 
disturbance of gait, starting with a limp and sometimes progressing to paraplegia 
(Voute et al., 1992). Massive involvement of the liver in metastatic disease is 
particularly frequent in infants (stage 4S) (Brodeur & Maris, 2002). Rapidly 
enlarging abdominal tumors or massive hepatomegaly in infants may cause 
respiratory distress due to the compression of the diaphragm (Cullen, 2003). Bone, 
lymph nodes, and bone marrow are the commonest metastatic sites. Metastases to 
the bone manifest as painful lesions which produce an irritable and unwell child. 
Bone marrow involvement generally presents with anemia and later 
thrombocytopenia (Caron & Pearson, 1998). Orbital metastases may cause proptosis 
or orbital ecchymoses, causing these patients to appear as if they have "raccoon eyes" 
(Haase & LaQuaglia, 2003). 
1.1.3 Diagnosis of Neuroblastoma 
An unequivocal pathologic diagnosis of neuroblastoma requires histologic 
diagnosis by light microscopic examination of tumor tissue along with appropriate 
immunohistology. A bone marrow biopsy is done to evaluate metastatic 
involvement. The diagnosis may be established by a bone marrow aspiration biopsy 
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containing definite tumor cells in association with elevation of the serum or urine 
catecholamine levels (Brodeur & Maris, 2002; Haase & LaQuaglia, 2003). Urinary 
levels of vanillylmandelic acid (VMA) and homovanillic acid (HVA) are the most 
useful catecholamine metabolites to support the diagnosis. Catecholamine 
metabolites are abnormally elevated in the urine of nearly all patients (90 - 95%) with 
neuroblastoma (Brodeur & Maris, 2002). Analysis of urine for catecholamine 
metabolites (VMA and HVA) not only aids in the diagnosis but also in monitoring 
tumor response (Reynolds & Seeger, 2001). 
Complete assessment of the primary tumor and extent of disease requires 
specific imaging studies. The conventional diagnostic imaging modalities include 
plain radiographs, bone scintigraphy, ultrasound, computer tomography (CT) 
scanning and magnetic resonance imaging (MRI). Plain radiography may show fine 
calcifications with a cervical, thoracic, or abdominal mass and may detect lytic lesions 
with cortical bone (Haase & LaQuaglia, 2003). Bone scintigraphy can be useful to 
detect cortical bone metastases (Brodeur & Maris, 2002). Ultrasound and CT 
provide more information about abdominal disease, including location of the tumor, 
lymph node enlargement and live metastases, while thoracic CT or MRI are useful in 
evaluating the extent of disease above the diaphragm. Moreover, CT or MRI of the 
head can further define metastases to the skull, orbits, mandible or brain (Brodeur & 
Maris, 2002). "il-Metaiodobenzylguanidine (MIBG) scanning is a specific and 
sensitive method of scintigraphic imaging for primary, metastatic or recurrent tumor 
and is better for assessing bone and soft tissue involvement since MIBG is taken up 
by catecholaminergic cells including most neuroblastomas (Brodeur & Maris, 2002; 
Cullen, 2003; Haase & LaQuaglia, 2003). However, about 15 — 20% of 
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neuroblastomas do not take up the tracer at all. At present, CT and MRI, that have 
excellent resolution and allow for three-dimensional reconstruction of tumors to 
assess volumes, are the most common imaging techniques used to detect and delineate 
neuroblastoma (Haase & LaQuaglia, 2003). 
1.1.4 Staging of Neuroblastoma 
Staging of the disease plays an important role in the evaluation of treatment 
results. This provides information relevant to prognosis and is useful in the selection 
of treatment. Four major staging systems have been developed for neuroblastoma. 
Before 1988, neuroblastoma was staged according to three different systems: (1) 
Evans classification, adopted by the Children's Cancer Group (CCG), (2) staging 
system developed at St. Jude Children's Research Hospital and used by the Pediatric 
Oncology Group (POG), and (3) the tumor-node-metastases (TNM) staging system 
formulated by the Union International Contra le Cancer (UICC). The oldest Evans 
system employs the initial distribution of disease without reference to respectability of 
the primary tumor. The POG system is based on a combination of tumor spread and 
degree of tumor resection. The TNM staging system consists of both clinical and 
surgicopathologic components (Caron & Pearson, 1998; Reynolds & Seeger, 2001; 
Haase & LaQuaglia, 2003). However, the existence of these systems raises the 
problems in comparing the results of therapy among various regions. This problem 
was solved by the emergence of International Neuroblastoma Staging System (INSS) 
that is being adopted worldwide. This system presents a standardized scheme for 
incorporating issues related to initial disease distribution, tumor resectability and 
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lymph node status (Reynolds & Seeger, 2001). 
1.1.5 Prognostic Considerations of Neuroblastoma 
Besides the stage of the disease, other clinical variables such as age of the patient 
at diagnosis, site of primary tumor, and biological variables such as tumor 
histopathology, serum markers and genetic markers have important implications on 
prognosis of the disease. 
1.1.5.1 Age 
Although the age of the patient does not seem to affect the prognosis of 
low-stage patients, the age of the patient at diagnosis is an important prognostic 
variable in the higher stages. A recent CCG study showed that the 4-year event-free 
survival (EFS) probability for patients with stage 3 neuroblastoma ranged from 98% 
for infants to 75% for patients older than two years at diagnosis (Brodeur & Maris, 
2002). The outcome of infants who are younger than one year of age is substantially 
better than older patients with the same stage of disease, particularly those with more 
advanced stages of disease (Brodeur, 2003). 
1.1.5.2 Primary Tumor Site 
Site of primary tumor has also been proposed to be prognostically important. 
Thoracic neuroblastoma has a more favorable outcome than does abdominal disease 
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and the adrenal tumor was reported to be associated with a more aggressive clinical 
course than tumors originating at other sites. Moreover, patients with pelvic tumors 
may have a better prognosis than that of children with nonpelvic lesions of similar age 
and initial stage of disease (Brodeur & Maris, 2002; Haase & LaQuaglia, 2003). 
1.1.5.3 Tumor Histopathology 
Tumor histology plays a role in the prognosis of the disease. A variety of 
histopathologic classification schemes have been used as prognostic indicators. 
Most of these classification schemes focus on the degree of differentiation of tumor. 
The more detailed analysis of histology devised by Shimada takes into consideration 
the amount of Schwann cells in the stroma, mitotic figures and degeneration of nuclei 
(Brodeur, 2003). The Shimada classification divides tumors into stroma-rich and 
stroma-poor groups, with the stroma-rich group considered favorable (>90% survival) 
unless nodular elements of mature cells are present (18% survival). Stroma-poor 
tumors are generally classified as unfavorable (<5% survival); however, if the patient 
is younger than 18 months and has a low mitotic-karyorrhexis index (MKI) or is 18 — 
60 months, has a low mitotic-karyorrhexis index, and at least 5% of cells show 
evidence of differentiation, good survival (84%) is predicted (Reynolds & Seeger, 
2001). The International Neuroblastoma Pathology Classification (INPC) that based 
on the Schimada classification has become the international standard for 
histopathological classification, particularly as a prognostic variable (Table 1.1) 
(Shimada etal., 1999). 
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Table 1.1: International Neuroblastoma Pathology Classification 
International Neuroblastoma Pathology ^Mmada Prognostic 
Classification , … g r o u p  classification ^ ^  
Neuroblastoma (Schwannian stroma-poor) Stroma-poor 
Favorable Favorable Favorable 
<1.5 yrs Poorly differentiated or 
differentiating & low or 
intermediate MKI tumor 
1.5-5 yrs Differentiating & low MKI 
tumor 
Unfavorable Unfavorable Unfavorable 
<1.5 yrs (a) undifferentiated tumor 
(b) high MKI tumor 
1.5-5 yrs (a) undifferentiated or 
poorly differentiated 
tumor 
(b) intermediate or high 
MKI tumor 
>5 yrs All tumors 
Ganglioneuroblastoma, (Schwannian stroma-rich) Stroma-rich Favorable* 
intermixed intermixed 
(favorable) 
Ganglioneuroblastoma, (composite Schwannian Stroma-rich Unfavorable* 
nodular stroma-rich/stroma-dominate nodular 
and stroma-poor) (unfavorable) 
Ganglioneuroma (Schwannian 
stroma-dominant) 




MKI: mitosis-karyorrhexis index. 
* Prognostic grouping for these tumor categories is not related to patient's age. 
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1.1.5.4 Serum Markers 
Serum markers that had been used in the past to predict outcome or follow 
disease activity include neuron-specific enolase (NSE), ferritin, lactate dehydrogenase 
(LDH) and disialoganglioside Gd2- NSE is a cytoplasmic protein that is associated 
with neural cells and survival is substantially worse for patients with advanced disease 
and high NSE levels (>100 ng/ml). Ferritin produced by neuroblastoma cells can 
lead to elevations of serum ferritin to above-normal levels. Patients with increased 
ferritin levels have a much worse prognosis. Elevated ferritin levels (>140 ng/ml) 
are associated with poorer outcome in stage 4 patients (8% survival) than are normal 
levels (21% survival). Despite not specific to neuroblastoma, serum LDH levels 
have been used as a prognostic marker for neuroblastoma, and they might reflect rapid 
cellular turnover or large tumor burden. The disialoganglioside Gd2 is found on the 
surface of most neuroblastomas. Increased levels have been found in the plasma of 
neuroblastoma patients and gangliosides that are shed by tumor cells might be 
important in accelerating tumor progression (Voute et al., 1992; Reynolds & Seeger, 
2001; Brodeur & Maris, 2002; Brodeur, 2003; Cullen, 2003). 
1.1.5.5 Genetic Markers 
Various genetic changes in neuroblastoma cells have been proposed as useful 
prognostic markers. These include changes in the DNA content or modal karyotype, 
gain or loss of genetic materials and changes in the gene expression. In children 
younger than two years old, tumors with an increased DNA content (DNA index > 1) 
exhibit a favorable response to chemotherapy. In contrast, children with diploid 
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tumors (DNA index = 1) have advanced-stage disease, and respond poorly to 
chemotherapy (Look et al., 1991). Genomic amplification of N-myc is generally 
associated with the aggressiveness of neuroblastomas (Look et al., 1991; Katzenstein 
et al., 1998). Amplification of N-myc was reported to be associated with the worst 
prognosis and the estimated progression-free survival at 18 months was 70%, 30%, 
and 5% for patients whose tumors had 1, 3 to 10, or more than 10 N-myc copies, 
respectively (Seeger et al, 1985). Moreover, recent study showed that infants with 
stage IV neuroblastoma whose tumors were without N-myc amplification had a 93% 
3-year event-free survival (EFS), whereas those with amplified N-myc had a 
markedly reduced 3-year EFS (10%) (Schmidt et al., 2000). Deletion of 
chromosome 1 is commonly found in patients with advanced stages of disease and Ip 
allelic loss is highly associated with N-myc amplification (Brodeur, 2003). 
Moreover, recent study indicates that allelic loss at lp36 is an independent predictor 
of decreased event-free survival but not overall survival in neuroblastoma patients 
(Maris et al, 2000). Gain of chromosome segment 17q is an important prognostic 
factor in children with neuroblastoma. This gain is common in advanced tumors, in 
tumors from children aged over one year and is strongly associated with deletion of 
Ip and amplification of N-myc. Among the patients with this abnormality, 5-year 
overall survival was 30.6%, as compared with 86% among those with normal 17q 
status (Bown et al., 1999). On the other hand, a high incidence of l lq deletion was 
observed in stage 4 neuroblastoma without N-myc amplification (59%) whereas l lq 
loss was only observed in 15% of neuroblastomas with N-myc amplification (Plantaz 
et al., 2001). Furthermore, l lq loss of heterozygosity (LOH) was not only 
inversely correlated with N-myc amplification but also positively associated with 
advanced stage disease, unfavorable histopathology, and decreased overall survival 
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probability in patients lacking N-myc amplification (Guo et al., 1999; Maris et al., 
2001). Therefore, loss of l l q might be a useful outcome predictor in clinically 
high-risk patients without N-myc amplification. Altered expressions of genes have 
also been associated with clinical behavior in neuroblastoma. Expression of the 
high-affinity nerve growth factor receptor (TrkA) gene is inversely correlated with 
N-myc amplification and high levels of its expression are strongly associated with 
low-stage tumors and a favorable outcome (Nakagawara et al., 1992; Suzuki et al,, 
1993; Nakagawara et al., 1993; Borrello et al., 1993; Tanaka et al., 1995; Tanaka et 
al, 1998). 
1.1.6 Standard Treatment Modalities for Neuroblastoma 
The conventional treatment modalities in the management of neuroblastoma 
include surgery, chemotherapy and radiotherapy. However, the use of each is 
determined by the anticipated clinical behavior of the tumor in individual cases 
regarding the age of patients at diagnosis, tumor location, stage of disease and 
biologic features of the tumors. 
1.1.6.1 Surgery 
Surgical removal of the tumor is the most effective treatment for neuroblastoma. 
The majority of localized tumors can be managed with surgery alone as primary 
therapy, even if complete gross resection is not feasible. A recent study conducted 
by the Children's Cancer Group showed that surgery alone is sufficient initial therapy 
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for almost all patients with Evans stage I and stage II disease, with overall survival 
(OS) of 99% for stage I and 98% for stage II patients, respectively (Perez et al., 2000). 
However, multimodal therapy (such as chemotherapy and radiation) should be 
reserved for those who develop progressive disease. Due to the difficulty in 
removing some stage 3 and many stage 4 tumors, it has become a common practice to 
delay attempts at definitive surgical removal of the primary tumor until after several 
courses of chemotherapy (Reynolds & Seeger, 2001). Complications generally are 
lower for delayed or second-look procedures, after tumor shrinkage by chemotherapy 
(Brodeur & Maris, 2002). It has been suggested that delayed surgery on the primary 
tumor should be done between the second to fourth cycle of a dose-intense regimen 
since neuroblastoma tumor volumes were shown to regress according to first-order 
kinetics and reach a plateau after the second to fourth cycle of chemotherapy in most 
patients (Haase & LaQuaglia, 2003). Moreover, surgery also plays a pivotal role for 
diagnosis. The goals of primary surgical procedures, performed before any therapy, 
are to provide tissue for biologic studies and to stage the tumor surgically (Brodeur & 
Maris, 2002). 
1.1.6.2 Chemotherapy 
Chemotherapy is the predominant modality for patients with intermediate- or 
high-risk disease. A number of drugs have been shown to be active against 
neuroblastoma as single agents and in various combinations. These include 
cyclophosphamide, ifosfamide, cisplatin, carboplatin, iproplatin, doxorubicin, 
teniposide, etoposide, L-phenylalanine mustard, vincristine, dacarbazine, and 
topotecan (Reynolds & Seeger, 2001). The commonly used agents are 
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cyclophosphamide, ifosfamide, vincristine, doxorubicin, teniposide, etoposide, 
cisplatin and carboplatin. Induction therapy attempts to deplete tumor cells rapidly, 
arrest tumor growth and prevent or impede tumor spread. A consolidation phase is 
given to eradicate residual tumor (Cullen, 2003). Multiagent regimens can be used 
for stage 3 patients who may not undergo consolidation but require aggressive 
cytoreductive chemotherapy before undergoing delayed surgery. Aggressive 
multiagent chemotherapy is used for high-risk patients but the chances of long-term 
survival for such patients treated with chemotherapy are not high. However, the 
probability of long-term survival can be improved for many high-risk patients by 
using consolidation with myeloablative chemoradiotherapy and autologous 
hematopoietic stem cell transplantation (Reynolds & Seeger, 2001). 
1.1.6.3 Radiotherapy 
Neuroblastoma is considered to be a radiosensitive tumor. Although 
radiotherapy is used infrequently, it may help to control the regional tumors of stage 3 
patients over one year of age (Cullen, 2003). In advanced neuroblastoma, local 
relapse may be decreased by radiotherapy given to the primary site in combination 
with chemotherapy (Haase & LaQuaglia, 2003). Radiotherapy may also be used for 
stage 4 patients as an adjunct to myeloablative therapy prior to bone marrow 
transplantation (Cullen, 2003). When treatment with chemotherapy is ineffective, 
low-dose hepatic irradiation could be helpful in infants with stage 4S disease who 
develop respiratory distress secondary to hepatomegaly. Moreover, palliative 
radiotherapy may be useful to diminish bone pain in children with bone metastases 
(Brodeur & Maris, 2002; Haase & LaQuaglia, 2003). 
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1.1.7 Differentiation of Neuroblastoma In Vivo and In Vitro 
The neural crest is an embryonic structure that is formed at the end of the third 
and beginning of the fourth week of human development. The neural crest cells 
migrate to many specific regions to form various structures, including the sympathetic 
nervous system (SNS). Neural crest cells are initially pluripotent but as they migrate 
from the neural tube, their pluripotency is gradually lost and a variety of structures are 
formed, depending on the inductive environment they encounter. Some ventrally 
migrating neural crest cells develop into the sympathoadrenal progenitor cells which 
subsequently differentiate into the three major adrenergic cell types (ganglionic cells, 
small intensely fluorescent (SIF) cells and chromaffin cells) constituting the SNS 
(Pahlman & Hedborg, 2000). 
Neuroblastomas are tumors that arise from the neural crest-derived multipotent 
peripheral neuroblasts that are blocked in their differentiation (Pahlman & Hedborg, 
2000). Despite its malignancy, neuroblastoma has the highest rate of spontaneous 
regression of any human tumor and maturation into a benign tumor known as 
ganglioneuroma can be observed in some patients (Westermann & Schwab, 2002; 
Brodeur, 2003). These clinical observations have stimulated studies of 
neuroblastoma differentiation in vitro. It has been reported that human 
neuroblastoma cell lines can differentiate along several pathways into cells with 
morphologically distinct phenotypes, with characteristics similar to the neuronal cells 
or to the immature Schwannian, glial or melanocytic cells (Abemayor & Sidell, 1989). 
Induced differentiation has been documented in neuroblastoma cell lines treated with 
a variety of agents including retinoic acid (RA), nerve growth factor, phorbol ester, 
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interferon-y, and cAMP elevating agents (Sidell, 1982; Pavelic & Spaventi, 1987; Wu 
et al., 1998; Guzhova et al., 2001). These in vitro studies suggest that agents that 
induce differentiation of the neuroblastoma cells can reverse the malignant state or 
suppress the tumorigenic phenotype. Among these differentiation inducers, retinoic 
acid appears to be quite potent and its effectiveness as a therapeutic agent has been 
evaluated in clinical trials. The exposure of some neuroblastoma cells to nanomolar 
to micromolar concentrations of diW-trans retinoic acid (ATRA), \l)-cis or 9-cis RA 
induces dramatic morphological and biochemical changes including neurite extension, 
increases in the biosynthesis of neurospecific enzymes (such as acetylcholinesterase), 
neurotransmitters (such as catecholamines) and up-regulation of the 180 kDa neuronal 
cell adhesion molecule (NCAM) isoform expression (Raschella et al., 2000). More 
recently, neuroblastoma differentiation-inducing property has been demonstrated in 
some natural products. Euxanthone isolated from the medicinal plant Polygala 
caudata was shown to be able to inhibit the growth and trigger differentiation in the 
murine neuroblastoma Neuro-2a, BU-1 cells (Mak et al., 2000). On the other hand, 
pyridoacridine alkaloids isolated from the Indonesian marine sponge Biemna fortis 
was found to be capable of inducing differentiation in the Neuro-2a cells and arresting 
the cell cycle at the G2/M phase (Aoki et al., 2003). It seems that natural products 
are rich sources of bioactive substances that can be used as a differentiation inducer in 
neuroblastoma. 
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1.1.8 Differentiation Therapy of Neuroblastoma 
Although the conventional modalities will continue to be important in the 
treatment of neuroblastoma, biologically based therapies will be used increasingly in 
the treatment of neuroblastoma. Retinoic acid derivatives have been shown to 
induce differentiation and slow the growth of neuroblastoma cells in culture (Sidell, 
1982; Reynolds et al., 1994; Lovat et al., 1994; Han et aL, 1995). The finding that 
treatment of high-risk neuroblastoma patients with 13-cz5'-retinoic acid after bone 
marrow transplantation or after continuation chemotherapy significantly improved the 
event-free survival of patients provides a promising prospect of differentiation therapy 
of neuroblastoma, especially for the minimal residual disease (Matthay et al., 1999). 
Induction of differentiation would seem to be a promising approach for the 
management of neuroblastoma in the future. It is hoped that more effective and less 
toxic differentiation-inducing agents could be found. 
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1.2 Glycyrrhizin 一 the Major Active Component of Licorice 
1.2.1 Chemistry of Licorice 
Licorice (Figure 1.1) has a long history and was used by the ancient Chinese, 
Egyptians and Greeks. The generic name for licorice is Glycyrrhiza. This name is 
derived from the Greek words meaning "sweet root" and the Chinese name "gancao" 
also means "sweet grass". This genus consists of 30 species and many of them are 
found in China. In traditional Chinese medicine, Radix glycyrrhizae is defined as 
Glycyrrhiza uralensis, G glabra or G. inflata (Mills & Bone, 2000; Wang & Nixon, 
2001). The licorice with which we are familiar in the Western part of the world 
comes from the plant Glycyrrhiza glabra. This plant is indigenous to Greece, 
Turkey, Spain, Iraq, Caucasian and Transcaspian Russia, and northern China (Davis & 
Morris, 1991). 
Licorice is one of the oldest and most frequently used drugs in traditional 
Chinese medicine. It possesses various pharmaceutical functions, such as 
detoxification, anti-ulcer, anti-inflammation, anti-viral, anti-atherogenic and 
anti-carcinogenic functions etc. It is recommended for its life-enhancing properties, 
for improving health, for cure of injury or swelling, and for its detoxification effects 
(Wang & Nixon, 2001). In traditional Chinese medicine, licorice is primarily used 
as a tonic, an antipyretic, an antidote, a demulcent to the lungs, an expectorant, an 
analgesic to soothe sore throats and coughs, to treat asthma, and to alleviate toxic 
abscesses and acute abdominal pains (Davis & Morris, 1991). In Western countries, 
licorice products are used as flavoring and sweetening agents for tobaccos, chewing 
gums, candies, toothpaste, and beverages (Wang & Nixon, 2001). 
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Licorice root (Figure 1.2) contains a variety of compounds including essential 
oils, alkaloids, polysaccharides, polyamines, triterpenes, and flavonoids. 
Glycyrrhizin, also known as glycyrrhizic acid or glycyrrhizinic acid, is a major 
component of roots and rhizomes of licorice. It is a triterpenoid saponin that is 
composed of a molecule of glycyrrhetinic acid and two molecules of glucuronic acid. 
The intense sweetness of licorice resides mainly in glycyrrhizin (present in form of 
potassium and calcium salts). Glycyrrhizin is approximately between 50 and 170 
times as sweet as sucrose. The content of glycyrrhizin in the licorice root depends 
on the source and the method of assay and varies from 6 - 14%. 18p-glycyrrhetinic 
acid, the aglycone of glycyrrhizin, is also present in the root of licorice (0.5% - 0.9%). 
Moreover, glycyrrhizin is hydrolyzed by glucuronidase to its aglycone which exists in 
18a-glycyrrhetinic acid and ISp-glycyrrhetinic acid stereoisomeric forms (Huang, 
1999; Mills & Bone, 2000; Wang & Nixon, 2001). The metabolism of glycyrrhizin 
will be discussed in a later section. The structures of glycyrrhizin and 
18P-glycyrrhetinic acid are shown in Figure 1.3. 
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m 
Figure 1.1: Licorice. Adapted from (Yang & Liu, 2001) 
Figure 1.2: Rhizome of licorice. Adapted from (Zhongguo yi yao za zhi she, 1995) 
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Figure 1.3: The chemical structures of (A) glycyrrhizin and (B) 
18p-glycyrrhetinic acid. 
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1.2.2 Metabolism of Glycyrrhizin 
The metabolism of glycyrrhizin was believed to take place in the liver and the 
large intestine. After oral administration of glycyrrhizin, it is almost completely 
hydrolyzed to glycyrrhetinic acid by specialized (3-glucuronidase of the intestinal 
bacteria. Glycyrrhetinic acid formed will be transformed partly into 
3 a-hydroxyglycyrrhetinic acid via a metabolic intermediate 3-oxo-glycyrrhetinic acid 
by the intestinal bacteria. The glycyrrhetinic acid is then absorbed in the intestine, 
entered the systemic circulation and delivered to the liver where it is conjugated to 
glucuronide or sulphate prior to biliary excretion. These glycyrrhetinic acid 
metabolites are subsequently excreted into the bile. After outflow of the bile into the 
duodenum, the conjugates are hydrolyzed to glycyrrhetinic acid again by the 
commensal bacteria and the glycyrrhetinic acid is subsequently reabsorbed. This 
enterohepatic cycling of glycyrrhetinic acid is the cause of delayed terminal plasma 
clearance of glycyrrhetinic acid (Gunnarsdottir & Johannesson, 1997; Mills & Bone, 
2000; Ploeger et al., 2001; Okamura et al., 2003). 
After intravenous administration of glycyrrhizin, it is metabolized in the liver by 
lysosomal (3-glucuronidase to glycyrrhetinic acid monoglucuronide (GAMG) via the 
removal of one glucuronic acid. GAMG is then excreted into bile and converted to 
glycyrrhetinic acid by intestinal bacteria via the removal of another glucuronic acid. 
The glycyrrhetinic acid formed is then absorbed as described previously. Therefore, 
after intravenous administration of glycyrrhizin, both glycyrrhizin and glycyrrhetinic 
acid could be found in the plasma (Akao et al., 1991; Akao, 1998; Kim et al,, 1999; 
Shibata, 2000). 
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1.2.3 Pharmacological Effects of Glycyrrhizin and ISP-Glycyrrhetinic Acid 
There have been a variety of studies on the pharmacological effects of licorice. 
The pharmacological activities of licorice are mainly, if not all, due to the main 
saponin, glycyrrhizin and its aglycone, glycyrrhetinic acid. Therefore, much of the 
focuses have been placed on glycyrrhizin and glycyrrhetinic acid. Although 
glycyrrhetinic acid lacks sweetness, it shares many diverse pharmacological effects 
with glycyrrhizin. 
1.2.3.1 Anti-inflammatory Effect 
The anti-inflammatory effect of glycyrrhizin and ISp-glycyrrhetinic acid has 
been demonstrated in a number of animal models (Mills & Bone, 2000). An earlier 
animal study demonstrated that oral administration of ISp-glycyrrhetinic acid to rats 
resulted in inhibition of carrageenan-induced inflammation (Capasso et al., 1983). 
Another study demonstrated that glycyrrhetinic acid was effective in inhibiting 
TPA-induced mouse ear edema (Inoue et al., 1989). The mode of actions of 
glycyrrhizin and ISP-glycyrrhetinic acid is still unclear yet. However, several 
possible mechanisms behind the anti-inflammatory activity have been proposed. 
Due to the observation that glycyrrhizin inhibited prostaglandin E2 production by 
activated rat peritoneal macrophages, it had been proposed that the anti-inflammatory 
activity of glycyrrhizin depends in part on its inhibitory effect on the formation of 
prostaglandin E2 (Ohuchi et al., 1981). Another study showed that glycyrrhizin 
decreased neutrophils-generated reactive oxygen species in a dose-dependent manner, 
suggesting that glycyrrhizin exerts anti-inflammatory activity by inhibiting the 
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generation of reactive oxygen species by neutrophils (Akamatsu et al., 1991). Due 
to the structural resemblance between ISP-glycyrrhetinic acid and corticosteroids, an 
action mechanism of 18p-glycyrrhetinic acid similar to that of glucocorticoids has 
been raised. However, a recent report showed that 1 SP-glycyrrhetinic acid is a 
potent inhibitor of the classical complement pathway and it acts at the level of 
complement component C2 but naturally occurring steroids, such as hydrocortisone 
and cortisone do not have anti-complementary activity. Therefore, the 
anti-complementary activity of ISp-glycyrrhetinic acid is likely to contribute to its 
anti-inflammatory effect (Kroes et al., 1997). Most recently, the complement C3 
was found to be a glycyrrhizin (GL)-binding protein and the glycyrrhetinic acid- and 
GL-binding domains were located to C3a. Moreover, the phosphorylation of C3a 
(pi 15) by casein kinase 2 (CK-2) was completely inhibited by glycyrrhizin and 
glycyrrhetinic acid. Therefore, the glycyrrhizin- and glycyrrhetinic acid-induced 
inhibitions of the physiological activities of C3a and C3a may partly explain their 
anti-inflammatory effect in vivo since complement plays an important role in many 
acute inflammatory processes (Kawakami et al., 2003). 
1.2.3.2 Hepatoprotective Effect 
In Japan, glycyrrhizin preparation under the name of Stronger Neo-Minophagen 
C (SNMC) has been used clinically for decades as an anti-allergic and anti-hepatitis 
agent. SNMC is an intravenous drug containing glycyrrhizin as a principal 
ingredient along with glycine and L-cysteine. Although no anti-viral effect has been 
attributed to SNMC in the treatment of chronic viral hepatitis, SNMC can 
significantly decrease patient's serum levels of alanine transaminase (ALT) (Ito et al., 
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1997; van Rossum et al., 1999; Miyake et al, 2002). Moreover, long-term 
administration of SNMC for chronic hepatitis C was reported to be effective in the 
reduction of hepatocellular carcinoma development (Arase et al., 1997). Study in 
rats also showed that both glycyrrhizin and 18|3-glycyrrhetinic acid had a 
hepatoprotective activity on carbon tetrachloride (CCl4)-induced hepatotoxicity of rats. 
The serum aspartate transaminase (AST) and ALT levels of rats treated with 
glycyrrhizin and 18p-glycyrrhetinic acid orally and intraperitoneally, respectively 
were significantly lower than those of the CCU-treated control group (Shim et al, 
2000). Although various pharmacological actions of glycyrrhizin such as 
anti-inflammatory activity, interferon-丫-inducing activity and 
corticosteroid-enhancing activity are considered as mechanisms by which glycyrrhizin 
lowers the transaminase levels, other mechanisms have been proposed for the 
hepatoprotective effect of glycyrrhizin and ISP-glycyrrhetinic acid. The protective 
function has recently been explained by the inhibitory effects of glycyrrhizin on 
immune-mediated cytotoxicity against hepatocytes and on nuclear factor (NF)-kappa 
B activity in the murine liver injury induced by CCU-ethanol (Yoshikawa et al., 1997; 
Wang et al., 1998). Furthermore, the finding that glycyrrhizin can inhibit the 
TNF-a-induced apoptosis in human hepatoblastoma HepG2 cells has raised the 
possibility that glycyrrhizin may inhibit the hepatocyte apoptotic cell death mediated 
by TNF-a receptor 1 that has been believed to be involved in the pathogenesis of 
chronic viral hepatitis (Yoshikawa et al, 1999). More recent finding suggests that 
glycyrrhizin and ISP-glycyrrhetinic acid may improve liver failure by stimulating 
liver regeneration in acute or chronic hepatitis since the growth-promoting effects of 
glycyrrhizin and ISP-glycyrrhetinic acid on adult rat hepatocytes via epidermal 
growth factor (EGF) receptors have been demonstrated in vitro (Kimura et al,, 2001). 
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1.2.3.3 Anti-carcinogenic and Anti-tumor Effects 
During the past few decades, animal and cell culture studies indicated that 
glycyrrhizin and glycyrrhetinic acid have inhibitory activities against certain tumors. 
An earlier animal study showed that glycyrrhetinic acid inhibited the tumor promoting 
activity of both TPA and teleocidin on skin tumor formation in ICR mice initiated 
with 7,12-dimethylbenz[a]anthracene (DMBA). The percentage of tumor-bearing 
mice of the group treated with DMBA plus TPA was 97% at week 20, whereas that of 
the group treated with DMBA plus TPA and glycyrrhetinic acid was 40%. The 
percentage of tumor-bearing mice in the group treated with DMBA and teleocidin was 
88% at week 18, whereas that of the group treated with DMBA plus teleocidin and 
glycyrrhetinic acid was 6% (Nishino et al., 1986). In another animal study, chronic 
oral feeding of 0.05% glycyrrhizin in drinking water to Senear mice resulted in 
substantial protection against DMBA-initiated and TPA-promoted skin tumorigenesis. 
Oral feeding of glycyrrhizin in drinking water also resulted in inhibition in the 
binding of topically applied [^H]benzo[a]pryene and [^H]DMBA to epidermal DNA 
and the authors raised the possibility that the anti-tumor-initiating activity of 
glycyrrhizin may be due to the involvement of glycyrrhizin as an inhibitor of the 
carcinogen metabolism and DNA adduct formation that finally lead to carcinogenesis 
(Agarwal et al., 1991). The same group also demonstrated that glycyrrhetinic acid 
inhibited the mutagenicity of benzo[a]pyrene, 2-aminofluorene and aflatoxin B1 in 
Salmonella typhimurium strain TA98 ad TAIOO. Moreover, both ISa-glycyrrhetinic 
acid and 18p-glycyrrhetinic acid inhibited the DMBA-induced skin tumor-initiating 
activity but ISP-glycyrrhetinic acid was shown to be more effective than 
18a-glycyrrhetinic acid as an anti-skin tumor initiating agent. However, 
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18a-glycyrrhetinic acid and 18p-glycyrrhetinic acid showed comparable effect as 
inhibitors of TPA-induced skin tumor promotion in mice (Wang et al, 1991). 
Besides the skin tumor, animal study also showed that long-term intramuscular 
treatment of mice with glycyrrhizin significantly decreased the occurrence of 
hepatocellular carcinoma in diethylnitrosamine-treated mice (Shiota et al., 1999). 
Furthermore, intraperitoneal administration of glycyrrhizin (10 mg/kg) was shown to 
be able to inhibit the incidence of pulmonary metastases of B16 melanoma in mice 
inoculated with B16F10 melanoma cells. Similarly, 84% of metastases were 
inhibited in those mice after they were adoptively transferred with splenic CD4+ T 
cells from mice treated with glycyrrhizin but not with normal CD4+T cells. Since 
tumor-associated T helper type 2 cells (Th2) play a role in the pulmonary metastasis 
of B16 melanoma cells, the authors proposed that glycyrrhizin inhibited pulmonary 
metastasis in melanoma inoculated mice by inducing antagonistic cells for Th2 cells 
(Kobayashi et al., 2002). 
The tumor suppression activity of glycyrrhizin and glycyrrhetinic acid could also 
be demonstrated by in vitro studies. An earlier study showed that both glycyrrhizin 
and glycyrrhetinic acid inhibited the growth of B16 melanoma cells and stimulated 
the melanogenesis and the growth inhibition of glycyrrhetinic acid was correlated 
with the inhibition of cell cycle progression from Gi to S phase (Abe et al., 1987). 
Another in vitro study also demonstrated that glycyrrhizin inhibited the proliferation 
of the mice submandibular gland fibrosarcoma cell line by blocking the transfer of 
cells from Gi to S phase (Ge et al., 1998). One study showed that glycyrrhizin, 
18a-glycyrrhetinic acid and 18p-glycyrrhetinic acid displayed differential growth 
inhibitory effects on lymphoma and leukemia cell lines (Malagoli et al., 1998). A 
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more recent study reported that glycyrrhizin and 18p-glycyrrhetinic acid exhibited 
cytotoxicity against a number of tumor cell lines including SNU C4, SNU-1, P-388, 
L-1210, HepG2 and A549 (Kim et al., 2000). In addition, previous study in our 
laboratory showed that glycyrrhizin and ISP-glycyrrhetinic acid inhibited the growth 
of human and murine leukemia cell lines by inducing apoptosis and/or differentiation 
in leukemia cells (Tsang, 2001). 
1.2.3.4 Anti-viral Effect 
Direct anti-viral effect of glycyrrhizin has been demonstrated by in vitro studies. 
An earlier study reported that 8 mM of glycyrrhizin inhibited both the growth and 
cytopathic effects of vaccinia, herpes simplex type 1, Newcastle disease and vesicular 
stomatitis viruses (Pompei et al., 1979). Apart from inhibiting the growth of several 
viruses, glycyrrhizin also produces irreversible inactivation of herpes simplex vims 
type 1 (Pompei et al., 1979; Pompei et al., 1980). Glycyrrhizin also possesses 
effective anti-viral properties against the varicella-zoster virus (VZV) (Baba & 
Shigeta, 1987), human immunodeficiency vims (HIV) (Ito et al., 1987; Ito et al., 1988; 
Sasaki et al., 2002), hepatitis A vims (HAV) (Crance et al,, 1990; Crance et al., 1994), 
human cytomegalovirus (HCMV) (Numazaki et al., 1994), Japanese encephalitis 
virus (JEV) (Badam, 1997), sandfly fever Sicilian virus (SFSV) (Crance et al., 1997) 
and flaviviruses (Crance et al., 2003). More recently, glycyrrhizin has been shown 
to be more effective than several other anti-viral drugs in inhibiting the replication of 
the severe acute respiratory syndrome-associated coronavims (SARS-CV) in Vero 
cells (Cinatl et al., 2003). In addition to the inhibition of SARS-CV replication, 
glycyrrhizin also prevented the adsorption and penetration of the virus into Vero cells. 
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The mechanisms by which glycyrrhizin can exhibit anti-viral activity against different 
viruses remain unclear. It has been suggested that direct binding of glycyrrhizin to 
the vesicular stomatitis vims causes the direct inactivation of virus-associated kinase 
and the reduction of the viral infectivity (Ohtsuki & lahida, 1988). Crance et al 
(1994) also reported that glycyrrhizin inhibited the early stage of HAV replication and 
the HAV penetration of the plasma membrane. Moreover, the abilities of 
glycyrrhizin to suppress the secretion of hepatitis B surface antigen (HBsAg), to 
interfere with the intracellular transport of HBsAg at the trans-Golgi area and to 
suppress sialylation of HBsAg have been demonstrated by in vitro studies (Takahara 
et al., 1994; Sato et aL, 1996). In the same study, glycyrrhetinic acid was found to 
be more effective than glycyrrhizin in suppressing the secretion of HBsAg (Sato et al., 
1996). Glycyrrhizin might also inhibit HIV-1 in vivo as suggested by one human 
clinical study that intravenous administration of glycyrrhizin to three hemophiliacs 
with acquired immune deficiency syndrome (AIDS) reduced the viral antigens levels 
in these patients (Hattori et al., 1989). It is believed that glycyrrhizin may exert its 
anti-HIV-1 activity by inhibiting the vims replication and the vims-cell binding (Ito et 
al” 1988). 
On the other hand, two recent animal studies have demonstrated that the 
anti-viral effect of glycyrrhizin may be indirect. One animal study showed that 
when thermally injured mice were treated intraperitoneally with glycyrrhizin, the 
resistance of these mice to herpes simplex vims type 1 (HSV-1) was improved to 
levels observed in normal mice. In addition, adoptive transfer of splenic 
mononuclear cells from normal mice treated with glycyrrhizin to thermally injured 
mice (recipients) resulted in improved resistance of recipients to HSV infection 
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(Utsunomiya et al., 1995). Utsunomiya et al (1997) also reported that when splenic 
T cells from glycyrrhizin-treated mice were adoptively transferred to mice exposed to 
influenza vims, 100% of the recipients survived, compared to 0% survival for 
recipient mice inoculated with naive T cells or splenic B cells and macrophages from 
glycyrrhizin-treated mice. Moreover, the anti-viral activity of glycyrrhizin on 
influenza virus infection in mice was abolished when it was administered to infected 
mice in combination with anti-gamma interferon (anti-IFN-y) monoclonal antibody, 
suggesting that glycyrrhizin may protect mice exposed to a lethal amount of influenza 
virus through the stimulation of interferon-gamma (IFN-y) production by T cells 
(Utsunomiya et al., 1997). Therefore, these in vitro and in vivo studies suggest that 
the anti-viral effect of glycyrrhizin may exert through its direct inhibitory action on 
viral replication and function, and indirectly by stimulating the host immune system. 
1.2.3.5 Immunomodulatory Effect 
Various immunomodulatory effects of glycyrrhizin and glycyrrhetinic acid have 
been reported. An earlier report showed that intravenous administration of 
glycyrrhizin or glycyrrhetinic acid induced IFN-y production in mice (Abe et al,, 
1982). However, another report showed that lymphocyte-macrophage culture treated 
with 10 - 100 jag/ml of glycyrrhizin alone did not produce interferon whereas similar 
glycyrrhizin treatment significantly enhanced the IFN-y production in response to 
concanavalin A and surface antigen of hepatitis B vims (Shinada et aL, 1986). 
Besides, Zhang et al (1993) reported that glycyrrhizin promotes receptor-mediated 
T-cell proliferation through the augmentation of interleukin-2 (IL-2) production and 
IL-2 receptor (IL-2R) expression and the primary site of action for the augmented 
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IL-2 production is after the activation of immediate early genes. In addition, 
previous studies demonstrated that nitric oxide (NO) production was enhanced in 
lipopolysaccharide (LPS)- or IFN-y-activated macrophages isolated from 
glycyrrhizin-treated mice although glycyrrhizin alone did not induce NO from resting 
macrophages (Kondo & Takano, 1994; Yi et al, 1996). On the contrary, 
ISP-glycyrrhetinic acid significantly elicited a dose-dependent increase in NO 
production in the absence of any stimulator and the increased production of NO was 
mediated by the up-regulation of inducible nitric oxide synthase (iNOS) expression 
via N F - K B transactivation in macrophages (Jeong & Kim, 2002). Based on the 
relationship between NO production and the anti-viral and anti-tumor function of 
macrophages, it has been suggested that the anti-viral and anti-tumor effects of 
glycyrrhizin and ISP-glycyrrhetinic acid in vivo might be mediated in part through the 
activation of NO production (Kondo & Takano, 1994; Jeong & Kim, 2002). 
Furthermore, a recent study showed that glycyrrhizin enhanced both IL-12 messenger 
RNA accumulation and protein secretion by peritoneal macrophages in response to 
LPS, and the priming effect of glycyrrhizin on IL-12 production did not depend on 
IFN-y or granulocyte-macrophage colony-stimulating factor (GM-CSF) (Dai et al., 
2001). Therefore, glycyrrhizin and ISP-glycyrrhetinic acid seem to have an 
important potential in activating certain immune functions. 
1.2.3.6 Mineralocorticoid Effect 
It has been observed that long-term administration of licorice or glycyrrhizin in 
humans may cause pseudohyperaldosteronism. Based on the structural similarities 
between glycyrrhetinic acid and the corticosteroid hormones, the mineralocorticoid 
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effect of glycyrrhizin had been proposed to be mediated by the direct binding of 
glycyrrhetinic acid to the mineralocorticoid receptor. However, the affinity of 
glycyrrhetinic acid for the mineralocorticoid receptor was found to be about 3,000 and 
10,000 times lower than that of aldosterone itself in human mononuclear leucocytes 
and in renal tissue of rats, respectively. Moreover, licorice does not exert its 
mineralocorticoid activity in adrenalectomised animals. These observations indicate 
that direct binding of glycyrrhetinic acid to mineralocorticoid receptors is unlikely the 
predominant mode of action (Armanini et al, 1983; Stewart et al, 1987; Armanini et 
al., 1989). The mineralocorticoid effect is however, mainly due to the inhibition of 
lip-hydroxysteroid dehydrogenase activity by glycyrrhetinic acid (Stewart et al., 
1987; Monder et al., 1989). The mineralocorticoid receptors have equal affinity for 
the aldosterone and for the glucocorticoids (Cortisol and corticosterone), which 
circulate at much higher concentrations than aldosterone. In mineralocorticoid target 
tissues (kidney, parotid and colon), the mineralocorticoid receptors are selective for 
aldosterone because of the presence of lip-hydroxysteroid dehydrogenase which 
converts Cortisol and corticosterone to their 11-keto analogs (cortisone and 
11 p-dehydrocorticosterone) that cannot bind to mineralocorticoid receptors (Funder et 
al., 1988). Inhibition of lip-hydroxysteroid dehydrogenase by ISP-glycyrrhetinic 
acid thus leads to increased Cortisol levels and exerts the mineralocorticoid effect by 
the binding of Cortisol to the mineralocorticoid receptors. In addition, a more recent 
study showed that chronic high dose of glycyrrhizin (120 mg/kg of glycyrrhizin twice 
a day for 2 weeks) given to rats not only inhibited the lip-hydroxysteroid 
dehydrogenase activity but also suppressed the mRNA and protein expression of 
lip-hydroxysteroid dehydrogenase (Tanahashi et al., 2002). 
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1.2.4 Pharmacokinetics of Glycyrrhizin and Glycyrrhetinic Acid 
When 80 mg glycyrrhizin was injected into normal subjects, the maximum level 
of glycyrrhizin in serum was found to be 10 - 15 [ig/m\, with a half-life of about 5 
hours. Glycyrrhetinic acid appeared after 6 hours with a maximum level of about 
150 ng/ml at 15 hours. However, when normal subjects were given 100 mg 
glycyrrhizin orally, a glycyrrhetinic acid level of about 50 - 500 ng/ml (100 - 1000 
nM) was detected in serum. The maximum level of glycyrrhetinic acid in serum was 
detected between 2 and 25 hours in different individuals (Stormer et al., 1993). 
Another study reported that glycyrrhetinic acid (< 200 ng/ml) but not glycyrrhizin 
appeared in plasma of healthy volunteers after oral administration of 100 mg 
glycyrrhizin and the appearance of glycyrrhetinic acid in the blood after oral 
administration of glycyrrhizin was due to the hydrolysis of glycyrrhizin by the 
intestinal bacteria. Moreover, the same study showed that the plasma clearance of 
glycyrrhizin was not dose-dependent for intravenous doses of 40 - 120 mg. For the 
intravenous administration of glycyrrhizin (40, 80 and 120 mg), the terminal 
half-life of glycyrrhizin was 2.7 — 4.8 hours (Yamamura et aL, 1992). Another 
pharmacokinetic study in 10 healthy young volunteers reported that a maximum 
serum level of 18p-glycyrrhetinic acid (6.3 \ig/m\) was reached 2 - 4 hours after 
ingestion of 500 mg ISp-glycyrrhetinic acid. Moreover, seven subjects still had 
18p-glycyrrhetinic acid with a mean level of 0.33 |Lig/ml 24 hours after ingestion 
(Heilmann et al., 1997). As stated in the literatures, the pharmacokinetics of 
glycyrrhizin and glycyrrhetinic acid are characterized by a biphasic elimination from 
the central compartment with a dose-dependent second elimination phase. After oral 
dose of 1,000 mg and 1,500 mg of ISp-glycyrrhetinic acid, the mean half-life of the 
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second elimination phase was 11.5 士 1.2 hours and 38.7 土 10.5 hours, respectively 
(Krahenbuhl et al., 1994a). The peak plasma concentration increased with 
increasing ISP-glycyrrhetinic acid doses. The major part of both glycyrrhizin and 
glycyrrhetinic acid is eliminated via the bile and the urinary elimination of 
glycyrrhizin and glycyrrhetinic acid over 24 hours was less than 1% of the dose 
administered. Glycyrrhizin can be eliminated unmetabolized while glycyrrhetinic 
acid is conjugated to glucuronide or sulfate prior to biliary excretion. Orally 
administered glycyrrhizin is almost completely hydrolyzed by intestinal bacteria and 
reaches the systemic circulation as glycyrrhetinic acid (Krahenbuhl et al., 1994a; 
Krahenbuhl et al., 1994b). Liver function has been shown to influence the plasma 
clearance of glycyrrhizin after chronic intravenous administration to patients with 
acute hepatitis and liver cirrhosis. The elimination half-life for glycyrrhizin in the 
hepatitis (2.7 — 7.6 hours) and the cirrhosis (6.2 - 40.1 hours) groups was about twice 
and eight times longer than that in normal subjects, respectively (Yamamura et al., 
1995). 
1.2.5 Health Hazards of Glycyrrhizin and Glycyrrhetinic Acid 
Since glycyrrhizin is converted to glycyrrhetinic acid in the intestine and 
absorbed as glycyrrhetinic acid, the main hazards of licorice or glycyrrhizin 
administration are due to the mineralocorticoid effects of glycyrrhetinic acid. 
Chronic administration of licorice or glycyrrhizin in humans may cause 
pseudohyperaldosteronism. This syndrome is characterized by sodium retention, 
potassium loss, low aldosterone level, depression of the rennin-angiotensin system 
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and increased levels of the atrial natriuretic hormone (ANH). A number of clinical 
signs such as edema, hypertension, headache and symptoms of hypokalemia were 
observed (Stormer et al., 1993; Huang, 1999; Shibata, 2000). There is apparently a 
great individual variation in the susceptibility to glycyrrhizin. Most individuals who 
consume 400 mg glycyrrhizin daily experience adverse effects. In the most sensitive 
individuals, a regular daily intake of no more than about 100 mg glycyrrhizin is 
enough to produce the adverse effects (Stormer et al., 1993). Moreover, people with 
hypertension are more sensitive to the inhibition of 11 P-hydroxysteroid 
dehydrogenase by licorice and the inhibition of 11 p-hydroxysteroid dehydrogenase 
causes more pronounced clinical symptoms in women than in men (Sigurjonsdottir et 
al, 2003). In a recent study, a no-effect level of 2 mg glycyrrhizin/kg body weight is 
proposed. The acceptable daily intake (ADI) of 0.2 mg/kg body weight proposed 
lies below the quantity advised by the Dutch Nutrition Council of 200 mg/day and the 
relatively mild acute toxicity of glycyrrhizin may account for the large difference 
between the no-effect level, the doses of case reports and the quantity advised by the 
Dutch Nutrition Council (van Gelderen et al., 2000). In addition, intravenous 
administration of glycyrrhizin up to 240 mg, thrice weekly for 4 weeks to patients 
with chronic hepatitis C appears to be safe and is well tolerated (van Rossum et al., 
1999) A more recent clinical study showed that intravenous administration of 200 
mg glycyrrhizin (100 ml of SNMC) to patients with chronic hepatitis C six times per 
week, for 4 weeks only produced minor reversible symptoms of pseudoaldosteronism 
(van Rossum et al, 2001). In fact, licorice was approved by the German 
Commission E to treat peptic ulcer at relatively high doses (200 - 600 mg 
glycyrrhizin daily) but for treatment period not exceeding 6 weeks. In USA, licorice 
is used as a food additive and is designated as "Generally Recognized as Safe" 
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(GRAS). In Japan, daily administration of glycyrrhizin is also a standard practice to 
treat chronic hepatitis (Newton & Cupp, 2000; Shibata, 2000). 
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1.3 Aims and Scopes of This Study 
As stated in Section 1.2.3, a number of reports showed that glycyrrhizin and 
18p-glycyrrhetinic acid possess many diverse pharmacological properties. However, 
there are very few studies on the action mechanisms of the direct anti-tumor activity 
of these two natural products on the cancer cells. In addition, to our knowledge, 
there has been no report demonstrating the effects of glycyrrhizin and 
ISP-glycyrrhetinic acid on the growth and differentiation of neuroblastoma cells. 
Thus, it is of great interest to study the direct anti-tumor activity of glycyrrhizin and 
ISp-glycyrrhetinic acid on neuroblastoma cells and to fiirther elucidate the cellular 
and molecular mechanisms of the anti-tumor activity of these two compounds. 
In my study, the anti-proliferative effect of glycyrrhizin and ISp-glycyrrhetinic 
acid on one murine and two human neuroblastoma cell lines will be first examined by 
the tritiated thymidine (^H-TdR) incorporation assay. In addition, the 
anti-proliferative effect of glycyrrhizin and ISP-glycyrrhetinic acid on a well 
characterized and subcloned murine neuroblastoma Neuro-2a BU-1 cell line will also 
be assessed by the neutral red assay, clonogenic assay and limiting dilution assay. 
The kinetics and reversibility of glycyrrhizin and ISp-glycyrrhetinic acid with respect 
to their anti-proliferative effect on BU-1 cells will be determined by the ^H-TdR 
incorporation assay. Moreover, the cytotoxicity of glycyrrhizin and 
18 (3-glycyrrhetinic acid on the murine neuroblastoma BU-1 cells will be assessed by 
the trypan blue exclusion test. Furthermore, the ability of glycyrrhizin and 
18p-glycyrrhetinic acid to induce apoptosis in the neuroblastoma BU-1 cells will be 
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measured by the DNA fragmentation assay and Hoechst 33342 staining. 
Since there has been an increasing interest in studying the differentiation therapy 
of neuroblastoma, therefore, the ability of glycyrrhizin and ISP-glycyrrhetinic acid to 
trigger neuronal cell differentiation will also be investigated in my present study. 
The differentiation-inducing capacity of glycyrrhizin and ISp-glycyrrhetinic acid on 
the BU-1 cells will be assessed by the morphological, biochemical as well as 
molecular studies. Morphological changes of glycyrrhizin- or 18(3-glycyrrhetinic 
acid-treated BU-1 cells will be examined by microscopic observation after cell 
staining. The biochemical changes of drug-treated BU-1 cells will be assessed by 
examining the expression of neuronal cell differentiation marker proteins by 
immunocytochemisty. The differentiation-related gene expression in BU-1 cells will 
also be examined at the molecular level by the RT-PCR technique. 
To provide better insights into the mechanisms of the anti-proliferative effect of 
glycyrrhizin and 18|3-glycyrrhetinic acid on the BU-1 cells, the cell cycle kinetics of 
drug-treated BU-1 cells will be analyzed by flow cytometry. In addition, the effects 
of ISP-glycyrrhetinic acid on the expression of cell cycle regulatory genes and 
proteins will be further studied by the RT-PCR technique and Western blot, 
respectively. Furthermore, attempts will be made to investigate whether the 
combination of glycyrrhizin, ISP-glycyrrhetinic acid and diW-trans retinoic acid will 
have additive or synergistic effect on the growth inhibition and differentiation of 
BU-1 cells. Finally, the possible involvements of protein kinase C (PKC) and 
protein kinase A (PKA) on the ISp-glycyrrhetinic acid-induced anti-proliferation and 
differentiation of BU-1 cells will be elucidated using the RT-PCR technique and by 
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the combined use of activators or inhibitors of PKC and PKA with ISp-glycyrrhetinic 
acid. 
CHAPTER 2 
MATERIALS AND METHODS 
Chapter 2 Materials & Methods 
2.1 Materials 
2.1.1 Cell Lines 
1) Neuro-2a BU-1 (BU-1) 
BU-1 is a subclone of the murine neuroblastoma Neuro-2a cell line which was 
established from a spontaneous tumor of a strain A albino mouse (Klebe & Ruddle, 
1969). BU-1 cells were derived from the Neuro-2a cells (ATCC CCL-131) by a 
limiting dilution method as described previously (Mak et al, 2000) and was a kind 
gift of Dr. N.K. Mak (Department of Biology, the Hong Kong Baptist University). 
2) SK-N-DZ 
SK-N-DZ (ATCC CRL-2149) purchased from the American Type Culture 
Collection (ATCC), USA, is a human neuroblastoma cell line which was derived in 
1978 from a bone marrow metastasis from a child with poorly differentiated 
embryonal neuroblastoma. 
3) SH-SY5Y 
SH-SY5Y (ATCC CRL-2266) purchased from ATCC is a thrice cloned 
(SK-N-SH->SH-SY->SH-SY5->SH-SY5Y) subline of the neuroblastoma cell line 
SK-N-SH which was established in 1970 from a metastatic bone tumor (Biedler et al, 
1978). 
2.1.2 Cell Culture Media, Buffers and Other Reagents 
1) Cell Culture Media 
(a) RPMI1640 Medium (Powder Form) 
The powder form of RPMI 1640 medium (Gibco BRL Life Technologies, Inc.), 
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supplemented with 25 mM N-2-hydroxy-ethyl-piperazine-N'-2-ethane-sulfonic acid 
(HEPES) and 2 mM L-glutamine was used for the preparation of culture medium that 
was used for sub-culturing of BU-1 cells. The powder was dissolved in double 
distilled water and buffered with 2 g sodium bicarbonate (NaHCOs) (Sigma Chemical 
Co.) per liter. The pH value of the medium was adjusted to 7.2 by 1 M HCl or 
NaOH (Sigma Chemical Co.). Thereafter, the medium was sterilized by filtration 
through a 0.22 \im Millipore filter and stored at 4°C until use. 
(b) Dulbecco's Modified Eagle's Medium (DMEM Powder Form) 
The powder form of DMEM medium (Gibco BRL Life Technologies, Inc.), 
supplemented with 4,500 mg/L D-glucose, 4 mM L-glutamine, 110 mg/L sodium 
pyruvate, and 4 mg/L pyridoxine HCl was used for the preparation of culture medium 
that was used for sub-culturing of SK-N-DZ cells. The powder was dissolved in 
double distilled water and buffered with 1.5 g sodium bicarbonate (NaHCOs) (Sigma 
Chemical Co.) per liter. The pH value of the medium was adjusted to 7.2 by 1 M 
HCl or NaOH (Sigma Chemical Co.) and the medium was then sterilized by filtration 
through a 0.22 ^m Millipore filter and stored at 4 � C until use. 
(c) Minimum Essential Medium (MEM Powder Form) 
The powder form of MEM medium (Gibco BRL Life Technologies, Inc.), 
supplemented with Earle's salts, 2 mM L-glutamine, and non-essential amino acids, 
was used for the preparation of culture medium which was used for sub-culturing of 
SH-SY5Y cells. The powder was dissolved in double distilled water and buffered 
with 2.2 g sodium bicarbonate (NaHCOs) (Sigma Chemical Co.) per liter. The pH 
value of the medium was adjusted to 7.2 by 1 M HCl or NaOH (Sigma Chemical Co.) 
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and the medium was then sterilized by filtration through a 0.22 jim Millipore filter 
and stored at 4°C until use. 
2) Serum Supplements 
Fetal calf serum (FCS) (Gibco BRL Life Technologies, Inc.) was stored as 50 ml 
and 10 ml aliquots in sterile universal bottles. Heat-inactivated fetal calf serum 
(HI-FCS) was prepared by heating the FCS at 56°C for 30 minutes. The aliquots 
were then kept frozen at -20°C until use. 
3) Antibiotic Mixture Solution (lOOx) 
Penicillin-Streptomycin-Neomycin (PSN) antibiotic mixture lOOx stock solution 
containing 5,000 |Lig/ml penicillin G (sodium salt), 5,000 jug/ml streptomycin sulfate 
and 10,000 ^ig/ml neomycin sulfate in 0.85% saline was purchased from Gibco BRL 
Life Technologies, Inc. It was stored at -20°C as 5 ml aliquots until use. lOOx 
PSN was added to culture medium to give 1% antibiotics to prevent any possible 
contamination of cell culture. 
4) Complete Medium 
RPMI 1640, DMEM or MEM medium supplemented with 1% antibiotics was 
called “Plain Medium". Complete medium (CM) was prepared by supplementing 
the plain medium with 10% FCS or HI-FCS. CM supplemented with 10% FCS was 
used for sub-culturing murine and human neuroblastoma cell lines while CM 
supplemented with 10% HI-FCS was used for assay. 
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5) Dulbecco's Phosphate-Buffered Saline (PBS) 
PBS (Gibco BRL Life Technologies, Inc.) was prepared by stirring the powdered 
salt (8 g sodium chloride, 0.2 g potassium chloride, 0.2 g monobasic potassium 
phosphate and 1.15 g dibasic sodium phosphate) in one liter of double distilled water 
until dissolved. The pH of the solution was adjusted to 7.4 by 1 M HCl or NaOH. 
It was then sterilized by autoclaving at 121°C for 20 minutes. 
6) Dye Solutions 
(a) Hemacolor Staining Solutions 
Hemacolor staining solutions (Diagnostica Merck) which consist of three different 
solutions were used to stain cells. Hemacolor solution 1 was a fixation solution, 
solution 2 was a buffered color reagent red and solution 3 was a buffered color 
reagent blue. All solutions were stored in light-protected, tightly closed glass bottles 
at room temperature. 
(b) Trypan Blue Staining Solution 
Trypan blue solution was purchased from Gibco BRL Life Technologies, Inc. It 
contains 0.4% (w/v) trypan blue dissolved in 0.85% saline. 
7) Trypsin-EDTA Solution 
Trypsin-EDTA solution (without Ca^^ and Mg2+) purchased from Gibco BRL Life 
Technologies, Inc., contains 0.25% (w/v) trypsin and 1 mM EDTA-tetrasodium in 
Hanks' balanced salt solution (HBSS). It was stored at -20°C as 20 ml aliquots 
until use. 
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2.1.3 Drugs and Chemicals 
1) Glycyrrhizin (GL) 
Glycyrrhizic acid ammonium salt (glycyrrhizin) with an estimated purity of -95% 
was purchased from Fluka Chemical Company Inc. It was freshly prepared by 
dissolving the powder in plain RPMI 1640 medium as 11 mM solution and then filter 
sterilized. HI-FCS was then added to the solution to give a 10 mM stock solution in 
IQo/oHI-FCS CM. 
2) ISp-Glycyrrhetinic Acid (GA) 
ISP-Glycyrrhetinic acid with an estimated purity of �97o/o was purchased from 
Aldrich Chemical Company Inc. It was dissolved in cell culture-tested, sterile 
dimethylsulfoxide (DMSO) as a 60 mM stock solution. The stock solution was 
stored in dark at -20°C until use and it was used within one month after preparation. 
3) Etoposide 
Etoposide with an estimated purity of >97% was purchased from Calbiochem. It 
was dissolved in DMSO as a 100 mM stock solution and stored in dark at -20°C. 
4) A\\-Trans Retinoic Acid (ATRA) 
ATRA obtained from Calbiochem was solubilized in DMSO at a concentration of 
30 mM and stored in dark at -20°C until use. 
5) Protein Kinase C Modulators 
Protein kinase C (PKC) activators phorbol 12-myristate 13-acetate (PMA) and 
phorbol 12,13-diacetate (PDA) were purchased from Sigma Chemical Co. They 
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were dissolved in DMSO and absolute ethanol respectively as a stock solution of 1 
mg/ml and stored at -20°C until use. The PKC inhibitors staurosporine and 
calphostin C were dissolved in absolute ethanol at a concentration of 100 jiM whereas 
Go 6976 was first dissolved in D M S O and further diluted in plain medium as a 10 |LIM 
stock solution and stored in dark. All PKC inhibitors were purchased from 
Calbiochem and all stock solutions were stored at -20°C until use. 
6) Protein Kinase A Modulators 
Protein kinase A (PKA) activators adenosine 3,,5,-cyclic phosphorothioate-Sp 
(Sp-isomer) and dibutyryl-cAMP, sodium salt (db-cAMP) were dissolved in sterilized 
double distilled water as 20 mM and 100 mM stock solution respectively while 
forskolin was dissolved in DMSO at a concentration of 10 mM. The PKA inhibitors 
14-22 amide and adenosine 3',5'-cyclic phosphorothiolate-Rp (Rp-isomer) were 
dissolved in sterilized double distilled water as 1 mM and 20 mM stock solution, 
respectively while H-89 and KT5720 were dissolved in DMSO as 5 mM and 500 i^M 
stock solution respectively and KT5720 was protected from light. All PKA 
activators and inhibitors were purchased from Calbiochem and the stock solutions 
were stored at —20°C until use. 
2.1.4 Reagents for ^H-Thymidine Incorporation Assay 
1) [methyl-^H] Thymidine ('H-TdR) 
The stock solution (Amersham Life Science Ltd.) with specific activity of 2 
Ci/mmol was kept as 500 aliquots at 4°C. It was freshly diluted with complete 
medium to make up the 25 |j.Ci/ml working solution before cell labeling. In cell 
labeling experiment, 20 |LI1 working solution was added to each well of the 96-well 
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flat-bottomed microliter plate. 
2) Liquid Scintillation Cocktail 
The OptiPhase 'HiSafe'2 liquid scintillation cocktail was purchased from 
Perkin-Elmer Co. The cocktail was stored in dark at room temperature. 
2.1.5 Reagents for Neutral Red Assay 
1) 0.5% Neutral Red Solution 
Neutral red solution (0.5%, w/v) was prepared by dissolving 0.5 g neutral red 
powder (Sigma Chemical Co.) in 100 ml normal saline. The neutral red solution was 
then filtered and stored at 4°C. 
2) Normal Saline 
Normal saline was prepared by dissolving 1.8 g sodium chloride (Sigma Chemical 
Co.) in 200 ml of double distilled water and sterilized by autoclaving at 121�C for 20 
minutes. 
3) 1% Sodium Dodecyl Sulfate (SDS) Solution 
SDS solution (1%, w/v) was prepared by dissolving 1 g SDS (Sigma Chemical 
Co.) in 100 ml double distilled water and kept at room temperature. 
2.1.6 Reagents for Clonogenic Assay 
1) Citrate Solution 
Citrate solution containing 18 mM citric acid, 9 mM sodium citrate and 12 mM 
sodium chloride was prepared and stored at 4°C until use. 
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2) Citrate-Acetone-Formaldehyde (CAF) Solution 
CAF solution was prepared by mixing 25 ml citrate solution, 65 ml acetone and 8 
ml 37% formaldehyde together and stored at 4°C before use. 
3) Hematoxylin Solution 
Hematoxylin solution containing 6 g/L hematoxylin, 52.8 g/L aluminum sulfate, 
and 0.6 g/L sodium iodate was purchased from Sigma Chemical Co. 
2.1.7 Reagents and Buffers for Immunocytochemistry 
1) 4% Paraformaldehyde 
Freshly prepared 4% (w/v) paraformaldehyde solution was used as the fixative. 
Briefly, 2 g paraformaldehyde (Sigma Chemical Co.) was first dissolved in 25 ml of 
double distilled water by heating to 60°C with stirring in a fume hood for one hour. 
A few drops of 1 M NaOH were added to help dissolving until the solution became 
clear. After cooling to room temperature, 25 ml 2X PBS was added to form 4% 
paraformaldehyde in IX PBS and stored in dark at 4 � C until use. 
2) 0.1% Triton X-100 
Triton X-100 solution (0.1%, w/v) was prepared by diluting one part of Triton 
X-100 solution (Sigma Chemical Co.) with 999 parts of PBS. It was used as a cell 
permeabilization agent. 
3) 1% BSA 
BSA solution (1%, w/v) was prepared by dissolving 1 g of bovine serum albumin 
(Sigma Chemical Co.) in 100 ml PBS and it was used as a blocking agent. 
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4) Normal Goat Serum 
Lyophilized normal goat serum was purchased from Zymed Laboratories, Inc. 
The lyophilized normal goat serum was reconstituted with 10 ml of double distilled 
water to give 10 ml of whole goat serum with 0.05% sodium azide. Reconstituted 
normal goat serum was stored at -20°C until use. Ten percent normal goat serum 
was prepared by diluting 1 part of the reconstituted normal goat serum with 9 parts of 
PBS. It was used as a diluting agent for secondary antibodies. 
5) Primary Antibodies 
(a) Rabbit Anti-MAP2 Polyclonal Antibody 
It is specific for microtubule-associated protein 2 (MAP2) and was purchased 
from Chemicon International, Inc. The antibody recognizes all types of MAP2 
isoforms (MAP2A, MAP2B, MAP2C and MAP2D) and it shows greatest 
immunoreactivity with MAP2A and MAP2B. The antibody reacts with MAP2 of 
human, rat, and mouse origin. Undiluted aliquots of antibody were kept at —20�C 
until use. 
(b) Mouse Anti-Neurofilament 200 Monoclonal Antibody 
It was purchased from Sigma Chemical Co. and reacts with an epitope in the tail 
domain of neurofilament 200 (also referred to as the H-subunit) that is present on both 
the phosphorylated and non-phosphorylated forms of this polypeptide. It shows 
broad species cross-reactivity by recognizing neurofilaments of human, monkey, pig, 
rabbit, hamster, rat and mouse. Undiluted aliquots of antibody were kept at -20°C 
until use. 
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6) Secondary Antibodies 
FITC Goat Anti-Rabbit IgG (H+L) Conjugate (ZyMax™ Grade) and FITC Goat 
Anti-Mouse IgG (H+L) Conjugate (ZyMax™ Grade) were purchased from Zymed 
Laboratories, Inc. The undiluted antibodies were stored in dark at 4°C until use. 
The secondary antibodies were diluted in 10% normal goat serum before use. 
2.1.8 Reagents for DNA Extraction 
1) IGEPAL CA-630 Lysis Buffer 
The buffer was prepared in 50 mM Tris [hydroxylmethyl] amino methane 
(Tris)-HCl, pH 7.5 with 3% non-ionic detergent IGEPAL CA-630 (Sigma Chemical 
Co.) and 20 mM EDTA. It was kept at room temperature. 
2) Proteinase K 
It was purchased from Boehringer Mannheim. It is a highly active subtilisin 
type of protease. It was purified from the mold Tritirachium album Limber and the 
stock solution was prepared by dissolving it in autoclaved double distilled water to a 
concentration of 20 mg/ml and stored as 500 aliquots at —20�C until use. 
3) RNase A 
The pancreatic RNase (Boehringer Mannheim) was dissolved at a concentration 
of 10 mg/ml in 10 mM Tris-HCl (pH 7.5) and 15 mM NaCl. The stock solution was 
stored as 500 ！aliquots at -20°C until use. 
4) Sodium Acetate Solution (NaOAc) 
Sodium acetate solution (3 M) was prepared by dissolving 24.61 g sodium 
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acetate (Sigma Chemical Co.) in 100 ml double distilled water. It was then sterilized 
by autoclaving at 121�C for 20 minutes. The solution was kept at room temperature. 
5) TioEo.i Buffer 
The TioEo.i buffer contains 10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA in 
double distilled water. The solution was kept at room temperature. 
2.1.9 Reagent for DNA Staining 
The membrane-permeable nucleic acid stain Hoechst 33342 dye of 10 mg/ml 
was purchased from Molecular Probes Inc. (USA) and stored in dark at 4°C. It is a 
nuclear counterstain that emits blue fluorescence when bound to double stranded 
DNA. 
2.1.10 Reagents and Buffers for Flow Cytometry 
1) Propidium Iodide (PI) DNA Staining Buffer 
The PI DNA staining buffer containing 400 jig/ml ribonuclease A (RNase A) 
(Boehringer Mannheim), 50 [ig/m\ propidium iodide (Boehringer Mannheim), 10 mM 
EDTA, pH 7.4 (Sigma Chemical Co.), 0.1% trisodium citric acid (Sigma Chemical 
Co.) and 0.1% Triton X-100 (Sigma Chemical Co.) was freshly prepared in PBS and 
kept in dark at 4°C until use. 
2) FACS Flow Shealth Fluid 
The shealth fluid is a ready-to-use balanced electrolyte solution containing 
sodium chloride, potassium chloride, disodium EDTA, sodium fluoride and 
anti-microbial agent. It was purchased from the Becton Dickinson International and 
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Stored at room temperature. 
2.1.11 Reagents for Total RNA Isolation 
1) DEPC-treated Double Distilled Water 
Diethyl pyrocarbonate (DEPC) (Sigma Chemical Co.) was added to double 
distilled water at 1:1,000 ratio to give 0.1% (v/v) DEPC water. Thereafter, it was 
shaken vigorously to disperse the DEPC. After standing overnight, the solution was 
autoclaved at 121°C for 20 minutes to destroy the remaining DEPC. 
2) Trizol Reagent 
Trizol reagent, a mono-phasic solution of phenol and guanidine isothiocyanate, 
was purchased from Gibco BRL Life Technologies, Inc. It is a ready-to-use reagent 
for the isolation of total RNA from cells and tissues. It was stored in dark at 4°C 
until use. 
2.1.12 Reagents and Buffers for RT-PCR 
1) Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) 
The M-MLV reverse transcriptase (Gibco BRL Life Technologies, Inc.) was 
isolated from E, coli expressing a portion of the pol gene of M-MLV on a plasmid. 
This enzyme was stored at —20�C in a buffer containing 20 mM Tris-HCl pH 7.5, 1 
mM dithiothreitol (DTT), 0.01% (v/v) NP-40, 0.1 mM EDTA, 100 mM NaCl and 
50% (v/v) glycerol. One unit of its activity was defined as the amount of enzyme 
that would incorporate 1 nmole of deoxythymidine triphosphate (dTTP) into 
acid-precipitable material in 10 minutes at 37�C using poly(A).oligo(dT)25 as 
template and primer respectively. 
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2) First Strand Buffer (5X) 
The first strand buffer (Gibco BRL Life Technologies, Inc.) supplied as a 5X 
solution of 250 mM Tris-HCl (pH 8.3), 375 mM KCl and 15 mM MgC^was stored 
at -20°C until use. 
3) 0.1 M Dithiothreitol (DTT) 
DTT (0.1 M) purchased from Gibco BRL Life Technologies, Inc. was stored 
at -20°C until use. 
4) TioEo.i Buffer 
The TioEo.i buffer contains 10 mM Tris-HCl pH 8 and 0.1 mM EDTA in 
DEPC-treated distilled water. All chemicals were purchased from Sigma Chemical 
Co. 
5) RNaseOUTTM Recombinant Ribonuclease Inhibitor 
RNASEOUT™ recombinant ribonuclease inhibitor (Gibco B R L Life Technologies, 
Inc.) was affinity purified from a recombinant strain of E. coli expressing a cloned 
porcine liver gene. This inhibitor has a very high binding affinity for pancreatic-type 
ribonucleases such as RNase A and is active against RNase A, RNase B and RNase C. 
It has a concentration of 40 units/jil but requires a minimum of 1 mM DTT to 
maintain activity. It was stored at - 2 0 � C in a buffer which contains 20 mM Tris-HCl 
(pH 8), 50 mM KCl, 0.5 mM EDTA, 8 mM DTT and 50% (v/v) glycerol. One unit 
was defined as the amount of inhibitor required to inhibit by 50% the activity of 5 ng 
of RNase A as determined by the inhibition of hydrolysis of cytidine 2,, 3'-cyclic 
monophosphate by RNase A. 
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6) 01igo(dT)i2-i8, Sodium Salt (pd(T)i2.i8 5，-P04, sodium salt) 
01igo(dT)i2-i8 purchased from Pharmacia Biotech was prepared as a stock 
solution of 1 |Lig/|il in TioEo.i buffer and stored at —20°C. 
7) Ultrapure dNTP Set, 2'-Deoxynucleoside 5'-Triphosphate, Sodium Salt 
The deoxynucleoside triphosphate (dNTP) set was purchased from Pharmacia 
Biotech, with each nucleotide supplied as 100 mM solution in double distilled water 
(pH 7.5). A stock solution with 10 mM of each dNTP was prepared in 1 mM 
Tris-HCl (pH 7.5) and was stored at —20�C. 
8) Thermoprime DNA Polymerase 
Thermoprime DNA Polymerase (Advanced Biotechnologies Ltd.) stored 
at —20°C is a thermostable DNA polymerase isolated from Thermophilic bacteria. 
Thermoprime P'US DNA Polymerase is a single polypeptide of approximately 94 kDa 
which has 5，to 3’ polymerization-dependent exonuclease replacement activity, but 
lacks the 3' to 5' exonuclease activity. One unit of enzyme was defined as the 
amount that would incorporate 10 nmoles of dNTPs into acid insoluble material in 30 
minutes at 47�C. 
9) Reaction Buffer IV (lOX) 
The reaction buffer (Advanced Biotechnologies Ltd.) supplied as a 1 OX solution 
of 200 mM (NH4)2S04, 750 mM Tris-HCl (pH 9) and 0.1% (w/v) Tween was stored 
at -20°C until use. 
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10) 25 mM MgCh solution 
MgCli solution (25 mM) purchased from Advanced Biotechnologies Ltd. was 
stored at -20°C until use. 
11) Primer Pairs 
The oligonucleotide primers were designed on the basis of the published 
sequences of cloned cDNA. They were designed to prime on the sense and antisense 
sequences of the corresponding cDNA respectively. The PCR primer sets for PGR 
amplifications of specific cDNA were synthesized by Gibco BRL Life Technologies, 
Inc. and their sequences and predicted sizes of the PCR products are shown in Table 
2.1. The lyophilized primer pairs were reconstituted in DEPC-treated double 
distilled water to a working concentration of 2.5 juM. The primers were stored as 
500 \i\ aliquots at -20°C. They have the annealing temperature of 52-61°C. 
Table 2.1: Primers used in RT-PCR and the predicted sizes of the PCR products. 
Predicted size of 
� Sequence (5，to 3，） the amplified PCR 
amplified product (bp) 
Sense strand: 
m CGA ATT GGG CTA CGG AGA TGC T 763 
-myc Antisense strand: 
TTG TGC TGC TGA TGG ATG GG  
Sense strand: 
TTT GGG GAC AGT GTT CTC TGC CT 
c-mye Antisense strand: 
GTT CTT GAT GAA GGT CTC GTC GTC  
Sense strand: 
CCA GTC AAG AGC ATC AGC AA ^47 
OS Antisense strand: 
AAG TAG TGC AGC CCG GAG TA  
Sense strand: 
GCA TGA GGA ACC GCA TTG CCG CCT 
CCA AGT 459 
c-jun Antisense strand: 
CGC AAA GTC TGC CGG CCA ATA GGC  
CGCT  
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Sense strand: 
NF-KB/P50 ^AA GGT TAT CGT TCA GTT 
Antisense strand: 
TTG TAG ATA GGC AAG GTC  
Sense strand: 
Bcl-2 AGC TGC ACC TGA CGC CCT T 
Antisense strand: 
CAG CCA GGA GAAATC AAA CAG AGG  
Sense strand: 
C dm A TAC TTC CTG CAC CTG CAG CCT 
y Antisense strand: 
AGC ATG GAC TCC GAG CGA CT  
Sense strand: 
P D C C A TTA T T G ATC G G T T C A T G C A G A … CyclinB “ . . , 584 J Antisense strand: 
ATG TGT AC A GTT CAG CTG TGC CAG  
Sense strand: 
� . CTC GGC TCG TTA CTC CAC TC 川 Cdc 2 A ‘ J 311 Antisense strand: 
CCA TTT TGC CAG AGA TTC GT  
Sense strand: 
n y p TGA ATC CTC AGT GGAATGAGT . . . PKC-a A , 1 324 Antisense strand: 
GGT TGC TTT CTG TCT TCT GAA  
Sense strand: 
Di^p . GAT CGC TGA CTT TGG GAT GT . . . 
r JvU-O A , • , 1 242 
Antisense strand: 
GGG GAT AGT GTG GTG TGT CC  
Sense strand: 
p CAT CGA TCT CTC GGG ATC ATC G 孤 
Antisense strand: 
CGG TTG TCAAAT GAC AAG GCC  
Sense strand: 
PKC r CGA TGG GGT GGA TGG GAT CAA AA 
Antisense strand: 
GTG TTC ATG TCA GGG TTG TCC G  
Sense strand: 
CGT TGG GAG CTC TGA CAA TC • 
‘ Antisense strand: 
ACC TGC TTT TGC TCC ATC ATG  
Sense strand: 
…TT AAT GGT GAA GGT CGG TGT GAA C ” < 
GAPDH Antisense strand: 226 
GAA GAT GGT GAT GGG CTT CC  
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2.1.13 Reagents and Buffers for Gel Electrophoresis 
1) Tris-Borate-EDTA (TBE) Electrophoresis Buffer (5X) 
The 5X TBE electrophoresis buffer stock was prepared by dissolving 54 g Tris, 
27.5 g boric acid and 20 ml 0.5 M EDTA in 1 liter double distilled water. The pH of 
the buffer was adjusted to 8. The working TBE buffer (0.5X) was prepared by 
diluting one part of the 5X stock TBE buffer with nine parts of double distilled water. 
Both of the working and stock solutions were kept at 4°C. 
2) Agarose Gel 
1 % (w/v) and 2% (w/v) agarose gels were prepared by dissolving 10 g and 20 g 
agarose (USB) respectively in 1 liter 0.5X TBE buffer by heating at 70°C with 
constant stirring on a hot plate. The solidified agarose gel was heated and melted in 
a microwave oven before use. The 1% agarose gel was used for RNA gel 
electrophoresis while the 2% agarose gel was used for DNA and PGR products gel 
electrophoresis. 
3) Gel Loading Solution (5X) 
The gel loading solution (Sigma Chemical Co.) was a 5X solution containing 
0.05% (w/v) bromophenol blue, 40% (w/v) sucrose, 0.1 M EDTA (pH 8.0) and 0.5% 
(w/v) sodium dodecyl sulfate (SDS). One volume of the solution was mixed with 
four volumes of sample before loading into agarose gel. The solution was used for 
non-denaturing agarose gel electrophoresis of nucleic acids. It was stored at room 
temperature. 
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4) Ethidium Bromide (EtBr) 
A stock solution (10 mg/ml) of ethidium bromide was prepared by dissolving the 
EtBr (Sigma Chemical Co.) in double distilled water. The working solution was 
prepared by diluting the stock solution by 1,000 fold. Both the stock and working 
solution were kept in dark at room temperature. 
2.1.14 Reagents and Buffers for Western Blot Analysis 
1) Cell Lysis Buffer 
The cell lysis buffer contains 1% (v/v) IGEPAL-CA 630 (Sigma Chemical Co.), 
150 mM NaCl, 50 mM Tris-HCl (pH 7.5) and one tablet of complete protease 
inhibitor cocktail (Complete; Roche Molecular Biochemicals) in 50 ml double 
distilled water. Each tablet of complete protease inhibitor cocktail when dissolved in 
50 ml lysis buffer yielded a mixture of several protease inhibitors with a broad 
spectrum of activity on serine, cysteine and metalloproteases and calpains inhibitors. 
The cell lysis buffer was kept at 4°C until use. 
2) 30% (w/v) Acrylamide / Bis Solution, 37.5:1 
The ready-to-use 500 ml acrylamide solution containing 30% (w/v) of 
acrylamide (146.1 g) and N,N'-methylene-bis-acrylamide (3.9 g) for a total monomer 
to crosslinker ratio of 37.5:1 was purchased from Bio-Rad Laboratories. It was 
light-protected and stored at 4°C until use. 
3) Lower Buffer for Separating Gel 
It is a 1.5 M Tris-HCl buffer adjusted to pH 8.8 (Sigma Chemical Co.) and kept 
at 4°C. 
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4) 10% Sodium Dodecyl Sulfate (SDS) Solution 
SDS solution (10%, w/v) was prepared by dissolving 10 g SDS (Sigma Chemical 
Co.) in 100 ml double distilled water and kept at room temperature. 
5) 10% Ammonium Persulfate (APS) 
Ammonium persulfate (10%, w/v) was prepared by dissolving 0.5 g APS 
(Bio-Rad Laboratories) in 5 ml double distilled water. The solution was kept as 500 
jal aliquots at -20°C until use. 
6) N,N,N',N'-Tetra-methylethylenediamine (TEMED) 
TEMED purchased from Bio-Rad Laboratories was the last to add to initialize 
the polymerization of the SDS-polyacrylamide gel. It was stored at until use. 
7) Upper Buffer for Stacking Gel 
It is a 0.5 M Tris-HCl buffer adjusted to pH 6.8 (Sigma Chemical Co.) and was 
kept at 4°C. 
8) 2X SDS Gel Loading Buffer 
2X SDS gel loading buffer containing 2-mercaptoethanol and bromophenol blue 
was prepared by mixing 0.2 ml 0.05% (w/v) bromophenol blue, 1 ml upper buffer, 1 
ml glycerol, 1 ml 10% (w/v) SDS, 4.7 ml double distilled water and 0.1 ml 
2-mercaptoethanol. All reagents were purchased from Sigma Chemical Co. The 
buffer was protected from light and stored at 4°C until use. 
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9) Kaleidoscope Prestained Standards 
The Kaleidoscope prestained standards (Bio-Rad Laboratories) consist of seven 
uniquely colored proteins including myosin (199,000 Da), P-galactosidase (128,000 
Da), bovine serum albumin (85,000 Da), carbonic anhydrase (41,700 Da), soybean 
trypsin inhibitor (32,100 Da), lysozyme (18,300 Da) and aprotinin (7,500 Da). The 
standard colored proteins prepared in 33% (v/v) glycerol, 3% SDS, 10 mM Tris (pH 
7), 10 mM DTT, 2 mM EDTA, 0.01% NaNs were stored at -20°C until use. 
10) Tris-Glycine-SDS Electrophoresis Buffer (lOX) 
Tris-glycine-SDS electrophoresis buffer lOX concentrate contains 0.25 M 
Tris-HCl, pH 8.6, 1.92 M glycine and 1% SDS in double distilled water. It was 
filtered by filtration through a 0.2 \im Millipore filter and was stored at 4°C. The 
lOX concentrate was freshly diluted to IX working buffer solution for SDS-PAGE. 
11) Coomassie Blue Staining and Destaining Solution 
The staining solution was prepared by mixing one volume of 0.05% Coomassie 
blue (Bio-Rad Laboratories) in one volume of acetic acid, three volumes of methanol 
and ten volumes of double distilled water. For the destaining solution, it was 
prepared by mixing one volume of acetic acid, three volumes of methanol and ten 
volumes of double distilled water. The Coomassie blue staining and destaining 
solutions were used to stain and destain the SDS-polyacrylamide gel and the PVDF 
Western blotting membrane. 
12) Tris-Glycine Buffer (lOX) 
Tris-glycine buffer lOX concentrate contains 0.25 M Tris-HCl, pH 7.5 and 1.92 
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M glycine in double distilled water. It was filtered by filtration through a 0.22 i^m 
Millipore filter and stored at 
13) Tris-Glycine-Methanol Transfer Buffer (IX) 
The transfer buffer was prepared by mixing 100 ml methanol with 50 ml lOX 
Tris-glycine buffer and 350 ml double distilled water. The buffer solution was stored 
at 4°C. 
14) PVDF Western Blotting Membranes 
The microporous polyvinylidene difluoride (PVDF) membrane (Roche Applied 
Science) with pore size of 0.45 |Lim was stored at room temperature. 
15) Washing Buffer 
The washing buffer contains 10 mM Tris-HCl (pH 7.5), 100 mM NaCl and 0.1% 
(v/v) Tween 20 (Sigma Chemical Co.). The solution was kept at 4�C. 
16) 5% Skimmed Milk Solution (Blocking Solution) 
It was prepared by dissolving Nestle,s skimmed milk powder in washing buffer 
at a concentration of 5% (w/v). 
17) Primary Antibodies 
(a) Mouse Anti-P-Actin Monoclonal Antibody 
It is a mouse monoclonal antibody (Sigma Chemical Co.) which recognizes an 
epitope located on the N-terminal end of the p-isoform of actin. It is provided as 
ascities fluid containing 0.1% sodium azide as a preservative. The antibody cross 
“ — “ 
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reacts with P-actin in human, bovine, sheep, pig, rabbit, cat, dog, mouse, rat, guinea 
pig, chicken, carp, leech, and fruit fly tissues. The antibody was stored as small 
aliquots at -20°C. 
(b) Rabbit Anti-Cyclin A Polyclonal Antibody 
It is an affinity purified rabbit polyclonal antibody (Santa Cruz Biotechnology, 
Inc.) raised against a recombinant protein corresponding to amino acids 1 - 432 
representing full length cyclin A of human origin. Each vial contains 200 \ig IgG in 
1 ml PBS supplemented with 0.1% sodium azide and 0.2% gelatin. It reacts with 
cyclin A p60 and cyclin Al of mouse, rat and human origin and was stored at 4°C. 
(c) Rabbit Anti-Cyclin B1 Polyclonal Antibody 
It is an affinity purified rabbit polyclonal antibody (Santa Cruz Biotechnology, 
Inc.) raised against a recombinant protein corresponding to amino acids 1 - 433 
representing full length cyclin B1 of human origin. Each vial contains 200 f^ g IgG 
in 1 ml PBS supplemented with 0.1% sodium azide and 0.2% gelatin. It reacts with 
cyclin B1 of mouse, rat and human origin and was stored at 4°C. 
(d) Rabbit Anti-Cdc2 Polyclonal Antibody 
It is an affinity purified rabbit polyclonal antibody (Santa Cruz Biotechnology, 
Inc.) raised against a peptide mapping at the carboxy terminus of Cdc2 p34 of human 
origin. Each vial contains 200 |ig IgG in 1 ml of PBS supplemented with 0.1% 
sodium azide and 0.2% gelatin. The antibody reacts with Cdc2 p34 of mouse, rat 
and human origin and is non cross-reactive with other cyclin dependent kinases. It 
— 
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was stored at 4°C. 
18) Secondary Antibodies 
Sheep anti-mouse IgG, peroxidase-linked species-specific whole antibody and 
donkey anti-rabbit IgG, peroxidase-linked species-specific whole antibody were 
purchased from Amersham Pharmacia Biotech. Both of them had a concentration of 
1 mg/ml and were stored at 4°C. 
19) RPN 2106 ECL™ Western Blotting Detection Reagents 
The Western blotting detection reagents (Amersham Pharmacia Biotech.) which 
contain detection reagent 1 (250 ml) and detection reagent 2 (250 ml) were stored at 
4°C. Equal volume of detection reagent 1 and 2 was mixed before use and a final 
volume of 0.125 ml/cm^ membrane was required. 
20) X-ray film (Fuji, Japan) 
The Fuji X-ray film was stored in dark at 4 
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2.2 Methods 
2.2.1 Cell Culture Methodology 
The murine neuroblastoma Neuro-2a BU-1 cells were maintained in RPMI 1640 
medium containing 2 mM glutamine and 2 g/L sodium bicarbonate supplemented 
with 10% FCS and 1% PSN antibiotics. For the human neuroblastoma SK-N-DZ 
cells, they were maintained in DMEM supplemented with 10% FCS and 1% PSN 
antibiotics and the SH-SY5Y cells were maintained in MEM supplemented with 10% 
FCS and 1% antibiotics. All the cell lines were maintained in tissue culture flasks 
under a humidifying atmosphere containing 5% CO2 / 95% humidified air at 37°C. 
The cell lines were subcultured every 2 - 3 days or twice weekly depending on their 
doubling times. Cells of 5 - 25 passages growing exponentially were used to 
perform all experiments and long-term storage of cell lines was done by 
cryo-preservation in liquid nitrogen. 
For the subculture procedure, growth medium was first decanted, and the 
adherent cells were rinsed once with warm PBS before mild trypsinization with 0.5 ml 
(for 25 cm^ culture flask) or 1 ml (for 75 cm^ culture flask) of trypsin-EDTA solution 
at 37�C for 2 minutes. Then 10 ml of complete medium (CM) was added to stop the 
trypsinization process when all the cells were detached from the culture flask. Cells 
were then collected by centrifugation. After resuspension in CM, appropriate 
aliquots of cell suspension were added to new culture flasks with complete medium. 
2.2.2 Determination of Cell Proliferation 
1) ^H-thymidine (^H-TdR) Incorporation Assay 
The anti-proliferative effect of glycyrrhizin and ISP-glycyrrhetinic acid on the 
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neuroblastoma cells was assessed by ^H-TdR incorporation. Briefly, cells with a 
specified cell number (in 100 CM) were seeded in quadruplicates in wells of 
96-well flat-bottomed microliter plates at 37°C overnight inside a humidified 5% CO2 
incubator, after which CM or different concentrations of drug (100 i^l) was added and 
further incubated for various time periods as indicated in the text. During this period, 
cells were pulsed with 0.5 |iCi ^H-TdR per well for the last 6 - 10 hours (6 hours for 
BU-1 cells and 10 hours for SK-N-DZ and SH-SY5Y cells) of incubation. The cells 
were then frozen in a -20°C freezer overnight, thawed at room temperature and 
harvested onto glass fiber filter with a cell harvester (Skatron). The filters were 
transferred to vials containing 0.5 ml scintillation fluid and the amount of ^H-TdR 
incorporated into DNA was determined by liquid scintillation counting. The 
radioactivity of each filter was measured by the Beckman LS6000 liquid scintillation 
counter. The results were expressed as the percentage inhibition of ^H-TdR 
incorporation, using the untreated cells as a control (Leung et al, 1994). The 
percentage inhibition of ^H-TdR incorporation was calculated as follows: 
0/0 inhibition = [(cpm of control - cpm of test sample) / cpm of control] x 100% 
2) Neutral Red Assay 
The neutral red assay was also used as a non-radioactive method for the 
measurement of cellular proliferation (Borenfreund et al, 1990). In brief, BU-1 
cells (7,500 cells/100|il) in quadruplicates were seeded in wells of 96-well 
flat-bottomed microtiter plates at 37°C overnight inside a humidified 5% CO2 
incubator, after which CM or different concentrations of drug (100 |LI1) was added and 
further incubated for 48 hours. At the end of the incubation period, the medium was 
discarded and the cells were washed with 150 \i\ pre-warmed normal saline. 
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Thereafter, cells were incubated with 50 |LI1 0.5% neutral red solution at 37 for one 
hour to allow the uptake of the neutral red. After incubation, the neutral red solution 
was removed and the cells were washed six times with pre-warmed normal saline. 
After washing, the intracellular neutral red absorbed by the cells was solubilized with 
100 of 1% (w/v) SDS on a shaker platform for 2 hours and the absorbance at 540 
nm was measured spectrophotometrically with a microplate reader (Bio-Rad, Model 
3550) using 1% SDS as blank. The result expressed as percentage decrease in 
absorbance measured at 540 nm was calculated as follows: 
% decrease in absorbance measured at 540 nm 
=XA540 of control - A540 of test sample) / A540 of control] x 100% 
2.2.3 Determination of Cell Viability by Trypan Blue Exclusion Test 
Trypan blue exclusion test was used to determine the number of viable cells in 
cultures (McGahon et al., 1995). BU-1 cells (7.5 x lO^ cells/ml) were cultured in 
6-well plates overnight for cell attachment. Different concentrations of drugs or CM 
were then added and further incubated for 48 hours at 37°C inside a humidified 5% 
CO2 incubator. Cells were then trypsinized and collected by centrifugation. After 
resuspension in PBS, cells were mixed with an equal volume (10 i^l) of 0.4% trypan 
blue staining solution. The viable cells were visible as clear cell bodies while the 
non-viable cells were stained blue. The number of viable and non-viable cells was 
counted using a hemacytometer. The results were expressed as the mean percentage 
of cell viability 士 S.E. of triplicate cultures. The percentage viability was calculated 
as follows: 
0/0 cell viability = (no. of unstained cells / total no. of cells counted) x 100% 
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2.2.4 Limiting Dilution Assay 
Limiting dilution assay was used to determine the proliferating potential of cells 
after drug treatment. Briefly, BU-1 cells (2.5 x 10^ cells/ml) were cultured overnight 
and incubated with 3.5 mM glycyrrhizin or 80 jiM 1 Sp-glycyrrhetinic acid in the 
wells of a 6-well plate for 4 days at 37°C. Thereafter, the cells were washed and 
harvested by mild trypsinization. Various concentrations of viable cells in a total 
volume of 200 jiil were seeded into the wells of 96-well plates, with 48 replicates for 
each cell concentration. The cells were allowed to incubate for 7 days at 37°C in a 
humidified 5% CO2 incubator. Each well was scored by microscopic observation as 
positive or negative growth based on the presence or absence of cell growth. The 
frequency of proliferating neuroblastoma cells was determined by analysis of the 
number of cells plated per well and the percentage of non-proliferating cultures using 
the limiting dilution analysis method based on Poisson distribution. In brief, the 
frequency is estimated by the cell concentration in which 37% of the wells are 
negative for growth (Hay & Westwood, 2002). 
2.2.5 Clonogenic Assay 
The clonogenic assay was carried out on 24-well flat-bottomed plates (Nunc Co.) 
as described by Kobayashi et al (1989) with minor modifications. Briefly, 0.4 ml 
semi-solid agar cell culture containing 0.33% Bacto agar (Difco, Detroit, MI), RPMI 
medium with 1% PSN and 20% FCS, 2 mM glutamine and 250 untreated BU-1 cells 
was set up in each well. When the agar culture was solidified, 20 ]i\ of appropriately 
diluted DMSO or ISP-glycyrrhetinic acid was added and slowly diffused into the agar. 
The plate was then put into the 37°C 5% CO2 incubator. After 9 day incubation, the 
agar disc was rinsed out by cold PBS and dried on microscopic slides. The disc was 
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then fixed with citrate-acetone-formaldehyde solution. Cell colonies formed were 
stained with hematoxylin solution and the number of colonies with at least 50 cells 
was counted using a dissecting microscope. 
2.2.6 Measurement of Apoptosis by DNA Fragmentation Analysis 
DNA fragmentation is one of the characteristics of apoptosis. DNA fragments 
were isolated from the cells by the method of Herrmann et al (1994). Briefly, 10^  
BU-1 cells (1 X 10^ cells/ml) were seeded in a 10-cm culture dish overnight and then 
incubated with appropriate concentrations of drugs at 37°C for different periods of 
time and the DMSO-treated cells were acted as a control. Cells were harvested by 
mild trypsinization, washed with PBS and pelleted by centrifugation. The cell 
pellets were then lysed in 200 i^l of IGEPAL CA-630 lysis buffer for 10 minutes at 
37°C. After centrifugation at 7,500 rpm for 5 minutes, the supematants containing 
the DNA were collected to a new microcentrifuge tube. Fifty microliter of 5% SDS 
was added to the supernatant and the mixture was incubated with 0.4 |Lig/jLil RNase A 
at 56�C for 1.5 hours to remove the cellular RNA. Thereafter, proteinase K (at a 
final concentration of 1.5 |Lig/|iil) was added and the mixture was incubated for 1.5 
hours at 56�C to remove the proteins. The DNA was then precipitated with 0.1 
volume of 3 M sodium acetate and 2.5 volumes of absolute ethanol. After 
centrifugation at 14,000 rpm for 30 minutes, the DNA pellets were washed with 70% 
ethanol followed by absolute ethanol. The DNA pellets were then air dried for about 
10 minutes. The dried pellets were resuspended in 20 \i\ TioEo.i buffer and 
incubated at 65�C for 5 minutes. Finally, the resuspended DNA was mixed with 5X 
gel loading solution and subjected to 2% agarose gel electrophoresis. 
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2.2.7 Assessment of Apoptosis by Hoechst 33342 Staining 
The membrane-permeable Hoechst 33342 fluorescent dye has been extensively 
used for staining the nuclei of living cells. The Hoechst 33342 dye binds to the 
minor groove of DNA at AT-rich sequences and is commonly used to distinguish the 
compact chromatin of apoptotic nuclei. The apoptotic cells with condensed 
chromatin or dispersed and fragmented nuclei can be easily observed after Hoechst 
33342 staining (Huschtscha et al., 1995). Briefly, BU-1 cells (40,000 cells/well) 
were grown on sterile microscopic cover glasses (Fisher Scientific) in the wells of a 
6-well plate in a total volume of 2 ml per well. After overnight incubation, control 
solvent, glycyrrhizin, 18 P-glycyrrhetinic acid or etoposide was added and incubated at 
37°C for 48 hours. After drug treatment, the culture medium was aspirated, and the 
cells were washed with PBS and fixed with 2% paraformaldehyde in PBS for 20 
minutes at room temperature. After washing with PBS, the cells were incubated 
with Hoechst 33342 (20 |Lig/ml) in PBS for 15 minutes at room temperature. After 
washing with PBS, the stained cells were observed under a fluorescence microscope 
(Zeiss Axioskop) using (G 365, FT 395, LP 420) filter set and 20 x Plan-NEOFLUAR 
objective. Nuclei were identified as normal, fragmented or condensed. Cells with 
fragmented or condensed nuclei were classified as apoptotic. 
2.2.8 Cell Morphological Study 
Morphological study of the effects of glycyrrhizin and ISP-glycyrrhetinic acid 
on the neuronal differentiation of the neuroblastoma cells was carried out as described 
by Mak et al. (2001). BU-1 cells (5,000 cells/well) were grown on sterile thermanox 
plastic 13 mm coverslips (Nalge Nunc International) placed in the wells of a 24-well 
plate in a total volume of 0.25 ml per well overnight. Cells were then incubated with 
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different concentrations of drugs in a final volume of 0.5 ml at ?>TC for 3 - 4 days. 
After washing with PBS, the cells were stained with each Hemacolor staining 
solutions for 15 seconds. After destaining with distilled water, the coverslips were 
air dried and mounted onto glass slides with nail tonish. The morphology of the 
cells was observed under the Zeiss Axioskop microscope and photographs were taken 
at 200x magnification. Differentiation of BU-1 cells was characterized by the 
enlargement in cell size and elongation in neurite length. 
2.2.9 Immunocytochemistry 
BU-1 cells (20,000 cells/well) were grown on sterile microscopic cover glasses 
(Fisher Scientific) in the wells of a 6-well plate in a total volume of 1 ml per well. 
After overnight incubation, control solvent, glycyrrhizin or ISP-glycyrrhetinic acid 
was added and incubated at 37°C for an additional 4 days. After drug treatment, the 
culture medium was aspirated, and the cells were washed with PBS and fixed with 4% 
freshly made paraformaldehyde in PBS for 15 minutes at room temperature. After 
washing twice with PBS, cells were permeabilized by treatment with PBS containing 
0.1 % Triton X-100 for 30 minutes at room temperature. After a brief wash with 
PBS, nonspecific binding sites were blocked with 1% BSA in PBS for 3 hours. Cells 
were then washed with PBS and incubated overnight at 4°C with appropriately diluted 
rabbit anti-MAP2 (1:500) polyclonal antibody or mouse anti-Neurofilament 200 
(1:200) monoclonal antibody in PBS. Samples incubated without primary antibody 
served as negative controls. Following incubation with the primary antibody, 
cultures were extensively washed and then incubated with the appropriately diluted 
FITC-conjugated goat anti-rabbit IgG (1:100) or FITC-conjugated goat anti-mouse 
IgG (1:100) secondary antibodies in 10% goat serum for 1 hour at room temperature. 
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After the washing and drying procedures, the microscopic cover glasses with 
immunostained cells were mounted onto the glass slide with 50% glycerol as 
mounting medium, examined and photographed under a laser confocal microscope. 
A laser scanning confocal microscope (Leica Model TCS-NT) with epifluorescence 
and a phase contrast system was used. An argon/krypton laser line with a 
wavelength of 488 nm was used for excitation, and a predefined filter setting for FITC 
was used for emission. The oil immersion objective with magnification of 40 times 
(UV 40x1.25NA oil PL APO 1.25-0.75) was used for image capturing. The images 
were analyzed by the PowerScan software LEICA TCS NT 1.6.582. 
2.2.10 Flow Cytometric Analysis of Cell Cycle Profile 
The cell cycle profile of drug-treated BU-1 cells was analyzed by flow cytometry. 
Briefly, BU-1 cells (2 x 10^  cells) were seeded at a density of 10^  cells/ml in the wells 
of 6-well plates in RPMI medium supplemented with 2% HI-FCS for synchronization. 
After serum starvation overnight, the culture medium was replaced with RPMI 
medium containing 10% HI-FCS. Glycyrrhizin or 1 Sp-glycyrrhetinic acid was 
added and incubated for 1 - 3 days at 37°C. After drug treatment, cells were 
trypsinized, washed with PBS and pelleted by centrifugation at 2,000 rpm for 3 
minutes. Cells were then fixed with 70% ethanol (10^ cells/ml) at 4°C for 30 
minutes. For staining, fixed cells were centrifuged at 2,000 rpm for 10 minutes and 
washed with PBS to remove the ethanol. After removal of ethanol, cells were 
resuspended in 1 ml freshly prepared DNA staining solution containing 50 ^ig/ml 
propidium iodide (PI) and 400 |ig/ml RNase A and incubated for 1.5 hours in dark at 
room temperature. Stained cells were analyzed for fluorescence intensity with a 
fluorescence-activated cell sorter (Becton Dickinson FACSort) equipped with an 
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argon laser emitting at 488 nm, using the CellQuest software. A minimum of 10,000 
events were acquired for each determination. The percentages of cells in GQ/GI, S 
and G2/M cell cycle phases were calculated by the ModFit program (Becton 
Dickinson). 
2.2.11 Gene Expression Study 
1) Isolation of Total Cellular RNA 
Briefly, 10^  BU-1 cells (10^ cells/ml) were cultured in a 10-cm culture dish at 
37°C in a humidified 5% CO2 incubator. After overnight incubation, the cells were 
exposed to appropriate concentrations of ISp-glycyrrhetinic acid for different periods 
of time as indicated in the text. The cells were then collected by mild trypsinization 
and centrifligation at 2,000 rpm for 3 minutes at 4°C. The cell pellets were then 
lysed by 1 ml TRIZOL reagent containing guanidine thiocyanate with vigorous 
shaking. The cell lysate solutions were incubated at room temperature for 5 minutes 
to permit the complete dissociation of nucleoprotein complexes. RNA was then 
extracted by adding 200 chloroform (BDH), followed by shaking vigorously for 15 
seconds. After incubation at room temperature for 3 minutes, the mixture was 
centrifuged at 12,000 x g for 15 minutes at 4°C. Thereafter, the upper aqueous phase 
containing RNA was collected (-400 |LI1) and transferred to another new 
microcentrifuge tube. RNA was then precipitated by mixing with 500 |LI1 isopropanol 
(Merck) and standing at -20°C overnight. After centrifligation at 12,000 x g at 4°C 
for 10 minutes, the supematants were discarded and the RNA pellets were washed 
once with 1 ml ice-cold 75% ethanol. After centrifligation at 7,500 x g at 4°C for 5 
minutes, the supematants were removed by aspiration and the RNA pellets were 
air-dried for about 5 minutes. The RNA pellets were redissolved in 30 i^l 
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DEPC-treated water and stored at -70°C until use. The RNA concentration was 
quantified by spectrophotometry at 260 nm. The purity was estimated by the ratio of 
A260/A280 and was found to be between 1.6 and 1.8. Small aliquots of RNA with a 
working concentration of 0.5 )Lig/|Lil were prepared with DEPC-treated water and 
stored at —70°C. The integrity of the isolated RNA was checked by gel 
electrophoresis on 1% agarose gel and was found to be intact. 
2) Reverse Transcription (RT) 
The reverse-transcription polymerase chain reaction (RT-PCR) was used to study 
the differentiation and growth-related gene expression. One microgram of the total 
RNA was reverse transcribed in a 20 |il reaction mixture containing 40 units of 
RNASEOUT™ recombinant ribonuclease inhibitor, IX M-MLV first strand buffer, 0.5 
mM of each dNTP, 10 mM DTT, 0.1 ^g oligo(dT)I2-I8 and 200 units of M-MLV 
reverse transcriptase. The reaction mixture was incubated at 37°C for 1 hour, 
followed by 99�C for 5 minutes to inactivate the reverse transcriptase and to 
completely denature the template, and then cooled to 4 The resulting RT sample 
was stored at -20°C until use. 
3) Polymerase Chain Reaction (PGR) 
PCR was performed in a 25 reaction mixture containing cDNA equivalent to 
0.1 lag of total RNA, IX reaction buffer, 1.5 mM MgCl�，0.2 mM of each dNTPs, 1 
unit of ThermoprimePius 通八 polymerase, and 0.2 }iM of both sense and antisense 
oligonucleotide primers by the GeneAmp PCR System 9700 programmable thermal 
controller (Perkin-Elmer Co.). Cycling conditions comprised an initial denaturation 
of 5 minutes at 94°C, followed by 20 - 30 thermal cycles with denaturation at 94�C for 
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30 seconds, annealing at 52-61�C for 1 minute to 1 minute and 15 seconds and 
elongation at 72°C for 1 minute. A final extension of 5 minutes at 72°C was 
performed to complete the reaction. The annealing temperature and the number of 
PCR cycles were varied and optimized empirically for each primer set to allow the 
detection of the amplified products. 
4) Agarose Gel Electrophoresis 
The PCR products were analyzed by 2% agarose gel electrophoresis. Briefly, 5 
|Lil aliquot of PCR product was mixed with 1 of 5X gel loading buffer. The 
mixtures were electrophoresed through a 2% agarose gel in 0.5X TBE electrophoresis 
buffer at a constant voltage of 100 volts for 1.5-2 hours. Five hundred nanogram of 
100 bp DNA ladder (Gibco BRL Life Technologies, Inc.) was loaded as a size marker. 
After electrophoresis, the gel was stained with 10 |Lig/ml ethidium bromide solution 
for 5 minutes and destained with distilled water for 10 minutes. The stained gel was 
visualized and photographed by the Bio-Rad Gel Doc 2000 under UV illumination. 
5) Quantification of RT-PCR Product Band Intensity 
The gel photographs were analyzed in an objective manner by ImageQuant 
software (Molecular Dynamics) on a densitometry system. The relative intensity of 
each band of the RT-RCR product was normalized after dividing by the relative 
intensity of the corresponding band of GAPDH, and the relative intensity of each 
GAPDH band in the experimental group was expressed as the fraction of the control 
GAPDH band which was taken as unity. 
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2.2.12 Protein Expression Study 
1) Treatment of Cells and Protein Extraction 
In brief, 1.5 x 10^ BU-1 cells (1.5 x 10^  cells/ml) were cultured in a 10-cm 
culture dish overnight. Cells were then either treated with DMSO as a control or 
with different concentrations of ISp-glycyrrhetinic acid for different periods of time 
as indicated in the text at 37°C. The cells were harvested by mild trypsinization, 
washed with cold PBS and collected by centrifugation at 2,000 rpm for 3 minutes at 
4°C. Cell pellets were then resuspended and vortexed vigorously with lysis buffer 
and stand on ice for at least 30 minutes. The cell lysates were clarified by 
centrifugation at 14,000 rpm for 5 minutes at 4°C, and the resulting supematants were 
collected and stored at -20°C until further assay. 
2) Quantification of Proteins 
The protein content of the cell lysate was estimated by the Bio-Rad protein assay 
with bovine serum albumin (BSA) as standard. BSA solutions at 2 jug/ml, 4 |Lig/ml, 6 
l^g/ml, 8 i^g/ml, and 10 |ig/ml were prepared with double distilled water in duplicate 
with 2 mg/ml BSA stock solution. Two microliters protein samples were diluted 
with 1,598 lull double distilled water. Diluted BSA standards or protein samples (800 
111) were mixed with 200 of Bio-Rad protein assay dye reagent concentrate. The 
reaction mixtures were allowed to stand at room temperature for 5 minutes before the 
absorbance at 595 nm was recorded using the dye reagent as a blank. The 
concentrations of the protein samples were determined spectrophotometrically by 
BioPhotometer (Eppendorf) and an equal amount of the protein (25 |ag) was subjected 
to SDS-PAGE after equalizing the amount of protein loaded per lane. 
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3) Western Blot Analysis 
SDS-PAGE was carried out to separate the proteins according to the molecular 
weights before Western blotting. The percentage of acrylamide added in the running 
gel varied according to the molecular weight of the target protein being separated. 
Table 2.2 shows the composition of the chemical reagents needed for various 
percentages of SDS-polyacrylamide gel. Samples containing the same amount of 
protein (25 |Lig) were mixed with an equal volume of 2X SDS gel loading buffer and 
boiled for 10 minutes before loading onto the SDS-polyacrylamide gel with a 5% 
stacking gel. Eight microliters of Kaleidoscope prestained standards was loaded as 
molecular weight marker and the gel was run under constant voltage of 100 volts for 2 
to 3 hours. 
Table 2.2: Composition of the SDS-polyacrylamide gel. 
Separating Gel (5ml) 
Reagents 5 % Stacking Gel (3 ml)  
各 7.5% 10% 12% 
Distilled water 1.65 ml 2.4 ml 2 ml 1.65 ml 
Lower Buffer - 1.25 ml 1.25 ml 1.25 ml 
Upper Buffer 0.75 ml - - -
30% Acrylamide Stock 0.5 ml 1.25 ml 1.665 ml 2 ml 
10% SDS 30 III 25 25 jil 25 \x\ 
10% APS 40 III 75 1^1 75 jul 75 jul 
TEMED 3 III 2 2 2 |il 
After electrophoresis, the stacking gel was cut and removed. The gel was 
rinsed with distilled water for 10 minutes to remove SDS that could hinder the protein 
transfer. Thereafter, the gel was soaked in transfer buffer for 10 minutes. Three 
pieces of 3 MM Whatman chromatography papers soaked with transfer buffer were 
placed on the semi-dry blotting apparatus (Bio-Rad Laboratories). They were then 
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covered by one piece of PVDF membrane activated by soaking in 100% methanol for 
2 seconds and in transfer buffer for 10 minutes. The gel was carefully placed on the 
membrane and three more pieces of chromatography papers soaked with transfer 
buffer were placed on the gel. Finally, air bubbles were excluded by rolling a glass 
tube on the whole pack. The proteins on the gel were then electroblotted onto the 
PVDF membrane at 16 volts for 35 minutes. After the transfer, the membrane with 
transferred proteins was washed with washing buffer and incubated with 5% skimmed 
milk blocking solution with constant rotation at room temperature for at least 1 hour 
to block the non-specific sites for probing. The membrane was then incubated with 
the desired primary antibody diluted at a ratio of 1:250 - 1:100,000 in 5% skimmed 
milk at 4°C overnight. After blotting with primary antibody, the membrane was 
washed for 20 minutes with three changes of washing buffer. After washing, the 
membrane was incubated with the corresponding appropriately diluted (1:1,000) 
horseradish peroxidase-linked secondary antibody in washing buffer for one hour at 
room temperature. Incubation was followed by four washes in washing buffer for 20 
minutes. After a final round of washing, the membrane was subjected to ECL assay. 
4) ECL Assay 
ECL™ detection reagent 1 (0.5 ml) was freshly mixed with 0.5 ml of detection 
reagent 2 and poured onto the membrane. The membrane was then immersed in the 
reagent mixture and allowed to react for 1 minute. Excess reagent mixture was 
removed by holding the membrane vertically and touching the edge of the membrane 
against tissue paper. The membrane covered with Glad Wrap, with the protein side 
up, was placed in the film cassette. A sheet of X-ray film (Fuji, Japan) was then 
carefully placed on top of the membrane and allowed to expose in dark for times 
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varying from 30 seconds to 5 minutes. Finally, the film was developed and the 
immunoreactive bands could be visualized on the X-ray film. Semi-quantitative 
scanning densitometry was performed using the ImageQuant software (Molecular 
Dynamics). Bands for analysis were outlined and their volumes were integrated to 
obtain an indication of band density. The densitometric values were normalized with 
respect to the value obtained for a control protein ((3-actin) in order to correct for any 
deviation in the loaded protein. 
2.2.13 Statistical Analysis 
Each experiment was performed at least twice and the results of only one 
representative experiment were presented. All data were presented as arithmetic 
mean 士 standard error. The Student's 广-test was used for statistical comparison of 
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3.1 Introduction 
Herbs have been used for medicinal purposes for centuries. Herbal medicine is 
based on the premise that plants contain natural substances that promote health and 
alleviate illness. A variety of herbs and herbal extracts contain different 
phytochemicals with a wide range of biological activities that may have therapeutic 
effects. Moreover, many Western drugs have their origin in a plant extract (Craig, 
1999). The traditional Chinese medicine licorice {Glycyrrhiza glabra L.) has been 
widely used for the treatment of cough, bronchitis, peptic ulcer, gastritis, adrenal 
insufficiency and urinary tract inflammation (Mills & Bone, 2000). Recently, 
research interest has focused on herbs that possess anti-tumor or immune-stimulating 
properties that may be useful adjuncts which can help to reduce the risk of cancer. 
Glycyrrhizin, a major component of licorice root, is a sweet-tasting triterpenoid 
saponin. Glycyrrhizin and its aglycone, glycyrrhetinic acid, have been reported to 
possess anti-mutagenic, anti-carcinogenic, anti-tumor, anti-inflammatory, anti-viral, 
immunomodulatory and hepatoprotective activities (Mills & Bone, 2000; Wang & 
Nixon, 2001). 
Earlier work had shown that glycyrrhizin and ISp-glycyrrhetinic acid could 
inhibit the growth of B16 melanoma cells (Abe et al., 1987), SupTl non-Hodgkin's 
lymphoma cells, JJhan and HSB-2 chronic myeloid leukemia cells in vitro (Malagoli 
et al., 1998). More recently, glycyrrhizin and ISP-glycyrrhetinic acid were found to 
inhibit the growth of myeloid leukemia cells in vitro by inducing the apoptosis and 
differentiation of the leukemia cells (Tsang, 2001). These studies showed that 
glycyrrhizin and ISP-glycyrrhetinic acid could inhibit the growth of various types of 
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cancer cells in vitro. A recent report showed that euxanthone isolated from the 
medicinal plant Polygala caudata could inhibit the growth and induce the 
differentiation of neuroblastoma cells (Mak et al., 2000). To our knowledge, 
however, there has been no report demonstrating the effect of glycyrrhizin and 
ISp-glycyrrhetinic acid, the major active constituents of licorice, on the growth of 
neuroblastoma cells. Therefore, in this chapter, attempts have been made to 
investigate the effects of glycyrrhizin and ISp-glycyrrhetinic acid on neuroblastoma 
cells and to further elucidate their anti-tumor mechanisms. Firstly, the differential 
anti-proliferative and cytotoxic effects of glycyrrhizin and 18p-glycyrrhetinic acid on 
various murine and human neuroblastoma cell lines were studied. In addition, the 
kinetics and reversibility of glycyrrhizin and ISP-glycyrrhetinic acid with respect to 
their anti-proliferative effect on a murine neuroblastoma cell line (Neuro-2a, subclone 
BU-1 cells) were examined. Furthermore, the ability of glycyrrhizin and 
ISP-glycyrrhetinic acid to induce apoptosis in BU-1 cells was also investigated. 
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3.2 Results 
3.2.1 Differential Anti-proliferative Effect of Glycyrrhizin and 
18P-Glycyrrhetinic Acid on Various Neuroblastoma Cell Lines In Vitro 
The effect of glycyrrhizin and ISP-glycyrrhetinic acid on the proliferation of 
3 * • 
neuroblastoma cells was studied using tritiated thymidine ( H-TdR) incorporation 
assay. The incorporation of labeled DNA precursor, H-TdR, into the DNA of the 
cells is directly proportional to the extent of cell proliferation. Two human and one 
murine neuroblastoma cell lines with appropriate cell density were treated with 
various concentrations of glycyrrhizin and ISP-glycyrrhetinic acid for 48 hours as 
indicated in the figures and the amount of radioactivity incorporated into DNA was 
measured. It was found that both glycyrrhizin and ISp-glycyrrhetinic acid could 
inhibit the proliferation of the murine neuroblastoma BU-1 cells (Figure 3.1 & 3.4), 
and the human neuroblastoma SK-N-DZ (Figure 3.2 & 3.5), and SH-SY5Y (Figure 
3 . 3 & 3 . 6 ) cells in a dose-dependent manner. The estimated IC50 values of 
glycyrrhizin and ISP-glycyrrhetinic acid at 48 hours of incubation were summarized 
in Table 3.1. 
It is interesting to note that at lower concentrations of ISP-glycyrrhetinic acid (< 
80 jiM), the anti-proliferative effect on murine and human neuroblastoma cells was 
minimal but it was sharply increased at concentrations > 80 \iM (Figure 3.4 - 3.6). 
As indicated in Table 3.1, different neuroblastoma cell lines had differential 
sensitivity to the anti-proliferative effect of glycyrrhizin and ISP-glycyrrhetinic acid. 
By comparing the IC50 values at 48 hours of treatment, the SK-N-DZ and BU-1 cells 
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were found to be more sensitive to the anti-proliferative effect of glycyrrhizin than the 
SH-SY5Y cells, with an estimated IC50 value of about 3 mM. On the other hand, the 
BU-1 cells were found to be the most sensitive cells in response to ISP-glycyrrhetinic 
acid, with an estimated IC50 value of about 75 juM. The proliferation of 
neuroblastoma cells was completely inhibited by ISP-glycyrrhetinic acid at a 
concentration of 120 - 130 jiM but no complete inhibition of cell proliferation was 
achieved at the highest concentration of glycyrrhizin (4.5 mM) tested in this study. 
This suggests that 1 Sp-glycyrrhetinic acid was more potent than glycyrrhizin as it 
inhibited the growth of neuroblastoma cells at micromolar level while glycyrrhizin 
inhibited the growth of neuroblastoma cells at millimolar level. 
The neutral red assay was also used as a non-radioactive method for the 
measurement of cellular proliferation of BU-1 cells after 48 hours of treatment with 
different concentrations of glycyrrhizin and ISp-glycyrrhetinic acid. The uptake, 
transport, and storage of neutral red dye occurs via active biological processes that 
require energy, as well as intact cellular and lysosomal membranes. Viable cells take 
up the neutral red dye and transport it to a specific cellular compartment, the 
lysosome. Damage to any of the systems involved in the process or a reduction in 
cell number due to cell death would result in decreased uptake of the neutral red dye. 
Therefore, the number of viable cells can be indicated by the amount of neutral red 
taken up by the cells. The neutral red taken up by the cells was released by 1% SDS 
and can be quantified by measuring the absorbance at 540 nm which reflects the 
number of viable cells. 
The results of neutral red assay (Figure 3.7 & 3.8) showed that glycyrrhizin and 
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ISP-glycyrrhetinic acid caused a dose-dependent reduction in the absorbance 
measured at 540 nm, indicating that glycyrrhizin and ISp-glycyrrhetinic acid exerted 
an inhibitory effect on the growth of BU-1 cells in vitro. Moreover, the results were 
similar to that of H-TdR incorporation assay although the estimated IC50 values were 
slightly higher than that of ^H-TdR incorporation assay. Due to the higher sensitivity 
of the ^H-TdR incorporation assay, it was the method of choice for measuring the 
proliferation of neuroblastoma cells in all subsequent experiments. 
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Figure 3.1: Anti-proliferative effect of glycyrrhizin on the murine neuroblastoma 
Neuro-2a BU-1 cells as determined by the tritiated thymidine incorporation 
assay. BU-1 cells (7.5 x cells/ml) were cultured overnight and incubated with 
different concentrations (0 - 4.5 mM) of glycyrrhizin at 37�C for 48 hours and were 
pulsed with 0.5 jaCi of ^H-TdR during the last 6 hours. Radioactivity expressed as 
counts per minute (cpm), was measured using a Beckman liquid scintillation counter. 
Results were expressed as % inhibition of ^H-TdR incorporation, using the untreated 
cells as a control. Each point represents the mean 土 S.E. of quadruplicate cultures. 
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Figure 3.2: Anti-proliferative effect of glycyrrhizin on the human neuroblastoma 
SK-N-DZ cells as determined by the tritiated thymidine incorporation assay. 
SK-N-DZ cells (10^ cells/ml) were cultured overnight and incubated with different 
concentrations (0 - 4.5 mM) of glycyrrhizin at 37�C for 48 hours and were pulsed 
with 0.5 i^Ci of ^H-TdR during the last 10 hours. Radioactivity expressed as counts 
per minute (cpm), was measured using a Beckman liquid scintillation counter. 
Results were expressed as % inhibition of ^H-TdR incorporation, using the untreated 
cells as a control. Each point represents the mean 土 S.E. of quadruplicate cultures. 
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Figure 3.3: Anti-proliferative effect of glycyrrhizin on the human neuroblastoma 
SH-SY5Y cells as determined by the tritiated thymidine incorporation assay. 
SH-SY5Y cells (1.5 x 10^  cells/ml) were cultured overnight and incubated with 
different concentrations (0 - 4.5 mM) of glycyrrhizin at 37°C for 48 hours and were 
pulsed with 0.5 jdCi of ^H-TdR during the last 10 hours. Radioactivity expressed as 
counts per minute (cpm), was measured using a Beckman liquid scintillation counter. 
Results were expressed as % inhibition of ^H-TdR incorporation, using the untreated 
cells as a control. Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Figure 3.4: Anti-proliferative effect of 18p-glycyrrhetinic acid on the murine 
neuroblastoma Neuro-2a BU-1 cells as determined by the tritiated thymidine 
incorporation assay. BU-1 cells (7.5 x 10^  cells/ml) were cultured overnight and 
incubated with different concentrations (0 - 120 ^iM) of 18P-glycyrrhetinic acid at 
37�C for 48 hours and were pulsed with 0.5 \iCi of ^H-TdR during the last 6 hours. 
Radioactivity expressed as counts per minute (cpm), was measured using a Beckman 
liquid scintillation counter. Results were expressed as % inhibition of ^H-TdR 
incorporation, using the untreated cells as a control. Each point represents the mean 
土 S.E. of quadruplicate cultures. 
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Figure 3.5: Anti-proliferative effect of ISP-glycyrrhetinic acid on the human 
neuroblastoma SK-N-DZ cells as determined by the tritiated thymidine 
incorporation assay. SK-N-DZ cells (10^ cells/ml) were cultured overnight and 
incubated with different concentrations (0 - 130 |aM) of ISP-glycyrrhetinic acid at 
37°C for 48 hours and were pulsed with 0.5 of ^H-TdR during the last 10 hours. 
Radioactivity expressed as counts per minute (cpm), was measured using a Beckman 
liquid scintillation counter. Results were expressed as % inhibition of H-TdR 
incorporation, using the untreated cells as a control. Each point represents the mean 
± S.E. of quadruplicate cultures. 
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Figure 3.6: Anti-proliferative effect of ISP-glycyrrhetinic acid on the human 
neuroblastoma SH-SY5Y cells as determined by the tritiated thymidine 
incorporation assay. SH-SY5Y cells (1.5 x 10^  cells/ml) were cultured overnight 
and incubated with different concentrations (0 - 130 of ISP-glycyrrhetinic acid at 
37°C for 48 hours and were pulsed with 0.5 \iCi of ^H-TdR during the last 10 hours. 
Radioactivity expressed as counts per minute (cpm), was measured using a Beckman 
liquid scintillation counter. Results were expressed as % inhibition of H-TdR 
incorporation, using the untreated cells as a control. Each point represents the mean 
土 S.E. of quadruplicate cultures. 
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Table 3.1: The estimated IC50 values of glycyrrhizin and ISP-glycyrrhetinic acid 
on various neuroblastoma cell lines after 48 hours of treatment. 
Estimated ICgn Value 







SK-N-DZ 3 97 
Neuroblastoma 
Human 
SH-SY5Y > 4.5 93 
Neuroblastoma 
IC50 value is the estimated concentration of glycyrrhizin or 18p-glycyrrhetinic acid 
which can cause 50% inhibition of ^H-TdR incorporation under the specified 
experimental conditions. 
“ “ ‘ 









i 2 � - X 
I  
—~I 1 1 1  
0 1 2 3 4 5 
Concentration of Glycyrrhizin (mM) 
Figure 3.7: Anti-proliferative effect of glycyrrhizin on the murine neuroblastoma 
BU-1 cells as determined by the neutral red assay. BU-1 cells (7.5 x lO"^  cells/ml) 
were cultured overnight and incubated with different concentrations (0 — 4.5 mM) of 
glycyrrhizin at 37�C for 48 hours and cell proliferation was determined by the neutral 
red assay as described under Materials and Methods. Results were expressed as % 
decrease in absorbance measured at 540 nm, using the untreated cells as a control. 
Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Figure 3.8: Anti-proliferative effect of 18p-glycyrrhetinic acid on the murine 
neuroblastoma BU-1 cells as determined by the neutral red assay. BU-1 cells 
(7.5 X 10^  cells/ml) were cultured overnight and incubated with different 
concentrations (0 - 120 [M) of 18p-glycyrrhetinic acid at 37�C for 48 hours and cell 
proliferation was determined by the neutral red assay as described under Materials 
and Methods. Results were expressed as % decrease in absorbance measured at 540 
nm, using the untreated cells as a control. Each point represents the mean 土 S.E. of 
quadruplicate cultures. 
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3.2.2 Effect of ISp-Glycyrrhetinic Acid on the Clonogenicity of the Murine 
Neuroblastoma BU-1 Cells In Vitro 
In the clonogenic assay, the ability of a single cell to divide enough times to form 
a visible, countable colony is evaluated. The ability to form colonies is a measure of 
the reproductive integrity or the proliferative capability of a cell population and this 
assay is widely used to determine the effect of cytostatic/cytotoxic agents on tumor 
cells in vitro. Since 18p-glycyrrhetinic acid exhibited potent anti-proliferative effect 
on BU-1 cells in vitro, its influence on the clonogenicity of BU-1 cells in vitro was 
also examined. It was found that the colony-forming ability of 1813-glycyrrhetinic 
acid-treated BU-1 cells in soft agar was markedly reduced when compared with the 
control cells. Moreover, this effect seems to be dose-dependent with the cloning 
efficiency reduced from 44.13% for DMSO-treated control BU-1 cells to 22.53% and 
12.53% for 80 |LIM and 100 [iM ISp-glycyrrhetinic acid-treated cells, respectively 
(Table 3.2). 
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Table 3.2: Effect of 18p-glycyrrhetinic acid on the colony-forming ability of BU-1 
cells in soft agar. 
Concentration of Number of colonies % Cloning efficiency in 
ISP-glycyrrhetinic acid (|LIM) formed in soft agar soft agar 
DMSO control 110±6.51 44.13 ±2.60 
^ 56 ±3.06* 22.53 ±1.22* 
31 ±2.52* 12.53 土 1.01 * 
BU-1 cells (250 cells in each well of the soft agar plate) were incubated with two 
different concentrations of 18|3-glycyrrhetinic acid (80 and 100 ^iM) at 37�C for 9 
days. After staining with hematoxylin, the number of colonies containing more than 
50 cells was counted. The results of triplicate cultures were expressed as % cloning 
efficiency in soft agar, which represents the number of colonies per 100 cells initially 
plated in soft agar plate. * p < 0.01 vs. DMSO control. 
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3.2.3 Kinetic and Reversibility Studies of the Anti-proliferative Effect of 
Glycyrrhizin and ISP-Glycyrrhetinic Acid on the Neuroblastoma BU-1 
Cells 
Kinetic study using the well-characterized and subcloned murine neuroblastoma 
BU-1 cells showed that glycyrrhizin and 18p-glycyrrhetinic acid inhibited the 
proliferation of the neuroblastoma cells time-dependently (Figure 3.9 & 3.10) and 
marked inhibition of BU-1 cell proliferation was observed after 24 hours of treatment. 
However, for both glycyrrhizin and ISP-glycyrrhetinic acid treatment, only a slight 
difference in the extent of growth inhibition was found between 24 and 48 hours of 
incubation although maximum inhibition of cell growth was obtained after 48 hours 
of treatment. 
To test whether the neuroblastoma cells resume proliferation after the removal of 
drugs, reversibility study was performed. In this study, the cells were treated either 
with 70 and 80 jiiM ISP-glycyrrhetinic acid or 3.5 and 4.5 mM glycyrrhizin and the 
culture medium containing the drug was removed, replaced with fresh culture medium 
8 or 24 hours after drug addition, and the ^H-TdR incorporation assay was performed 
48 hours after the initiation of experiment. As shown in Figure 3.11, exposure of the 
BU-1 cells to glycyrrhizin and ISp-glycyrrhetinic acid for only 8 or 24 hours still 
resulted in growth inhibition although the percentage inhibition was less than that 
observed with 48 hours of drug treatment. Moreover, the effect of glycyrrhizin on 
BU-1 cells seems to be more reversible than that of 18p-glycyrrhetinic acid since the 
BU-1 cells were more capable of regaining proliferation after removal of glycyrrhizin 
and the percentage inhibition of cell growth decreased to less than 20%. 
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Furthermore, for both treatments with glycyrrhizin and ISp-glycyrrhetinic acid, the 
higher the concentration of drugs used, the greater the growth inhibitory effect was 
observed despite the drug was removed. Therefore, the capability of neuroblastoma 
cells to recover from treatment with glycyrrhizin or ISP-glycyrrhetinic acid was 
dependent on both drug concentration and duration of incubation. 
Besides the reversibility test, limiting dilution assay was also employed to 
determine the proliferating potential of BU-1 cells after drug treatment. This assay 
system is efficient and provides an informative method to quantitatively analyze the 
responding cell frequencies. BU-1 cells treated with glycyrrhizin or 
18|3-glycyrrhetinic acid for 4 days were harvested and seeded into the wells of 
96-well flat-bottomed plates with different cell densities for 7 days and finally the 
fraction of negative wells in log scale was plotted against each cell concentration. 
The frequency of proliferative cells was estimated by the cell concentration in which 
37% of the wells were negative for growth. 
As shown in Figure 3.12, the frequency of proliferative cells in medium control 
was 1 in 1.6 while treatment of BU-1 cells with 3.5 mM glycyrrhizin for 4 days 
reduced the frequency of proliferative cells to 1 in 6. Moreover, Figure 3.13 shows 
that the frequency of proliferative cells after 4 days of treatment with 80 jiiM 
ISP-glycyrrhetinic acid declined from 1 in 1.9 of solvent control to 1 in 7.9 of 
drug-treated cells. These results confirmed that both glycyrrhizin and 
18p-glycyrrhetinic acid could exert some irreversible changes to the BU-1 cells so 
that the proliferating potential of drug-treated cells decreased despite the drugs were 
removed. 
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Figure 3.9: Kinetic study on the anti-proliferative effect of glycyrrhizin on the 
murine neuroblastoma BU-1 cells. BU-1 cells (7.5 x ceils/ml) were cultured 
overnight and incubated with different concentrations (0 - 4.5 mM) of glycyrrhizin at 
37�C for different periods of time (8, 24 or 48 hours). Cultures were then pulsed 
with 0.5 \xCi of ''H-TdR for 6 hours before harvest. Radioactivity expressed as 
counts per minute (cpm), was measured using a Beckman liquid scintillation counter. 
Results were expressed as % inhibition of '^ H-TdR incorporation, using the untreated 
cells as a control. Each point represents the mean 土 S.E. of quadruplicate cultures. 
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Figure 3.10: Kinetic study on the anti-proliferative effect of ISp-glycyrrhetinic 
acid on the murine neuroblastoma BU-1 cells. BU-1 cells (7.5 x Kf cells/ml) 
were cultured overnight and incubated with different concentrations (0 - 120 ^M) of 
ISP-glycyrrhetinic acid at 37�C for different periods of time (8, 24 or 48 hours). 
Cultures were then pulsed with 0.5 jiiCi of "^ H-TdR for 6 hours before harvest. 
Radioactivity expressed as counts per minute (cpm), was measured using a Beckman 
liquid scintillation counter. Results were expressed as % inliibition of H-TdR 
incorporation, using the untreated cells as a control. Each point represents the mean 
土 S.E. of quadruplicate cultures. 
- 9 6 - “ ~ 
Chapter 3 Anti-proliferative Effects 
100 
•Drug removal after 8 hours of treatment ! 
• Drug removal after 24 hours of treatment 丨 








i r - n r i -
I 20 -
0 I r ^ H I i f l ——r^-Tl ——ll 
70 i^M GA 80 i^ M GA 3.5 mM GL 4.5 mM GL 
Figure 3.11: Reversibility study on the anti-proliferative effect of 
18j3-glycyrrhetinic acid (GA) and glycyrrhizin (GL) on the murine 
neuroblastoma BII-1 cells. BU-1 ceils (7.5 x 10"^  cells/ml) were cultured overnight 
and incubated with two different concentrations (70 or 80 juiM) of 18p-glycyrrhetimc 
acid (GA) and two different concentmtions (3.5 or 4.5 mM) of glycyrrhizin (GL) at 
37°C. Drugs were removed and replaced by fresh culture medium at the 
corresponding time periods (8 or 24 hours after drug addition) and all cultures were 
incubated up to 48 hours after drug addition. Cultures were then pulsed with 0.5 juCi 
of ^H-TdR for 6 hours before harvest. Radioactivity expressed as counts per minute 
(cpm), was measured using a Beckman liquid scintillation counter. Results were 
expressed as % inhibition of ^H-TdR incorporation, using the untreated cells as a 
control Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Figure 3.12: Frequency analysis of proliferative BU-1 cells after 4 days of 
treatment with glycyrrhizin (GL). BU-1 cells (2.5 x 10^  cells/ml) were cultured 
overnight and incubated with either culture medium (solid circle) or 3.5 mM 
glycyrrhizin (open circle) in the wells of a 6-well plate for 4 days. The cells were 
then washed and various concentrations of viable cells were seeded into the wells of 
96-well plates, with 48 replicates for each cell concentration. The cells were 
incubated for 7 days at 37°C in a humidified 5% CO2 incubator. The frequency of 
proliferating neuroblastoma cells indicated in the figure was determined as stated 
under Materials and Methods. 
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Figure 3.13: Frequency analysis of proliferative BU-1 cells after treatment with 
ISP-glycyrrhetinic acid (GA). BU-1 cells (2.5 x cells/ml) were cultured 
overnight and incubated with either DMSO control solvent (solid circle) or 80 [iM 
18p-glycyrrhetinic acid (open circle) in the wells of a 6-well plate for 4 days. The 
cells were then washed and various concentrations of viable cells were seeded into the 
wells of 96-well plates, with 48 replicates for each cell concentration. The cells 
were incubated for 7 days at 37�C in a humidified 5% CO2 incubator. The frequency 
of proliferating neuroblastoma cells indicated in the figure was determined as stated 
under Materials and Methods. 
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3.2.4 Cytotoxic Effect of Glycyrrhizin and ISp-Glycyrrhetinic Acid on the 
Neuroblastoma BU-1 Cells In Vitro 
To determine whether the anti-proliferative effect of glycyrrhizin and 
18p-glycyrrhetinic acid was due to their direct cytotoxicity on the treated cells, the 
viability of glycyrrhizin- and 18p-glycyrrhetinic acid-treated murine neuroblastoma 
BU-1 cells was examined by the trypan blue exclusion assay after 48 hours of 
treatment, an incubation time that yielded maximum inhibition of neuroblastoma cell 
proliferation. It was found that at all concentrations of glycyrrhizin and 
18p-glycyrrhetinic acid tested, the percentage of viable cells remained over 90% after 
48 hours of treatment (Table 3.3). This suggests that glycyrrhizin and 
18p-glycyrrhetinic acid did not exhibit any significant direct cytotoxic activity on the 
neuroblastoma cells. Taken together with the findings of previous experiments, it is 
believed that glycyrrhizin and ISP-glycyrrhetinic acid exert a cytostatic rather than 
cytotoxic effect on the neuroblastoma cells. 
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Table 3.3: Effect of glycyrrhizin and ISP-glycyrrhetinic acid on the viability of 
the murine neuroblastoma BU-1 cells in vitro, 
BU-1 cells treated with Concentration (mM) Cell viability (%) 
0 95.40 ±0.004 
1 93.79 ±0.015 
Glycyrrhizin 2 95.94 ±0.002 
3 95.03 ±0.012 
4 96.49 士 0.007 
96.91 土 0.003 
0 97.12 ±0.004 
^ 96.97 ±0.001 
18p-Glycyrrhetinic acid ^ 97.14 ±0.009 
^ 97.60 土 0.009 
^ 95.60 士 0.007 
0.12 95.29 ±0.009 
BU-1 cells (7.5 x lO* cells/ml) were cultured overnight and incubated with different 
concentrations of glycyrrhizin (0 - 4.5 mM) or 18P-glycyrrhetinic acid (0 - 0.12 mM) 
at 37°C for 48 hours. Cell viability was determined by the trypan blue exclusion test, 
and the results were expressed as mean % of viable cells 土 S.E. of triplicate cultures. 
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3.2.5 Inability of Glycyrrhizin and ISP-Glycyrrhetinic Acid to Induce DNA 
Fragmentation in the Neuroblastoma BU-1 Cells 
Recent researches have shown that induction of apoptosis is one of the 
anti-tumor mechanisms of natural products (Okabe et al., 1999; Ahmad et al., 2000). 
Morphological changes of apoptosis include shrinkage of cells and nuclei, chromatin 
condensation, and fragmentation into membrane-bound apoptotic bodies (Saraste & 
Pulkki, 2000). Moreover, the occurrence of DNA ladder is the result of cleavage of 
DNA by endonucleases (Herrmann et al., 1994). 
In the present study, the ability of glycyrrhizin and 18P-glycyrrhetinic acid to 
induce apoptosis in BU-1 cells was examined by DNA fragmentation assay. As 
shown in Figure 3.14, at all concentrations of glycyrrhizin and ISP-glycyrrhetinic 
acid tested, no DNA laddering was observed after 48 hours. No DNA fragmentation 
can be detected even after 72 hours of treatment with glycyrrhizin and 
18p-glycyrrhetinic acid (data not shown). Possible explanations for this could be 
due to the inability of glycyrrhizin and ISp-glycyrrhetinic acid to induce apoptosis in 
the BU-1 cells or due to the intrinsic property of BU-1 cells. In order to test whether 
BU-1 cells were intrinsically resistant to apoptosis induction or glycyrrhizin and 
ISP-glycyrrhetinic acid were incapable of inducing apoptosis in BU-1 cells, a well 
known apoptosis inducing agent, etoposide was employed in my study. The results 
showed that BU-1 cells responded dose-dependently to etoposide to give DNA 
ladders while glycyrrhizin and ISP-glycyrrhetinic acid failed to induce apoptosis 
(Figure 3.15). 
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In addition to the DNA fragmentation assay, Hoechst 33342 staining was also 
used to study the apoptosis-inducing capability of glycyrrhizin and ISp-glycyrrhetinic 
acid. In agreement with the DNA fragmentation assay, treatment with 4.5 mM 
glycyrrhizin and 100 ]iM ISP-glycyrrhetinic acid failed to induce apoptosis in BU-1 
cells, and giving the appearance of round and intact nuclei after staining with Hoechst 
33342 dye (Figure 3.16B & 3.16C). However, treatment of BU-1 cells with 1 |LIM 
etoposide as a positive control induced apoptosis of the cells, as evidenced by the 
formation of condensed chromatin and fragmented nuclei (Figure 3.16D). These 
results suggest that both glycyrrhizin and ISP-glycyrrhetinic acid are incapable of 
inducing apoptosis in BU-1 cells under the prescribed experimental conditions. 
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Figure 3.14: Inability of glycyrrhizin and 1 SP-glycyrrhetinic acid to induce 
apoptosis in the murine neuroblastoma BU-1 cells. BU-1 cells (10^ cells/ml) were 
cultured overnight and treated with control solvent ( L a n e s 2 & 6)，80 - 1 2 0 j u M 
ISP-glycyrrhetinic acid (Lanes 3 - 5) or 1.5 - 4.5 mM glycyrrhizin (Lanes 7 - 9) at 
37°C for 48 hours. DNA were extracted by mild detergent IGEPAL CA-630 lysis 
buffer, and analyzed by electrophoresis on 2% agarose gel stained with ethidium 
bromide. 
Lane 1: 100 bp D N A markers 
Lane 2: DMSO-treated cells Lane 6: Untreated cells 
Lane 3: With 80 |uM 18(3-glycyrrhetinic acid Lane 7: With 1.5 m M glycyrrhizin 
Lane 4: With 100 |LIM 18p-glycyrrhetinic acid Lane 8: With 3 m M glycyrrhizin 
Lane 5: With 120 |LIM 18(3-glycyrrhetinic acid Lane 9: With 4.5 m M glycyrrhizin 
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Figure 3.15: Inability of glycyrrhizin and ISP-glycyrrhetinic acid to induce 
apoptosis in the murine neuroblastoma BU-1 cells. BU-1 cells (10^ cells/ml) 
were cultured overnight and treated with control solvent (Lane 2), 100 \iM 
ISp-glycyrrhetinic acid (Lane 3)，4.5 mM glycyrrhizin (Lane 4) or 0.1 - 2.5 jLiM 
etoposide (Lanes 5 - 7) at 37�C for 48 hours. DNA were extracted by mild detergent 
IGEPAL CA-630 lysis buffer, and analyzed by electrophoresis on 2% agarose gel 
stained with ethidium bromide. 
Lane 1: 100 bp D N A markers 
Lane 2: DMSO-treated cells Lane 5: With 0.1 fiM etoposide 
Lane 3: With 100 fiM ISP-glycyrrhetinic acid Lane 6: With 0.5 \iM etoposide 
Lane 4: With 4.5 m M glycyrrhizin Lane 7: With 2.5 |iM etoposide 
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Figure 3.16: Fluorescent images of Hoechst 33342 stained BU-1 cells. BU-1 cells 
(40,000 cells/well) grown overnight on cover glasses in the wells of a 6-well plate 
were incubated with (A) control solvent (0.17% DMSO), (B) 4.5 mM glycyrrhizin, (C) 
100 [iM 18P-glycyrrhetinic acid or (D) 1 (iM etoposide (a positive control) at 37�C 
for 48 hours. The cells were stained with Hoechst 33342 as described under 
Materials and Methods. The apoptotic cells were indicated by white arrows. 
(Magnification x 200) 
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3.3 Discussion 
In this chapter, the effects of the glycyrrhizin and ISP-glycyrrhetinic acid on the 
proliferation of neuroblastoma cells were investigated, using well-characterized 
murine and human neuroblastoma cell lines as the cellular models. In the present 
study, both glycyrrhizin and ISP-glycyrrhetinic acid were found to inhibit the 
proliferation of murine and human neuroblastoma cells in a dose-dependent manner 
as determined by the ^H-TdR incorporation assay and the neutral red assay. 
Moreover, the effect of 18p-glycyrrhetinic acid was found to be more pronounced 
than glycyrrhizin as it exerted its effect at micromolar concentrations. The results 
are in agreement with an earlier finding that the effective concentration of 
glycyrrhizin to inhibit the growth of B16 melanoma cells was about 20 times more 
than that required for glycyrrhetinic acid (Abe et al., 1987). It had been suggested 
that the difference in the effects of glycyrrhizin and glycyrrhetinic acid on the cell 
membrane caused the different efficacy in cell growth inhibition (Abe et al., 1987). 
Similarly, 18p-glycyrrhetinic acid was found to be a more potent anti-hepatotoxic 
agent than glycyrrhizin both in vitro and in vivo, and it had been suggested that the 
higher potency of ISP-glycyrrhetinic acid could be attributed to its higher 
adsorbability in hepatocytes (Nose et al., 1994). Furthermore, it is interesting to 
note that the shape of the growth inhibition curve for the glycyrrhizin- and 
ISP-glycyrrhetinic acid-treated neuroblastoma BU-1 cells was different (growth 
inhibition of cells increased gradually with increasing concentration of glycyrrhizin vs. 
growth inhibition of cells increased sharply within a narrow range of 
1 sp-glycyrrhetinic acid concentration). The reason for the difference in the growth 
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inhibition curves remains unclear, it may be due to the differential cellular uptake 
and/or metabolism of glycyrrhizin and ISP-glycyrrhetinic acid in neuroblastoma cells. 
Results of the clonogenic assay also showed that the colony-forming ability of the 
murine neuroblastoma BU-1 cells was reduced by the ISp-glycyrrhetinic acid 
treatment in a dose-dependent manner, further confirming the anti-proliferative effect 
of 18|3-glycyrrhetinic acid on neuroblastoma cells. This assay was not performed 
with glycyrrhizin due to the inability of dissolving high concentration of glycyrrhizin 
in the soft agar culture. In addition, the kinetic study of the anti-proliferative effect 
of glycyrrhizin and 18p-glycyrrhetinic acid on BU-1 cells showed that both 
glycyrrhizin and ISp-glycyrrhetinic acid could inhibit the proliferation of BU-1 cells 
in a time-dependent manner and maximal anti-proliferative effect could be 
demonstrated after 48 hours of treatment. Regarding the anti-proliferative effect of 
glycyrrhizin and 18P-glycyrrhetinic acid on cancer cells, the data in the literature are 
contradictory. Abe et al. (1987) showed that glycyrrhizin and 18|3-glycyrrhetinic 
acid alone was effective in inhibiting the growth of melanoma cells. More recent 
studies also showed that glycyrrhizin and ISP-glycyrrhetinic acid inhibited the growth 
of Vero and HepG2 cells with the IC50 values at millimolar and micromolar level, 
respectively (Hsiang et al., 2002). In addition, 5 )iM glycyrrhetinic acid alone was 
found to reduce the proliferation of pituitary tumor cells by 30% (Rabbitt et al., 2003). 
In contrast, 18p-glycyrrhetinic acid alone was reported to have no effect on the 
proliferation of breast cancer MCF-7 and ZR-75-1 cells but it could potentiate the 
growth inhibitory effect of glucocorticosteroids (Hundertmark et al., 1997). These 
discrepancies may be due to the differences in the concentration of drugs used and the 
sensitivity of different cell lines to the anti-proliferative effect of drugs. 
Glycyrrhizin and ISp-glycyrrhetinic acid had been shown to be inhibitors of 
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11 P-hydroxysteroid dehydrogenase (Stewart et al,, 1987; Monder et al., 1989). 
Elevated 11 p-hydroxysteroid dehydrogenase expression was found in breast cancer 
and pituitary tumor cells (Hundertmark et al, 1997; Koyama et al., 2001; Rabbitt et 
al., 2003) and 11 P-hydroxysteroid dehydrogenase expression was also demonstrated 
in human prostate and colon carcinoma cell lines and endometrial cancer cells (Nath 
et al., 1993; Reeves, 1995; Koyama & Krozowski，2001). It had been suggested that 
inappropriate expression of 11 P-hydroxysteroid dehydrogenase may act as a 
pro-proliferative and neoplastic stimulus to cell growth and thus modulation of 
11 p-hydroxysteroid dehydrogenase activity could alter the growth of cancer cells 
(Koyama & Krozowski, 2001; Rabbitt et al., 2003). However, to our knowledge, 
there are no literatures reporting the expression of 11 p-hydroxysteroid dehydrogenase 
in neuroblastoma cells. Whether neuroblastoma cells express 11 P-hydroxysteroid 
dehydrogenase and whether the anti-proliferative effect of glycyrrhizin and 
18P-glycyrrhetinic acid on neuroblastoma cells could be attributed by their inhibitory 
effects on 11 p-hydroxysteroid dehydrogenase await further investigations. 
In order to study the reversibility of the anti-proliferative effect of glycyrrhizin 
and ISp-glycyrrhetinic acid on BU-1 cells, these two drugs were replaced by 
complete medium at the specific times and all cultures were incubated up to 48 hours. 
It was found that the anti-proliferative effect of glycyrrhizin and ISP-glycyrrhetinic 
acid was reversible and that the ability of neuroblastoma cells to recover from 
treatment with glycyrrhizin and 18p-glycyrrhetinic acid was dependent on both the 
concentration and duration of exposure to the drug. The higher the concentration 
used and the longer the incubation time, the less the ability of cells to recover from 
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treatment. Long time treatment of cells with glycyrrhizin and ISp-glycyrrhetinic 
acid seems to result in irreversible changes as supported by the findings of limiting 
dilution assay that the proliferating potential of drug-treated cells was markedly 
decreased after 4 days of treatment. Our results are consistent with the previous 
findings that when glycyrrhetinic acid was removed after 84 hours of treatment, the 
growth of B16 melanoma cells recovered slightly but the doubling time was 
lengthened (Abe et al., 1987). 
The present study showed that glycyrrhizin and 18p-glycyrrhetinic acid did not 
exhibit any significant cytotoxic effect on the neuroblastoma cells. Moreover, these 
two drugs also failed to induce apoptosis in neuroblastoma cells over a wide range of 
concentrations after 48 hours of incubation. These imply that the observed 
growth-inhibitory effect of glycyrrhizin and 18p-glycyrrhetinic acid on neuroblastoma 
cells could not be attributed directly to their cytotoxic and/or apoptosis-inducing 
effects on the neuroblastoma cells. Our results are similar to the others who found 
that the growth-inhibitory effect of glycyrrhetinic acid on the B16 melanoma cells 
was due to the cytostatic but not the cytotoxic effect (Abe et al., 1987). Previous 
work in this laboratory had demonstrated that both glycyrrhizin and 
ISP-glycyrrhetinic acid were able to induce apoptosis in the human myeloid leukemia 
HL-60 cells and the murine myeloid leukemia WEHI-3B JCS cells (Tsang, 2001). 
On the contrary, one report showed that glycyrrhizin alone did not induce apoptosis in 
the human T cell leukemia Jurkat and Molt-4F cells (Ishiwata et al., 1999). 
Moreover, no apoptotic effect was found in cultured splenocytes treated with 
glycyrrhetinic acid (Horigome et al, 2001) and the present study also showed that 
both glycyrrhizin and ISP-glycyrrhetinic acid failed to induce apoptosis in 
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neuroblastoma cells, suggesting that the apoptosis-inducing effect of glycyrrhizin and 
18p-glycyrrhetinic acid is cell type-specific. 
In conclusion, both glycyrrhizin and ISP-glycyrrhetinic acid could exert 
significant anti-proliferative effect on the murine and human neuroblastoma cells. It 
is clear that the anti-proliferative effect of glycyrrhizin and 18p-glycyrrhetinic acid on 
the neuroblastoma cells was cytostatic rather than cytotoxic in nature as the viability 
of the drug-treated BU-1 cells remained high and no apparent apoptosis could be 
detected. Among the three neuroblastoma cell lines tested, it was found that BU-1 
cells were the most sensitive cells in response to 18|3-glycyrrhetinic acid. Therefore, 
the BU-1 cells were chosen as a model for further mechanistic studies of the 
anti-tumor effect of 18p-glycyrrhetinic acid on neuroblastoma cells. 
“ 一 -111 - ‘ 
CHAPTER 4 
DIFFERENTIATION-INDUCING 
EFFECTS OF GLYCYRRHIZIN 
AND ISP-GLYCYRRHETINIC ACID 
ON NEUROBLASTOMA CELLS 
Chapter 4 Differentiation-inducing Effects 
4.1 Introduction 
Neuroblastoma is a childhood tumor that arises from the neural crest 
neuroectodermal cells (Westermann & Schwab, 2002). Despite their tumoral origin, 
neuroblastoma cell lines can be induced to differentiate in vitro by several agents 
including retinoic acid, nerve growth factor, phorbol ester TPA, dibutyryl cyclic AMP 
and phytochemicals (Ghigo et al., 1998; Guzhova et al., 2001; Pavelic & Spaventi, 
1987; Fagerstrom et al., 1996; Wu et al., 1998; Wong et al., 2002; Mak et al., 2000). 
In vitro differentiated neuroblastoma cells have a neuronal phenotype, as judged by 
their morphology and the expression of biochemical and functional markers. 
Glycyrrhizin and glycyrrhetinic acid had been reported to have 
differentiation-inducing activity (Abe et al., 1987; Tsang, 2001). An earlier study 
showed that glycyrrhizin and glycyrrhetinic acid inhibited the growth of melanoma 
B16 cells as well as inducing morphological alterations and melanogenesis (Abe et al., 
1987). Moreover, previous study in our laboratory showed that glycyrrhizin and 
ISP-glycyrrhetinic acid could trigger the monocytic differentiation of the leukemia 
JCS cells accompanied with the enhancement of macrophage differentiation antigen 
and adhesion molecule expressions on the cell surfaces (Tsang, 2001). 
The concept of "differentiation therapy" of cancer has gained considerable 
interest in recent years. This strategy is based on observations that neuroblastoma 
and leukemic cell lines represent immature, multipotent malignant cells that are 
blocked in their differentiation pathway(s), yet they can be induced to terminal 
differentiation and permanent cell cycle arrest in vitro by physiologic or 
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non-physiologic agents that apparently re-establish normal growth control. Recently, 
there has been an increasing interest in the therapeutical use of agents known to 
induce differentiation and growth arrest of neuroblastoma cells in vitro, in particular 
their applications for treatment of minimal residual disease (Lovat et al., 1997). In 
chapter three, it was found that glycyrrhizin and 18p-glycyrrhetinic acid exhibited 
potent anti-proliferative activity on human and murine neuroblastoma cells in vitro. 
In the present study, the differentiation-inducing effects of glycyrrhizin and 
ISp-glycyrrhetinic acid on the murine neuroblastoma Neuro-2a BU-1 cells had been 
investigated. The BU-1 cell line is a recently established and well characterized 
model and can be induced to undergo differentiation in response to the phytochemical 
euxanthone (Mak et al., 2000; Mak et al., 2001). The differentiation-inducing 
effects were investigated by a number of criteria, including morphological and 
biochemical changes. Morphological changes were examined by microscopic 
observation of drug-treated cells while the biochemical changes were studied by 
immunocytochemistry. Moreover, the modulation of differentiation-related gene 
expressions by 1 Sp-glycyrrhetinic acid was investigated by the RT-PCR technique. 
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4.2 Results 
4.2.1 Morphological Changes in Glycyrrhizin and ISP-Glycyrrhetinic 
Acid-treated Neuroblastoma BU-1 Cells. 
As demonstrated in the previous chapter, glycyrrhizin and 18p-glycyrrhetinic 
acid exhibited potent anti-proliferative activity on the murine neuroblastoma BU-1 
cells, and the proliferative potential of the BU-1 cells was markedly decreased after 4 
days of treatment with glycyrrhizin and ISP-glycyrrhetinic acid. It is possible that 
glycyrrhizin and 18p-glycyrrhetinic acid may cause terminal differentiation of the 
BU-1 cells, thus decreasing their proliferative potential. Therefore, the 
differentiation-inducing effects of glycyrrhizin and ISp-glycyrrhetinic acid were 
investigated. It is well known that neurite extension is a morphological expression 
of neuronal differentiation (Wu et al., 1998) and thus morphological study was carried 
out in order to investigate the differentiation-inducing effects of glycyrrhizin and 
18p-glycyrrhetinic acid on neuroblastoma cells. Briefly, BU-1 cells were incubated 
at 37�C for 3 - 4 days with 0 - 4 mM glycyrrhizin, or 0 - 100 ]iM ISp-glycyrrhetinic 
acid. The cells were then stained with Hemacolor solutions and examined for the 
morphological changes under the light microscope. Differentiation of BU-1 cells 
was characterized by the enlargement in cell size and the elongation in their neurite 
length. 
As shown in Figure 4.1 & 4.2, differentiation could be induced in BU-1 cells 
after treatment with glycyrrhizin and ISp-glycyrrhetinic acid with significant, albeit 
morphologically diverse, neurite outgrowth. Untreated BU-1 cells grew as densely 
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packed, rounded and flattened cells with generally oval appearance (Figure 4.1 A & 
4.2A). However, cells treated with 3 and 4 mM glycyrrhizin showed a different 
spatial configuration with a flattened morphology and a considerably extended cell 
body with long and multipolar neurites around the cell body (Figure 4.1C & 4.ID). 
Such morphological changes were not observed in cells treated with a lower 
concentration of glycyrrhizin (Figure 4.IB), suggesting that the 
differentiation-inducing effect of glycyrrhizin was dose-dependent. On the other 
hand, treatment of BU-1 cells with 60 juM 18(3-glycyrrhetinic acid had not resulted in 
any significant morphological changes (Figure 4.2B) but treatment with 80 jiM 
ISP-glycyrrhetinic acid produced multipolar (multiple neurite bearing) star-shaped 
cells with several neurites projecting from the cell bodies along with cell body and 
nucleus enlargement (Figure 4.2C). However, these changes did not equally affect 
the entire cell population and some cells retained their basic spherical form. In 
contrast to the multipolar type of neurite growth observed in cells treated with 80 jiiM 
ISp-glycyrrhetinic acid, treatment of cells with 100 juM ISP-glycyrrhetinic acid 
produced thin and bipolar cells with two long neurites emanating from opposite sides 
of the cell body (Figure 4.2D). Treatment of cells with glycyrrhizin and 
18p-glycyrrhetinic acid for 4 days resulted in similar morphological changes with 
slightly greater extent of differentiation than that observed after 3 days of treatment 
(data not shown). These results indicated that both glycyrrhizin and 
18p-glycyrrhetinic acid exhibited differentiation-inducing activities on the 
neuroblastoma BU-1 cells. 
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Figure 4.1: Morphological changes in glycyrrhizin-treated BU-1 cells. BU-1 
cells (5,000 cells/well) grown overnight on coverslips in the wells of a 24-well plate 
were incubated with (A) culture medium; (B) 1 mM glycyrrhizin; (C) 3 mM 
glycyrrhizin; or (D) 4 mM glycyrrhizin at 37�C for 3 days. The treated cells were 
then stained with Hemacolor solutions (Magnification x 200). 
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Figure 4.2: Morphological changes in 18p-glycyrrhetinic acid-treated BU-1 cells. 
BU-1 ceils (5,000 cells/well) grown overnight on coverslips in the wells of a 24-well 
plate were incubated with (A) control solvent (0.17% DMSO); (B) 60 JUM 
ISp-glycyrrhetinic acid; (C) 80 |LIM 18p-glycyrrhetinic acid; or (D) 100 JUM 
ISp-glycyrrhetinic acid at 37°C for 3 days. The treated cells were then stained with 
Hemacolor solutions (Magnification x 200). 
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4.2.2 Immunocytochemistry of Glycyrrhizin and 18|3-Glycyrrhetinic 
Acid-treated Neuroblastoma BU-1 Cells 
Apart from morphological changes, the differentiation of the neuroblastoma 
BU-1 cells induced by glycyrrhizin and ISp-glycyrrhetinic acid was studied 
biochemically by examining the expression of neuronal differentiation markers. As 
well-known markers for neuronal differentiation, the expression of 
microtubule-associated protein 2 (MAP2) and neurofilament-200 was analyzed by 
immunocytochemistry after 4 days of drug treatment. Confocal microscopy was 
used to determine if there was any up-regulation of neuronal cell differentiation 
marker expression. The BU-1 cells were first incubated with 3 mM glycyrrhizin or 
80 |iM ISP-glycyrrhetinic acid at 37°C for 4 days and immunofluorescence study on 
drug-treated BU-1 cells was then performed using an antibody that specifically 
recognizes MAP2 and one that recognizes the neurofilament-200. MAP2 is a 
dendritic marker that is present in the dendrites and the perikaryon of neurons 
(Bernhardt & Matus, 1984; De Camilli et al., 1984). It is a major component of the 
neuronal cytoskeleton that promotes the assembly and stabilization of microtubules 
and is implicated in neuronal differentiation (Przyborski & Cambray-Deakin, 1995). 
Neurofilament-200 is a high molecular weight neurofilament (NF-H) with an apparent 
molecular mass of 200 kDa (Shea et al., 1988). It is a neuronal differentiation 
marker whose expression increases during neuronal differentiation and is localized in 
the mature axons (Patemo et al., 1997; Wu et al., 1998). 
Figure 4.3 shows that MAP2 was minimally expressed in control BU-1 cells and 
that treatment of cells with glycyrrhizin increased the expression of MAP2 since 
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glycyrrhizin-treated cells showed more intense labeling of MAP2. Similarly, there 
was little staining of MAP2 in solvent-treated control cells but treatment of cells with 
80 |aM 1 Sp-glycyrrhetinic acid resulted in increased intensity of the MAP2 
immunofluorescence staining (Figure 4.4). The same phenomenon was observed in 
the expression of neurofilament-200, little staining of neurofilament-200 was 
observed in control cells while neuroblastoma cells treated with 3 mM glycyrrhizin or 
80 i^ M ISP-glycyrrhetinic acid showed an enhanced labeling of neurofilament-200 
(Figure 4.5 & 4.6). Moreover, the weak staining of MAP2 and neurofilament-200 in 
control cells was localized almost exclusively in the cell bodies while exposure of 
cells to glycyrrhizin and 18p-glycyrrhetinic acid for 4 days showed intense staining of 
both cell bodies and neuritic processes. The immunostaining of MAP2 and 
neurofilament-200 was specific since the negative controls without primary antibodies 
failed to show any significant increase in staining in the drug-treated cells as 
compared to the untreated control cells (data not shown). Taken together, these 
results suggest that both glycyrrhizin and ISP-glycyrrhetinic acid could induce 
morphological as well as biochemical differentiation of neuroblastoma cells. 
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Figure 4.3: Immunocytochemical localization of MAP2 in glycyrrhizin-treated 
BU-1 cells. BU-1 cells (20,000 cells/well) grown overnight on cover glasses in the 
wells of a 6-well plate were incubated with glycyrrhizin at 37°C for 4 days. 
Immunocytochemistry was done as described under Materials and Methods. 
Confocal fluorescent images were shown in parallel with the phase-contrast images. 
(A-B): Fluorescent images. (A，-B,): Corresponding phase-contrast images. (A,A’)： 
Medium control. (B,B，)： 3 mM glycyrrhizin-treated cells. Scale bars represent 50 
}jin. 
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Figure 4.4: Immunocytochemical localization of MAP2 in 18p-glycyrrhetinic 
acid-treated BU-1 cells. BU-1 cells (20,000 cells/well) grown overnight on cover 
glasses in the wells of a 6-well plate were incubated with 18 P-glycyrrhetinic acid at 
37°C for 4 days. Immunocytochemistry was done as described under Materials and 
Methods. Confocal fluorescent images were shown in parallel with the 
phase-contrast images. (A-B): Fluorescent images. (A'-B'): Corresponding 
phase-contrast images. (A^'): Solvent control (0.13% DMSO). (B,B，)： 80 i^M 
18P-glycyrrhetinic acid-treated cells. Scale bars represent 50 i^m. 
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Figure 4.5: Immunocytochemical localization of neurofilaineiit-200 in 
glycyrrhizin-treated BU-1 cells. BU-1 cells (20,000 cells/well) grown overnight on 
cover glasses in the wells of a 6-well plate were incubated with glycyrrhizin at 37°C 
for 4 days. Immunocytochemistry was done as described under Materials and 
Methods. Confocal fluorescent images were shown in parallel with the 
phase-contrast images. (A-B): Fluorescent images. (A'-B'): Corresponding 
phase-contrast images. (A,A'): Medium control. (B,B'): 3 mM glycyrrhizin-treated 
cells. Scale bars represent 50 (xm. 
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Figure 4.6: Immunocytochemical localization of neurofilament-200 in 
ISP-glycyrrhetinic acid-treated BU-1 cells. BU-1 cells (20,000 cells/well) grown 
overnight on cover glasses in the wells of a 6-well plate were incubated with 
1 SP-glycyrrhetinic acid at 37°C for 4 days. Immunocytochemistry was done as 
described under Materials and Methods. Confocal fluorescent images were shown in 
parallel with the phase-contrast images. (A-B): Fluorescent images. (A,-B’)： 
Corresponding phase-contrast images. (A^A,): Solvent control (0.13% DMSO). 
(B,B,): 80 |iM ISP-glycyrrhetinic acid-treated cells. Scale bars represent 50 jiin. 
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4.2.3 Effect of ISp-Glycyrrhetinic Acid on the Expression of Proto-oncogenes in 
Neuroblastoma BU-1 Cells 
N-myc is one of the members of the myc transcription factor family (Cole & 
McMahon, 1999) and its overexpression has been closely associated with malignancy 
and poor prognosis of neuroblastoma (Taguchi et al., 1997; Goodman et al., 1997; 
George et al., 2001). Previous studies have shown that N-myc expression in 
neuroblastoma cells is associated with high proliferative rate and is rapidly repressed 
by retinoic acid in vitro (Peverali et al,, 1996). In addition to its association with 
neuroblastoma progression, it is also a critical factor in the capacity of neuroblastoma 
cells to terminally differentiate in response to retinoic acid (Wada et aL, 1997). 
Decreased expression of N-myc during neuroblastoma differentiation induced by 
agents such as retinoic acid, interferon-y and dibutyryl cAMP had been reported 
(Amatruda, III et al., 1985; Thiele et al., 1985; Peverali et al., 1996; Wada et al., 1997; 
Murakami et al, 1991). Moreover, introduction of N-myc antisense oligomer to the 
human neuroblastoma cell line LAN-5 that is known to have N-myc amplification 
caused the induction of differentiation (Negroni et al., 1991). On the other hand, 
transfection of N-myc gene construct into neuroblastoma SK-N-BE cells blocked the 
retinoic acid-induced differentiation (Peverali et al., 1996). In addition, decreased 
N-myc expression is considered to be a molecular marker of differentiation of 
neuroblastoma cell lines (De, V et al., 2000; Han et al., 2001). In some studies, the 
expression of c-myc, another member of the myc family of nuclear phosphoproteins, 
was reported to be reduced upon differentiation induction (Hammerling et al., 1987; 
Cohrs et al, 1991). Therefore, it is intriguing to examine whether the expression of 
N-myc and c-myc would be modulated by 18p-glycyrrhetinic acid which could 
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induce differentiation in the neuroblastoma BU-1 cells. 
In the present study, the modulatory effect of 18(3-glycyrrhetinic acid on the 
expression of two proto-oncogenes N-myc and c-myc in the BU-1 cells was 
investigated by the technique of RT-PCR after the cells were treated with various 
concentrations of ISp-glycyrrhetinic acid for 8 and 24 hours. The amount of PCR 
product was normalized by comparison with the amplification of the house-keeping 
gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Figure 4.7 shows that the expression of N-myc in BU-1 cells decreased to about 
55% of that of the control as early as 8 hours after treatment with 100 \iM and 120 
\iM of 18p-glycyrrhetinic acid. However, a decrease in the level of N-myc was 
observed in 80 |liM ISP-glycyrrhetinic acid-treated BU-1 cells only after a longer 
period (24 hours) of treatment. The extent of decline in N-myc mRNA level (25 -
80% decrease) was more significant after 24 hours of treatment, suggesting that 
ISP-glycyrrhetinic acid could down-regulate the expression of N-myc both dose- and 
time-dependently. In contrast, no significant change could be observed in the 
expression level of c-myc in BU-1 cells even after 24 hours of treatment with three 
different concentrations of ISP-glycyrrhetinic acid. 
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8 hr 24 hr 
^ A： A ^ 
r \ r ^ 
Ctl 80 100 120 Ctl 80 100 120 ^M 
N-myc 763 bp 
(28 cycles) 2.49 2.63 1.31 1.37 2.16 1.62 0.46 0.43 
c_myc I •.丨… B . . : . . . . I一罾」 • . . . . . � • • U l L i m 501 bp 
(24 cycles) 1.60 1.61 1.44 1.37 1.28 1.42 1.48 1.57 
GAPDH 226 bp 
(20 cycles) 
Figure 4.7: Effect of 18P-glycyrrhetinic acid on the mRNA expression of N-myc 
and c-myc genes in BU-1 cells. BU-1 cells (10^) were cultured overnight and 
treated with either 0.2% DMSO (Ctl) or 80 - 120 juM ISp-glycyrrhetinic acid for 8 
and 24 hours. Total RNA was isolated and subjected to RT-PCR as described under 
Materials and Methods. PCR products were electrophoresed on a 2% agarose gel, 
stained with ethidium bromide. The amounts of the PCR cDNA products were 
semi-quantified by the ImageQuant software (Molecular Dynamics). The value 
below each band represents the relative intensity after normalization with respect to 
GAPDH. The number of PCR cycles completed for each set of primers is indicated 
in the parentheses and the number on the right indicates the size of the band in base 
pairs (bp). 
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4.2.4 Effect of ISP-Glycyrrhetinic Acid on the Expression of 
Differentiation-Related Genes in Neuroblastoma BU-1 Cells 
Besides N-myc, a number of differentiation-related genes had been identified. 
An earlier study reported that the c-fos mRNA expression was increased in 
TPA-treated SH-SY5Y cells (Hammerling et al, 1987). Moreover, Sano et al (1991) 
showed that there were a decrease in the N-myc gene expression and an increase in 
the c-fos gene expression during the differentiation of NB-1 cells. On the other hand, 
the expression of an immediate early gene, c-jun, was enhanced during differentiation 
of NlE-115 neuroblastoma cells in the absence of c-fos induction (de Groot & Kruijer, 
1991). A recent study demonstrated that c-fes, c-fos, and RAG-1 gene activator 
(RGA) were significantly up-regulated during the differentiation of mouse 
neuroblastoma NBP! cells (Rudie et al., 2001). Therefore, it is of interest to 
investigate the modulatory effect of ISP-glycyrrhetinic acid on the expression of the 
immediate early genes. Figure 4.8 shows that transient up-regulation of c-fos was 
observed after treatment of BU-1 cells with 100 [iM 18p-glycyrrhetinic acid. The 
expression of c-fos increased as early as 30 minutes after treatment (67% increase), 
peaked at 1 hour (3.5 fold increase) and declined to the level slightly higher than that 
of the control at 8 hours of drug treatment. In contrast, the expression level of c-jun 
remained relatively constant throughout the time period examined. 
It had been suggested that one of the potential mechanisms of N-myc action may 
be mediated through suppression of p50 expression, a component of the NF-KB 
transcription factor (van't Veer et al., 1993). Moreover, transient activation of 
NF-KB was reported to be essential for retinoic acid- or TPA-induced differentiation 
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of SH-SY5Y cells (Feng & Porter, 1999). As mentioned before, N-myc expression 
in BU-1 cells was decreased by treatment with ISp-glycyrrhetinic acid, it is of interest 
to investigate whether the expression of NF-KB/p50 would be increased due to the 
decreased expression of N-myc. As shown in Figure 4.8, the expression level of 
NF-KB/p50 increased gradually from 30 minutes to 8 hours following treatment with 
18(3-glycyrrhetinic acid and a 64% increase was observed after 8 hours of treatment. 
It has been reported that Bcl-2, in addition to its ability to protect cells against 
apoptosis, may also be involved in the regulation of cell differentiation, as elevated 
expression of the Bcl-2 protein had been found in differentiated neuroblastoma cells 
induced by TPA (Hanada et al., 1993). Moreover, overexpression of Bcl-2 cDNA 
induced extensive neurite outgrowth and increased expression of neuronal marker in a 
human neural crest-derived tumor cell line, Paju (Zhang et al., 1996). Therefore, 
Bcl-2 can also be considered as a biochemical marker of neuronal cell differentiation 
(Feng & Porter, 1999). In the present study, the expression level of Bcl-2 was 
examined by RT-PCR after treatment with 18p-glycyrrhetinic acid. Figure 4.8 
shows that the Bcl-2 mRNA level in BU-1 cells increased gradually and a 73% 
increase was found after 8 hours of treatment with ISp-glycyrrhetinic acid. 
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(28 cycles) I ^ ^ E ^ ^ S ^ E I B S B 247 bp 
0.73 1.22 2.57 1.84 1.49 1.18 0.88 
(26 cycles) 459 bp 
1.54 1.78 1.78 1.58 1.72 1.63 1.51 
NF-KB/p50 MlMIMHiBHi^BBBi^MiBBHI^^aHil^MBlil^MiBilM 
(28 cycles) 25U bp 
1.88 2.43 2.73 2.59 2.71 2.78 3.08 
Bcl-2 ^ ^ ^ ^ ^ ^ ^ M B I M I M M P l P ^ M P l B I ^ H P B i * * 
(27 cycles) 293 bp 
1.08 1.42 1.51 1.62 1.69 1.71 1.87 
(20 cycles) ^ " i ^ i i M L — J L i J B L ^ J L ^ ^ ^ ^ ^ ^ ^ 226 bp 
Figure 4.8: Effect of 18p-glycyrrhetinic acid on the mRNA expression of c-fos, 
c-jun, NF-KB/p50 and Bcl-2 genes in BU-1 cells. BU-1 cells (10^) were cultured 
overnight and treated with either 0.17% DMSO (Ctl) or 100 juM 18p-glycyrrhetinic 
acid for various time periods (30 minutes to 8 hours). Total RNA was isolated and 
subjected to RT-PCR as described under Materials and Methods. PGR products 
were electrophoresed on a 2% agarose gel, stained with ethidium bromide. The 
amounts of the PCR cDNA products were semi-quantified by the ImageQuant 
software (Molecular Dynamics). The value below each band represents the relative 
intensity after normalization with respect to GAPDH. The number of PCR cycles 
completed for each set of primers is indicated in the parentheses and the number on 
the right indicates the size of the band in base pairs (bp). 
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4.3 Discussion 
Neuroblastoma, a tumor of the sympathetic nervous system, is the most common 
solid tumor in children. In the majority of patients, neuroblastoma is metastatic at 
the time of diagnosis and rapid progression results in a fatal outcome. However, 
neuroblastoma has the highest rate of spontaneous regression among other human 
cancers and some tumors may undergo complete spontaneous regression even without 
therapy (Westermann & Schwab, 2002). A number of differentiating agents 
including retinoic acid (Sidell, 1982; Sidell et al., 1983), interferon-y (Watanabe et al., 
1989; Parodi et al., 1989), dibutyryl cAMP (Rupniak et al., 1984; Wong et al., 2002) 
and phorbol esters (Pahlman et al., 1981; Pahlman et al., 1983) that induce 
neuroblastoma cell differentiation in vitro had been reported. Moreover, a recent 
study demonstrated that high-dose 13-c/^-retinoic acid treatment after autologous 
bone marrow transplantation showed encouraging results for the therapy of high-risk 
neuroblastoma in children (Matthay et al., 1999). This fact has prompted 
investigations into the possibility of differentiation therapy for this malignancy. 
Since glycyrrhizin and ISP-glycyrrhetinic acid had been reported to induce 
morphological differentiation of melanoma B16 cells and myeloid leukemia JCS cells 
(Abe et aL, 1987; Tsang, 2001), it is of interest to investigate whether glycyrrhizin 
and ISp-glycyrrhetinic acid can induce differentiation of the neuroblastoma cells. In 
the present study, morphological examination showed that both glycyrrhizin and 
18P-glycyrrhetinic acid could induce differentiation of BU-1 cells after 3 days of 
treatment. Differentiation was characterized by the increase in neurite outgrowth 
and cell size enlargement. However, exposure of BU-1 cells to glycyrrhizin and 
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18p-glycyrrhetinic acid resulted in different morphological changes. Treatment of 
cells with 80 |liM ISP-glycyrrhetinic acid produced multipolar cells with a general 
increase in cell size while treatment of cells with 100 [iM 18p-glycyrrhetinic acid and 
3 - 4 mM glycyrrhizin resulted in extension of neurites without any changes in the 
size of the cells. This discrepancy in the morphological changes of drug-treated cells 
remains unknown and further investigation is required. However, it is not 
uncommon that different concentrations of drug result in different morphological 
changes. One report showed that treatment of Neuro-2a cells with the PKC inhibitor 
H7 induced unipolar neurites at lower concentrations of H7 whereas bipolar or 
multipolar neurites were seen at higher concentrations (Minana et al., 1990). 
To further characterize the effects of glycyrrhizin and ISP-glycyrrhetinic acid on 
the differentiation of BU-1 cells, immunocytochemistry was carried out to investigate 
whether the morphological differentiation was accompanied by biochemical 
differentiation of BU-1 cells. The neuronal phenotype of differentiated BU-1 cells 
was demonstrated by immunocytochemistry using specific antibodies to neuronal 
markers MAP2 and neurofilament-200. Microtubule-associated protein-2 (MAP2) is 
a prominent cytoskeletal protein in the mammalian nervous system (Kalcheva et al., 
1998). It is a neuron-specific MAP which is a major component of the neuronal 
cytoskeleton. It promotes the assembly and stabilizes the microtubule bundles, 
allows outgrowth of cellular processes and is implicated in neuronal differentiation 
(Przyborski & Cambray-Deakin, 1995). Neurofilament-200, a high molecular 
weight neurofilament (NF-H) with an apparent molecular mass of 200 kDa (Shea et 
al., 1988), is localized in the mature axons and its level is increased during neuronal 
differentiation (Patemo et al, 1997; Wu et al., 1998). Using the laser confocal 
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scanning microscopy, the neuronal phenotype of differentiated BU-1 cells was 
demonstrated by increased expression of MAP2 and neurofilament-200, which are 
markers of neuronal cell differentiation. Therefore, in addition to induction of 
morphological changes, glycyrrhizin and 18p-glycyrrhetinic acid also induced the 
expression of biochemical markers characteristic of the neuronal differentiation. The 
positive staining of both markers was indicative of mixed phenotypes with 
dendrite-like and axon-like processes. 
N-myc, like other members of the myc gene family, encodes a nuclear 
phosphoprotein containing a transactivation domain at the N-terminal and a 
C-terminal domain with regions that are required for dimerization with Max and for 
sequence specific DNA binding (Cole & McMahon, 1999). A close relationship 
between N-myc amplification and advanced stages of neuroblastoma, rapid tumor 
progression and poor prognosis was documented by clinical studies (George et al., 
2001). Moreover, N-myc expression is intimately related to an undifferentiated 
phenotype in neuroblastoma cells and a number of studies demonstrated that the 
induction of neuronal differentiation of neuroblastoma cells in vitro is accompanied 
by N-myc down-regulation (Amatruda, III et al., 1985; Thiele et aL, 1985; Murakami 
et al., 1991; Peverali et al, 1996; Wada et al, 1997). On the other hand, the 
expression of c-myc, another member of the myc family of nuclear phosphoproteins, 
was also reported to be reduced upon differentiation (Hammerling et al., 1987; Cohrs 
et al., 1991). In the present study, ISp-glycyrrhetinic acid was found to be able to 
induce the differentiation of BU-1 cells at micromolar concentrations, therefore, we 
further examined the modulatory effect of ISP-glycyrrhetinic acid on the expression 
of N-myc and c-myc. It has been reported that retinoic acid-induced differentiation 
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of SMS-KCNR neuroblastoma cells caused a reduction in the levels of N-myc mRNA 
within 6 hours of treatment and this change preceded the onsets of both cell-cycle 
changes and morphological differentiation (Thiele et al., 1985). Using RT-PCR, our 
results showed that the mRNA level of N-myc decreased as early as 8 hours after 
treatment of the neuroblastoma BU-1 cells with ISP-glycyrrhetinic acid, the time at 
which no obvious morphological change was observed. In contrast, no significant 
difference between the level of c-myc in 1 Sp-glycyrrhetinic acid-treated cells and 
control cells was found. Therefore, our results suggest that ISP-glycyrrhetinic acid 
may induce the differentiation of neuroblastoma cells by the reduction of N-myc 
expression and this is consistent with an earlier study showing that down-regulation of 
N-myc preceded the morphological differentiation of neuroblastoma cells (Thiele et 
al., 1985). Interestingly, another study showed that treatment of SH-SY5Y cells 
with TPA and retinoic acid induced morphological and functional differentiation in 
SH-SY5Y cells and resulted in a decrease in the expression of both N-myc and c-myc 
genes (Hammerling et al., 1987). However, in the present study, the 
down-regulation of N-myc cannot be ascribed to be a general effect of 
1 Sp-glycyrrhetinic acid on the myc family since no significant change in the level of 
c-myc was found at the times when N-myc expression was dramatically altered by 
ISP-glycyrrhetinic acid. It seems that N-myc and c-myc expressions are 
differentially regulated in 18p-glycyrrhetinic acid-treated neuroblastoma BU-1 cells. 
A recent study using transfection assay showed that retinoic acid and interferon-y 
regulated N-myc expression through different regions of the N-myc promoter. 
Interferon-y was also found to exert post-transcriptional effects on N-myc expression 
by shortening the half-life of N-myc mRNA (Wada et al., 1997). However, the 
mechanism for the down-regulation of N-myc expression by 1 Sp-glycyrrhetinic acid 
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awaits further investigations. 
A number of studies showed that the immediate early genes, including c-fos and 
c-jun, were up-regulated during differentiation of neuroblastoma cells (Hammerling et 
al., 1987; Sano et al., 1991; de Groot & Kruijer, 1991; Rudie et al., 2001), suggesting 
that these genes may be involved in the differentiation of neuroblastoma cells. In 
view of these findings, we had investigated whether these genes might be involved in 
the differentiation of BU-1 cells induced by 18|3-glycyrrhetinic acid. Our results 
showed that c-fos mRNA was transiently up-regulated after treatment with 
18p-glycyrrhetinic acid whereas the mRNA level of c-jun remained fairly constant. 
C-fos encodes a nuclear protein that is a member of activator protein-1 (AP-1) 
transcription factor. C-fos protein activates transcription of target genes via the 
tetradecanoyl phorbol acetate response element (TRE) when bound as a heterodimer 
with Jim (McBride & Nemer, 1998). It is possible that up-regulation of c-fos by 
18p-glycyrrhetinic acid would increase the transcription of genes that are required for 
differentiation of neuroblastoma cells. 
The transient activation of the NF-KB transcription factor was reported to be 
essential for retinoic acid- or TPA-induced differentiation of SH-SY5Y cells (Feng & 
Porter, 1999). Moreover, an earlier study suggested that one of the potential 
mechanisms of N-myc action maybe mediated through suppression of p50 expression, 
a component of the NF-KB transcription factor (van't Veer et al., 1993). As 
mentioned before, N-myc expression in BU-1 cells was decreased by treatment with 
ISP-glycyrrhetinic acid, it is of interest to investigate whether the expression of 
NF-KB/p50 would be increased when there was a decreased expression of N-myc in 
“ - 1 3 4 - ”~ 
Chapter 4 Differentiation-inducing Effects 
BU-1 cells. Our results showed that the NF-KB/p50 mRNA level increased 
time-dependently after treatment with ISp-glycyrrhetinic acid. However, whether 
18p-glycyrrhetinic acid could directly activate the N F - K B protein complex in B U - 1 
cells is an intriguing aspect that is worthy of future investigations. 
The anti-apoptotic gene, Bcl-2, was found to be strongly up-regulated in parallel 
with neuronal differentiation (Hanada et al., 1993; Feng & Porter, 1999). In addition, 
Bcl-2 appears to be required for neuronal differentiation of neural crest-derived Paju 
cells (Zhang et aL, 1996). In the present study, we also found that the expression of 
Bcl-2 gene was up-regulated after treatment with 18(3-glycyrrhetinic acid, suggesting 
that there may be a close relationship between Bcl-2 expression and neuronal cell 
differentiation, though the precise mechanism has yet to be defined. 
In conclusion, both glycyrrhizin and ISP-glycyrrhetinic acid were found to be 
capable of inducing the morphological and biochemical differentiation of 
neuroblastoma BU-1 cells. Furthermore, the differentiation-inducing effect of 
ISP-glycyrrhetinic acid was accompanied with a down-regulation of N-myc gene 
expression, and an up-regulation of Bcl-2, NF-KB/p50 and c-fos gene expression. 
However, the mechanisms by which 18p-glycyrrhetinic acid could alter the 
expression of these genes remain unclear and await further investigations. 
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Chapter 5 Mechanistic Studies 
5,1 Introduction 
In the previous two chapters, glycyrrhizin and 18 p-glycyrrhetinic acid had been 
shown to exert anti-proliferative and differentiation-inducing effects on the 
neuroblastoma cells in vitro. However, the mechanisms by which they exerted their 
anti-tumor effects on the neuroblastoma cells had not been fully elucidated. It is 
well known that disturbance to the cell cycle may result in growth inhibition. 
Therefore, in the present study, the effects of glycyrrhizin and 18P-glycyrrhetinic acid 
on the cell cycle progression of BU-1 cells were studied by flow cytometry. In view 
of the fact that cell cycle progression is tightly regulated by cyclins and 
cyclin-dependent kinases, and progression through the cell cycle is brought about by 
the differential expression and activation of these cell-cycle regulatory proteins, thus, 
the modulatory effect of 18P-glycyrrhetinic acid on the mRNA and protein expression 
of the cyclins and cyclin-dependent kinases was further studied by RT-PCR and 
Western blot respectively. 
Results in chapter three showed that the effective concentration of glycyrrhizin 
was relatively high for the inhibition of neuroblastoma cell proliferation, therefore, it 
is of great interest to find a way that could increase the efficacy of glycyrrhizin. As 
shown in the previous two chapters, both glycyrrhizin and 18P-glycyrrhetinic acid 
were found to be able to inhibit the growth and induce differentiation in the 
neuroblastoma BU-1 cells. In addition, glycyrrhizin is hydrolyzed to its major 
metabolite 18P-glycyrrhetinic acid by the bacterial p-D-glucuronidase in the intestine. 
Thus, it is of interest to investigate whether there are any synergistic actions between 
glycyrrhizin and 18p-glycyrrhetinic acid on the proliferation and differentiation of 
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neuroblastoma cells. A\\-trans retinoic acid (ATRA) is a well documented 
anti-proliferative and differentiation-inducing agent on neuroblastoma cells (Sidell, 
1982; Sidell et al” 1983; Thiele et al., 1985). It is intriguing to investigate whether 
the combined treatment with ISp-glycyrrhetinic acid and ATRA would result in 
synergistic effect on the proliferation and differentiation of neuroblastoma cells. In 
the present study, the combined effect of glycyrrhizin, 18|3-glycyrrhetinic acid and 
ATRA on the proliferation and differentiation of neuroblastoma cells was examined 
by the H-TdR incorporation assay after 48 hours of treatment and by the 
morphological study after 4 days of treatment respectively. 
Protein kinase C (PKC) is a family of serine-threonine kinases that consists of at 
least 10 members. Based on the structural and enzymatic properties, the PKC 
isoforms are divided into three groups: the conventional PKC isoforms (a, pi, pil and 
y) that are Ca^^-dependent and activated by both phosphatidyl serine and 
diacylglycerol (DAG); the novel PKC isoforms (5, 8, r\ and 0) that are 
Ca^^-insensitive and regulated by DAG and phosphatidylserine; and the atypical PKC 
isoforms and i/X) that are Ca - and phospholipid-independent (Mellor & Parker, 
1998; Way et al., 2000). Moreover, PKC \i takes an intermediate position between 
the novel and atypical PKC subgroups (Liu, 1996). PKC was suggested to play an 
important role in the growth, survival and differentiation of cells (Zeidman et al, 
1999a; Zeidman et al, 1999b; Svensson et al., 2000; Mak et al., 2001). A number of 
reports had described an altered expression pattern of PKC isozymes during 
differentiation of neuroblastoma cells. An earlier study demonstrated that 
down-regulation of mRNAs for both PKC a and PKC s was associated with the in 
vitro differentiation of Neuro-2a cells (Wada et al., 1989). A more recent study 
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demonstrated that the differentiation of the murine neuroblastoma BU-1 cells induced 
by euxanthone was accompanied with induction of certain isoforms of PKC (PKC-a, 
-3, -5, -X and -Q (Mak et al., 2001). Therefore, it is of interest to examine whether 
the expression of PKC isoforms would be modulated by ISp-glycyrrhetinic acid using 
the RT-PCR technique. In addition, one earlier report showed that concentrations of 
ISP-glycyrrhetinic acid below 200 i^M slightly enhanced PKC activity in the presence 
of Ca and phosphatidylserine while higher concentrations of ISp-glycyrrhetinic acid 
inhibited PKC activity with IC50 of approximately 450 ^M (O'Brian et al., 1990). 
Therefore, in this chapter attempts had been made to investigate whether the 
anti-proliferative and differentiation-inducing effects of ISP-glycyrrhetinic acid were 
PKC dependent or not. The dependency of PKC on the anti-proliferative and 
differentiation-inducing effects of ISP-glycyrrhetinic acid was elucidated by the use 
of PKC activators and selective PKC inhibitors in combination with 
ISP-glycyrrhetinic acid. Their effects on the neuroblastoma BU-1 cells were 
measured by the ^H-TdR incorporation assay and morphological study. 
In view of the fact that cyclic AMP (cAMP) analogs are able to induce 
differentiation of cells of neuronal origin (Wu et al., 1998; Hansen et al., 2000; Wong 
et al,, 2002) and that a number of cAMP actions are mediated through the activation 
of the PKA signaling pathways, therefore, the role of PKA in the ISP-glycyrrhetinic 
acid-induced growth inhibition and differentiation in BU-1 cells was investigated by 
the use of PKA activators and inhibitors. 
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5.2 Results 
5.2.1 Effects of Glycyrrhizin and 1 Sp-Glycyrrhetinic Acid on the Cell Cycle 
Kinetics of Neuroblastoma BU-1 Cells In Vitro 
As shown in chapter three, glycyrrhizin and 18p-glycyrrhetinic acid were found 
to be able to exert a cytostatic effect on the neuroblastoma BU-1 cells. Thus, 
attempts were made to study the mechanistic actions of glycyrrhizin and 
ISp-glycyrrhetinic acid on the proliferation of the BU-1 cells. In order to determine 
whether the anti-proliferative effect of glycyrrhizin and 18|3-glycyrrhetinic acid was 
specific to the GQ/GI, S or G ! / M phase of the cell cycle, the effects of glycyrrhizin 
and 18 (3 - glycyrrhetinic acid on the cell cycle distribution of the neuroblastoma BU-1 
cells were examined by flow cytometry. BU-1 cells were either treated with 3 and 
4.5 mM of glycyrrhizin for 48 and 72 hours or treated with 80 and 100 |iM of 
18p-glycyrrhetinic acid for 24 and 48 hours before flow cytometric analysis. 
Cell cycle analysis of BU-1 cells treated with 4.5 mM glycyrrhizin for a period 
of 48 and 72 hours showed accumulation of cells in the Gi/M phase with a 
corresponding reduction in the percentage of cells in the GQ/GI and S phases (Figure 
5.IB & 5.2B). However, when the cells were treated with 3 mM glycyrrhizin, such 
changes were observed only after 72 hours (Figure 5.2A), suggesting that the effect of 
glycyrrhizin on the cell cycle profile of BU-1 cells was dose- and time-dependent. 
In the case of ISP-glycyrrhetinic acid, a more marked increase in the percentage of 
cells in the G2/M phase and a decrease in the percentage of cells in the GQ/GI and S 
phases of the cell cycle were observed for the two different concentrations (80 \iM 
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and 100 [iM) of ISP-glycyrrhetinic acid used as early as after 24 hours of treatment 
(Figure 5.3). The effect of 1 Sp-glycyrrhetinic acid on the cell cycle profile of BU-1 
cells was even more drastic after 48 hours of treatment (Figure 5.4), suggesting that 
the effect of 1 Sp-glycyrrhetinic acid on the cell cycle profile of BU-1 cells was also 
dose- and time-dependent. Therefore, cell cycle analysis clearly demonstrated that 
glycyrrhizin and ISP-glycyrrhetinic acid could suppress the proliferation of BU-1 
cells by arresting the cells at the G2/M phase. 
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Figure 5.1: Effect of glycyrrhizin on the cell cycle profile in BU-1 cells. BU-1 
cells (10^ cells/ml) were cultured overnight and incubated with either medium (the 
untreated control) or with two different concentrations of glycyrrhizin (3 and 4.5 mM) 
at for 48 hours. 10^  untreated and treated BU-1 cells were fixed with 70% 
ethanol and stained with PI under hypotonic conditions. Pl-stained cells were 
analyzed for fluorescence intensity using the FACSort flow cytometer. Cell cycle 
distribution was calculated by the MODFIT program using RFIT analysis model. 
Untreated BU-1 cells are shown in red DNA histogram and the black one indicates 
BU-1 cells cultured in (A) 3 mM and (B) 4.5 mM of glycyrrhizin. 
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Figure 5.2: Effect of glycyrrhizin on the cell cycle profile in BU-1 cells. BU-1 
cells (10^ cells/ml) were cultured overnight and incubated with either medium (the 
untreated control) or with two different concentrations of glycyrrhizin (3 and 4.5 mM) 
at 37�C for 72 hours. 10^ untreated and treated BU-1 cells were fixed with 70% 
ethanol and stained with PI under hypotonic conditions. Pl-stained cells were 
analyzed for fluorescence intensity using the FACSort flow cytometer. Cell cycle 
distribution was calculated by the MODFIT program using RFIT analysis model. 
Untreated BU-1 cells are shown in red DNA histogram and the black one indicates 
BU-1 cells cultured in (A) 3 mM and (B) 4.5mM of glycyrrhizin. 
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Figure 5.3: Effect of 1 Sp-glycyrrhetinic acid (GA) on the cell cycle profile in 
BU-1 cells. BU-1 cells (10^ cells/ml) were cultured overnight and incubated with 
either 0.17% DMSO (the solvent control) or with two different concentrations of 
ISp-glycyrrhetinic acid (80 and 100 _ ) at 37�C for 24 hours. 10^ treated BU-1 
cells were fixed with 70% ethanol and stained with PI under hypotonic conditions. 
Pl-stained ceils were analyzed for fluorescence intensity using the FACSort flow 
cytometer Cell cycle distribution was calculated by the MODFIT program using 
RFIT analysis model BU-1 cells cultured with the control solvent (0.17% DMSO) 
are shown in red DNA histogram and the black one indicates BU-1 cells cultured in 
(A) 80 nM and (B) 100 jiM of ISp-glycyrrhetinic acid. 
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Figure 5.4: Effect of 1 Sp-glycyrrhetinic acid (GA) on the cell cycle profile in 
BU-1 cells. BU-1 cells (10^ cells/ml) were cultured overnight and incubated with 
either 0.17% DMSO (the solvent control) or with two different concentrations of 
18(3-glycyrrhetinic acid (80 and 100 ^M) at 37°C for 48 hours. 10^ treated BU-1 
cells were fixed with 70% ethanol and stained with PI under hypotonic conditions. 
Pl-stained cells were analyzed for fluorescence intensity using the FACSort flow 
cytometer. Cell cycle distribution was calculated by the MODFIT program using 
RFIT analysis model. BU-1 cells cultured with the control solvent (0.17% DMSO) 
are shown in red DNA histogram and the black one indicates BU-1 cells cultured in 
(A) 80 |LIM and (B) 100 \xM of 18p-glycyrrhetinic acid. 
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5.2.2 Modulatory Effects of ISp-Glycyrrhetinic Acid on the Expression of Cell 
Cycle Regulatory Genes and Proteins 
Passage through the cell cycle is regulated by a family of cyclins that act as 
regulatory subunits for the cyclin-dependent kinases (CDK). The activity of various 
cyclin-CDK complexes that regulate the progression through G1-S-G2 phase of the 
cell cycle is controlled by the synthesis of the appropriate cyclins during a specific 
phase of the cell cycle as well as the sequential phosphorylation and 
dephosphorylation of the key residue of the complex, located principally on the CDK 
subunits (Puri et al., 1999; Denhardt, 1999). As mentioned previously, 
1 sp-glycyrrhetinic acid was shown to arrest the neuroblastoma BU-1 cells at the 
G2/M phase of the cell cycle. Therefore, the effect of ISp-glycyrrhetinic acid on the 
expression of G2 cyclins and cyclin-dependent kinase was examined. The 
modulatory effects of 1 Sp-glycyrrhetinic acid on the mRNA and protein expression of 
cyclin A, cyclin B and cdc2 (CDKl) were examined by RT-PCR and Western blot, 
respectively. The mRNA level was examined after treatment with 80 - 120 juM 
1 sp-glycyrrhetinic acid for 8 and 24 hours while the protein expression was examined 
after 24 and 48 hours of treatment. 
Figure 5.5 shows that the transcription of cyclin A, cyclin B and cdc2 decreased 
dose-dependent ly as early as after 8 hours of treatment with ISp-glycyrrhetinic acid. 
Moreover, the reduction in the mRNA levels of cyclin A, cyclin B and cdc2 persisted 
after 24 hours of treatment. However, the modulatory effect of ISP-glycyrrhetinic 
acid on the protein levels of cyclin A, cyclin B and cdc2 appeared at a later time 
period. As shown in Figure 5.6, the protein level of cdc2 remained fairly constant 
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after 24 hours of treatment with ISP-glycyrrhetinic acid. The decline in protein 
level of cdc2 was observed after 48 hours in a dose-dependent manner and its level 
reduced to 42% after treatment with 120 j^ M 18p-glycyrrhetinic acid. 
ISp-glycyrrhetinic acid also decreased the protein expression of cyclin A and cyclin B 
in a dose-dependent manner and such an effect occurred as early as after 24 hours of 
treatment, a time period at which no significant change in the expression of cdc2 was 
observed. Moreover, the effect of 18p-glycyrrhetinic acid on the expression of 
cyclin B seems to be more drastic than that of cyclin A since the protein expression of 
cyclin B was almost completely suppressed by a higher concentration (120 |uM) of 
18p-glycyrrhetinic acid. Together with the results of cell cycle analysis, it is 
believed that 18p-glycyrrhetinic acid arrested the BU-1 cells at the Gi/M phase by the 
down-regulation of cyclin A, cyclin B and cdc2 at both transcriptional and 
translational levels. 
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8 hr 24 hr 
A A 
r ^ r \ 
ct l 80 100 120 Ctl 80 100 120 i^M 
(22 cycles) 2.91 1.91 1.26 0.70 2.47 2.08 1.50 0.71 
Cyclin B B g ^ ^ ^ g g g i B 584 bp 
(22 cycles) 2.14 1.49 0.98 0.49 1.92 1.61 1.23 0.61 
(21 cycles) 2.69 2.06 1.63 1.31 2.89 2.65 2.32 1.53 
GAPDH 226 bp 
(20 cycles) 
Figure 5.5: Effect of 1 SP-glycyrrhetinic acid on the m R N A expression of cell 
cycle regulatory genes in BU-1 cells. BU-1 cells (10^) were cultured overnight and 
treated with either 0.2% DMSO (Ctl) or 80 - 120 juM 18p-glycyrrhetinic acid for 8 
and 24 hours. Total RNA was isolated and subjected to RT-PCR as described under 
Materials and Methods. PCR products were electrophoresed on a 2% agarose gel, 
stained with ethidium bromide. The amounts of the PCR cDNA products were 
semi-quantified by the ImageQuant software (Molecular Dynamics). The value 
below each band represents the relative intensity after normalization with respect to 
GAPDH. The number of PCR cycles completed for each set of primers is indicated 
in the parentheses and the number on the right indicates the size of the band in base 
pairs (bp). 
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Figure 5.6: Effect of 1 SP-glycyrrhetinic acid on the expression of cell cycle 
regulatory proteins in BU-1 cells. BU-1 cells (1.5 x 10^) were cultured overnight 
and treated with either 0.2% DMSO as a control (Ctl) or with 80 - 120 pM 
ISP-glycyrrhetinic acid for 24 and 48 hours. Proteins were extracted and subjected 
to Western blot as described under Materials and Methods. The extracted proteins 
(25 jag) were electrophoresed in a 10% polyacrylamide gel, transferred onto a PVDF 
membrane, exposed to anti-cdc2 (1:10,000), -cyclin A (1:1,000), -cyclin B (1:250) or 
"(3-actin (1:100,000) antibodies, then to horseradish peroxidase conjugated secondary 
antibodies (1:1,000) and subjected to ECL detection. The signal generated was 
detected by exposing the membrane to a X-ray film. (3-actin was used as a control 
for loading. Intensity of the signal was quantified and presented as relative units of 
protein expression after normalization with (3-actin. The value below each band 
represents the relative intensity. The molecular sizes of protein bands were indicated 
on the left. 
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5.2.3 Combined Effects of Glycyrrhizin, 18p-Glycyrrhetinic Acid and AW-Trans 
Retinoic Acid on the Proliferation of Neuroblastoma BU-1 Cells In Vitro 
As shown in chapter three, glycyrrhizin exerted its effects on the proliferation 
and differentiation of BU-1 cells at the millimolar level which is relatively high from 
the pharmacological point of view. Therefore, it is of great interest to examine 
whether the effective concentration of glycyrrhizin could be lowered by combining 
with another agent that is capable of modulating the growth and differentiation of 
neuroblastoma cells. In the present study, the combined effects of glycyrrhizin and 
its major metabolite, ISp-glycyrrhetinic acid, were examined since both of them were 
able to inhibit the growth and induce neuronal differentiation in BU-1 cells. 
Moreover, the combined effects of 18|3-glycyrrhetinic acid and d\\-trans retinoic acid 
(ATRA) on the proliferation and differentiation of BU-1 cells were also investigated. 
As shown in Figure 5.7, treatment of cells with 40 |LIM and 60 |LIM 
18p-glycyrrhetinic acid or 0.5 mM and 1 mM glycyrrhizin alone resulted in less than 
10% inhibition of the proliferation of BU-1 cells, as measured by the ^H-TdR 
incorporation assay. However, combined treatment of glycyrrhizin and 
18(3-glycyrrhetinic acid greatly enhanced the growth inhibition (> 70%) of BU-1 cells, 
suggesting that glycyrrhizin and 18p-glycyrrhetinic acid acted in synergy on the 
growth inhibition of BU-1 cells. Moreover, this synergistic effect occurred in a 
dose-dependent manner. 
Similar synergistic anti-proliferative effect could also be found between 
18p-glycyrrhetinic acid and ATRA. Figure 5.8 shows that combined treatment of 
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BU-1 cells with ISP-glycyrrhetinic acid and ATRA significantly increased the 
anti-proliferative effect of either compound when compared with the percentage 
growth inhibition of cells treated with either compound alone. Moreover, the 
synergistic effect was also dose-dependent. However, the extent of synergism 
between 18p-glycyrrhetinic acid and ATRA was less than that observed between 
glycyrrhizin and 1 SP-glycyrrhetinic acid. 
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Figure 5.7: Synergistic anti-proliferative effect of glycyrrhizin (GL) and 
18p-glycyrrhetinic acid (GA). BU-1 cells (7.5 x lO* ceiis/ml) were cultured 
overnight and incubated with 40 or 60 jiiM of 18p-glycyrrhetinic acid (green bars), 0.5 
or I mM of glycyrrhizin (orange bars), or combinations of glycyrrhizin and 
18p-glycyrrhetimc acid (purple bars) at 37�C for 48 hours. Cultures were then 
pulsed with 0.5 piCi of ^H-TdR for 6 hours before harvest. Radioactivity expressed 
as counts per minute (cpm), was measured using a Beckman liquid scintillation 
counter. Results were expressed as % inhibition of ^H-TdR incorporation, using the 
untreated ceils as a control Each point represents the mean 土 S.E. of quadruplicate 
cultures. 
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Figure 5.8: Synergistic anti-proliferative effect of 1 Sp-glycyrrhetinic acid (GA) 
and alUrans retinoic acid (ATRA). BU-1 cells (7.5 x lO* cells/ml) were cultured 
overnight and incubated with 50 or 60 |iM of 18j3-glycyrrhetinic acid (green bars), 15 
or 20 jjM of aW'trans retinoic acid (orange bars), or combinations of 
ISp-glycyrrhetinic acid and dill-trans retinoic acid (purple bars) at 37�C for 48 hours. 
Cultures were then pulsed with 0.5 fiCi of ^H-TdR for 6 hours before harvest. 
Radioactivity expressed as counts per minute (cpm), was measured using a Beckman 
* • 3 
liquid scintillation counter. Results were expressed as % inhibition of H-TdR 
incorporation, using the untreated cells as a control. Each point represents the mean 
土 S.E. of quadruplicate cultures. 
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5.2.4 Combined Effects of Glycyrrhizin, ISP-Glycyrrhetinic Acid and AW-Trans 
Retinoic Acid on the Differentiation of Neuroblastoma BU-1 Cells In Vitro 
In order to further investigate whether the synergistic effect observed in 
anti-proliferation assay could be applied to the differentiation of BU-1 cells, 
morphological study was performed after 4 days of treatment. As shown in Figure 
5.9, treatment of BU-1 cells with 40 \iM ISp-glycyrrhetinic acid or 0.5 mM 
glycyrrhizin did not cause any significant change in the morphology of the cells. 
However, combined treatment of cells with both glycyrrhizin and ISp-glycyrrhetinic 
acid caused the extension of neurite length and an increase in cell size of BU-1 cells 
characteristic of neuronal cell differentiation. 
Figure 5.10 shows that treatment of BU-1 cells with 60 |LIM ISp-glycyrrhetinic 
acid did not result in any morphological changes while treatment with 20 |aM ATRA 
resulted in differentiation of a small population of cells with neurite extension and an 
increase in cell size. However, combined treatment of cells with 18p-glycyrrhetinic 
acid and ATRA resulted in differentiation of nearly all cells with a marked increase in 
the neurite length. 
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Figure 5.9: Synergistic effect of glycyrrhizin and ISp-glycyrrhetinic acid in the 
induction of neuronal cell differentiation in BU-1 cells. The BU-1 cells (5,000 
cells/well) grown overnight on coverslips in the wells of a 24-well plate were treated 
with (A) control solvent (0.07 % DMSO), (B) 40 _ ISp-glycyrrhetinic acid, (C) 0.5 
mM glycyrrhizin, or (D) the combination of 40 |iM 18P-glycyrrhetmic acid and 0.5 
mM glycyrrhizin at 37°C for 4 days. The treated ceils were then stained with 
Hemacolor solutions (Magnification x 200). 
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Figure 5.10: Synergistic effect of ISp-glycyrrhetinic acid and all-trans retinoic 
acid in the induction of neuronal cell differentiation in BU-1 cells. The BU-1 
cells (5,000 cells/well) grown overnight on coversiips in the wells of a 24-well plate 
were treated with (A) control solvent (0.1 % DMSO), (B) 60 ^ ISp-glycyrrhetinic 
acid, (C) 20 sdl-tram retinoic acid, or (D) the combination of 60 juM 
ISP-glycyrrhetinic acid and 20 juM all-trans retinoic acid at 37°C for 4 days. The 
treated cells were then stained with Hemacolor solutions (Magnification x 200). 
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5.2.5 Modulatory Effect of ISP-Glycyrrhetinic Acid on the Expression of PKC 
Isoforms in Neuroblastoma BU-1 Cells 
Altered expression pattern of PKC isozymes during differentiation of 
neuroblastoma cells had been reported (Wada et al., 1989; Mak et al., 2001). 
Therefore, in the present study, the expression of various PKC isoforms in 
18(3-glycyrrhetinic acid-treated BU-1 cells was examined to see whether there are any 
correlations between their expressions and the 1 Sp-glycyrrhetinic acid-induced 
growth inhibition and differentiation of BU-1 cells. Previous study showed that 
BU-1 cells express two Ca^^-dependent PKC isoforms (PKC a and PKC P)，and four 
Ca2+-independent PKC isoforms (PKC 5, PKC s, PKC ； and PKC X) (Mak et al., 
2001). In the present study, the expression of PKC a, 5, s, (； and X was examined by 
RT-PCR after treatment with 100 |iM ISp-glycyrrhetinic acid for 30 minutes to 8 
hours. 
The expression profile of PKC isoforms in BU-1 cells after treatment with 100 
j^ M 18p-glycyrrhetinic acid was shown in Figure 5.11. The results showed that the 
expressions of PKC a, 5, s, (； and X isoforms remained fairly constant throughout the 
time period examined. 
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Ctl 30 60 120 240 360 480 min 
PKC a • • • • • • • • { • • • • • • • • • • • • I 
(28 cycles) • M f l h a J I I S H i ^ ^ H f i K i ^ ^ ^ S 324 bp 
1.75 1.99 2.07 2.13 1.84 1.89 1.83 
(26 cycles) 242 bp 
1.31 1.47 1.53 1.54 1.71 1.55 1.67 
(26 cycles) 732 bp 
1.26 1.30 1.29 1.36 1.36 1.39 1.46 
PKC^ _ _ _ • 圓 i l l m . . . . . . . . . . . . — . m m m bp 
^ ^ 2.01 2.15 1.96 2.16 2.12 1.89 1.95 
PKC X 240 bp 
(26 cycles) 2.02 2.18 2.39 2.53 2.28 2.28 2.20 
GAPDH 226 bp 
(20 cycles) 
Figure 5.11: Effect of ISP-glycyrrhetinic acid on the mRNA expression of PKC 
isoforms in BU-1 cells. BU-1 cells (10^) were cultured overnight and treated with 
either 0.17% DMSO (Ctl) or 100 |iM 18p-glycyrrhetinic acid for various time periods 
(30 minutes to 8 hours). Total RNA was isolated and subjected to RT-PCR as 
described under Materials and Methods. PGR products were electrophoresed on a 
2% agarose gel, stained with ethidium bromide. The amounts of the PCR cDNA 
products were semi-quantified by the ImageQuant software (Molecular Dynamics). 
The value below each band represents the relative intensity after normalization with 
respect to GAPDH. The number of PCR cycles completed for each set of primers is 
indicated in the parentheses and the number on the right indicates the size of the band 
in base pairs (bp). 
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5.2.6 The Possible Involvement of Protein Kinase C in the Anti-proliferative 
and Differentiation-Inducing Effects of ISP-Glycyrrhetinic Acid on the 
Neuroblastoma BU-1 Cells 
Modulation of PKC activity was shown to be correlated with differentiation of 
neuroblastoma cells (Minana et al., 1990; Fagerstrom et al., 1996; Mak et al, 2001). 
To gain better insights into the underlying signal transduction processes, the effects of 
modulators of protein kinase activity on the proliferation and differentiation of BU-1 
cells cultured with ISp-glycyrrhetinic acid were investigated. In the present study, 
the PKC activators [PMA, phorbol 12,13-diacetate (PDA)] and PKC inhibitors 
(staurosporine, calphostin C, Go 6976) were employed in combination with 
18p-glycyrrhetinic acid in the proliferation assay (^H-TdR incorporation assay) and 
morphological study to determine whether the anti-proliferative and 
d i f f e r e n t i a t i o n - i n d u c i n g effects of ISP-glycyrrhetinic acid were PKC-dependent or 
not. 
Combined treatment of BU-1 cells with PMA, PDA, staurosporine, and 
18(3-glycyrrhetinic acid did not result in any significant change in the 
anti-proliferative effect of ISP-glycyrrhetinic acid when compared with the growth 
inhibition of cells treated with 80 |LIM 18(3-glycyrrhetinic acid alone (data not shown). 
However, combined treatment of BU-1 cells with calphostin C or Go 6976 with 
18(3-glycyrrhetinic acid slightly enhanced the anti-proliferative effect of 
18p-glycyrrhetinic acid (Table 5.1 & 5.2). 
In addition, combined treatment of BU-1 cells with PMA, PDA and 
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18p-glycyrrhetinic acid did not modulate the differentiation-inducing effect of 
ISP-glycyrrhetinic acid compared with those treated with 80 )iM ISp-glycyrrhetinic 
acid alone (data not shown). In contrast, combined treatment of BU-1 cells with 1 
nM staurosporine, a broad spectrum PKC inhibitor and 80 |LIM 18|3-glycyrrhetinic 
acid significantly reduced the number of differentiated cells compared with BU-1 
cells treated with ISp-glycyrrhetinic acid alone (Figure 5.12). Moreover, Figure 
5.13 shows that calphostin C used at 150 nM clearly prevented the neurite outgrowth 
and cell size enlargement induced by 80 |liM 18P-glycyrrhetinic acid. Furthermore, 
treatment of BU-1 cell with 80 i^M ISp-glycyrrhetinic acid in the presence of 4 nM 
Go 6976, a PKC inhibitor that inhibits Ca^^-dependent isozymes a and pi at 
nanomolar concentrations without affecting the kinase activity of Ca^^-independent 
PKC 5, 8 and ( isozymes even at micromolar level (Martiny-Baron et al., 1993), 
effectively blocked the differentiation-inducing effect of ISP-glycyrrhetinic acid with 
a marked decrease in the number of differentiated cells (Figure 5.14). 
-159- — 
Chapter 5 Mechanistic Studies 
Table 5.1: Combined effect of 18P-glycyrrhetinic acid and calphostin C on the 
proliferation of BU-1 cells. 
% Inhibition of^H-TdR 
Treatment of BU-1 cells with 
Incorporation 
50 nM calphostin C 4.19 ± 1.10 
150 nM calphostin C 7.59 土 0.42 
80 )LIM 18p-glycyrrhetinic acid 48.13 土 0.42 
50 nM calphostin C + 80 |iM 18p-glycyrrhetinic acid 54.61 ± 1.08 * 
150 nM calphostin C + 80 |aM 18p-glycyrrhetinic acid 59.06 ±0.42** 
BU-1 cells (7.5 x cells/ml) were cultured overnight and incubated alone with 80 
jiM 18p-glycyrrhetinic acid, calphostin C (50 and 150 nM), or with combinations of 
1 sp-glycyrrhetinic acid and calphostin C at 37�C for 48 hours. Cultures were then 
pulsed with 0.5 |aCi of ^H-TdR for 6 hours before harvest. Radioactivity in counts 
per minutes (cpm) was measured by liquid scintillation counting. Results were 
expressed as % inhibition of ^H-TdR incorporation, using untreated BU-1 cells as a 
control. The data shown are the mean 士 standard error of quadruplicate wells. *p < 
0.01, **p < 0.001 vs. 18P-glycyrrhetinic acid alone. 
-160- ” 
Chapter 5 Mechanistic Studies 
Table 5.2: Combined effect of ISP-glycyrrhetinic acid and Go 6976 on the 
proliferation of BU-1 cells. 
% Inhibition of^H-TdR 
Treatment of BU-1 cells with 
Incorporation 
3 nM Go 6976 18.20 土 2.49 
4 nM Go 6976 52.83 ±3.41 
80 [lM 1 Sp-glycyrrhetinic acid 48.72 士 0.55 
3 nM Go 6976 + 80 |iM 18p-glycyrrhetinic acid 53.70 土 0.44 * 
4 nM Go 6976+ 80 ^M 1 Sp-glycyrrhetinic acid 61.26 ± 1.56 * 
BU-1 cells (7.5 X 104 cells/ml) were cultured overnight and incubated alone with 80 
|iM 1 Sp-glycyrrhetinic acid, Go 6976 (3 and 4 nM), or with combinations of 
18p-glycyrrhetinic acid and Go 6976 at 37�C for 48 hours. Cultures were then 
pulsed with 0.5 |iCi of ^H-TdR for 6 hours before harvest. Radioactivity in counts 
per minutes (cpm) was measured by liquid scintillation counting. Results were 
expressed as % inhibition of ^H-TdR incorporation, using untreated BU-1 cells as a 
control. The data shown are the mean 土 standard error of quadruplicate wells. *p < 
0.01 vs. 1 sp-glycyrrhetinic acid alone. 
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Figure 5.12: Combined effect of 1 Sp-glycyrrhetinic acid and staurosporine on the 
differentiation of BU-1 cells. The BU-1 cells (5,000 cells/well) grown overnight on 
coverslips in the wells of a 24-well piate were treated with (A) control solvent (0.13% 
DMSO)，(B) 80 ^M ISP-glycyrrhetinic acid, (C) 1 nM staurosporine, or (D) the 
combination of 80 jiM ISp-glycyrrhetinic acid and 1 nM staurosporine at 37�C for 4 
days. The treated cells were then stained with Hemacolor solutions (Magnification x 
200). 
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Figure 5.13: Combined effect of ISp-glycyrrhetinic acid and calphostin C on the 
differentiation of BU-1 cells. The BU-1 cells (5,000 cells/well) grown overnight on 
coversiips in the wells of a 24-weli plate were treated with (A) control solvent (0.13% 
DMSO), (B) 80 i M i8p-glycyrrhetimc acid, (C) 150 nM calphostin C，or (D) the 
combination of 80 fiM 18p-glycyrrhetinic acid and 150 nM calphostin C at 37�C for 4 
days. The treated cells were then stained with Hemacolor solutions (Magnification x 
200). 
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Figure 5.14: Combined effect of ISp-glycyrrhetinic acid and Go 6976 on the 
differentiation of BU-1 cells. The BU-1 cells (5,000 cells/well) grown overnight on 
coverslips in the wells of a 24-well plate were treated with (A) control solvent (0.13% 
DMSO), (B) 80 ixM ISp-glycyrrhetinic acid，(C) 4 nM Go 6976, or (D) the 
combination of 80 |LIM 18p-glycyrrhetinic acid and 4 nM Go 6976 at 37°C for 4 days. 
The treated cells were then stained with Hemacolor solutions (Magnification x 200). 
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5.2.7 The Possible Involvement of Protein Kinase A in the Anti-proliferative 
and Differentiation-Inducing Effects of ISP-Glycyrrhetinic Acid on the 
Neuroblastoma BU-1 Cells 
To investigate whether PKA signaling pathway is involved in the 
18P-glycyrrhetinic acid-induced growth inhibition and differentiation of BU-1 cells, 
several PKA activators (Sp-isomer, db-cAMP and forskolin) or inhibitors (Rp-isomer, 
H-89, KT5720 and 14-22 amide) were used in combination with ISP-glycyrrhetinic 
acid to see whether modulation of PKA activity would affect the effects of 
ISp-glycyrrhetinic acid. The results showed that treatment of BU-1 cells with 
Rp-isomer, H-89, KT5720 and 14-22 amide at pharmacological concentrations that 
are known to inhibit the PKA activity did not alter the ISp-glycyrrhetinic 
acid-induced growth inhibition and differentiation of BU-1 cells (data not shown). 
In contrast, the 18p-glycyrrhetinic acid-induced growth inhibition and differentiation 
of BU-1 cells were markedly augmented by PKA activators. As shown in Table 5.3 -
5.5, incubation of BU-1 cells with PKA activators alone slightly inhibited the growth 
of BU-1 cells while combined treatment of PKA activators and 18p-glycyrrhetinic 
acid significantly enhanced the anti-proliferative effect of 18p-glycyrrhetinic acid in a 
dose-dependent manner. The potentiation effect of PKA activators could also be 
applied to the ISp-glycyrrhetinic acid-induced differentiation of BU-1 cells. In 
general, for the dose of PKA activators employed in this study, treatment of cells with 
PKA activators alone did not result in any morphological changes of BU-1 cells 
(Figure 5.15D, 5.16D & 5.17D). Combined treatment of BU-1 cells with 70 |iM 
18p-glycyrrhetinic acid and PKA activator significantly induced extensive 
differentiation of BU-1 cells while treatment of cells with either 70 i^M 
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ISP-glycyrrhetinic acid or PKA activator alone did not induce significant 
differentiation (Figure 5.15 — 5.17). Combined treatment of cells with PKA 
activators and 80 ISP-glycyrrhetinic acid also significantly enhanced the extent of 
differentiation compared with cells that were treated with 80 jiM ISp-glycyrrhetinic 
acid alone (Figure 5.15 - 5.17). 
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Table 5.3: Combined effect of 18P-glycyrrhetinic acid and Sp-isomer on the 
proliferation of BU-1 cells. 
% Inhibition of ^H-TdR 
Treatment of BU-1 cells with 
Incorporation 
60 [iU Sp-isomer 4.01 土 0.78 
80 i^ M Sp-isomer 5.16 士 0.97 
80 |LiM 1 Sp-glycyrrhetinic acid 62.81 土 0.75 
60 Sp-isomer + 80 |iM 18p-glycyrrhetinic acid 80.88 土 0.06 ** 
80 laM Sp-isomer + 80 [iU 18p-glycyrrhetinic acid 85.43 土 0.49 ** 
BU-1 cells (7.5 x lO"^  cells/ml) were cultured overnight and incubated alone with 80 
I^ M 18p-glycyrrhetinic acid, Sp-isomer (60 and 80 |LIM), or with combinations of 
ISp-glycyrrhetinic acid and Sp-isomer at 37�C for 48 hours. Cultures were then 
pulsed with 0.5 |j.Ci of ^H-TdR for 6 hours before harvest. Radioactivity in counts 
per minutes (cpm) was measured by liquid scintillation counting. Results were 
expressed as % inhibition of ^H-TdR incorporation, using untreated BU-1 cells as a 
control. The data shown are the mean 土 standard error of quadruplicate wells. **p 
< 0.001 vs. ISp-glycyrrhetinic acid alone. 
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Table 5.4: Combined effect of 1 Sp-glycyrrhetinic acid and db-cAMP on the 
proliferation of BU-1 cells. 
% Inhibition of ^H-TdR 
Treatment of BU-1 cells with . 
Incorporation 
1 0 l u i M d b - c A M P 6 . 8 1 ± 1 . 3 7 
1 0 0 i ^ M d b - c A M P 1 5 . 6 3 土 1 . 2 7 
8 0 i ^ M 1 S p - g l y c y r r h e t i n i c a c i d 7 0 . 7 2 土 0 . 2 6 
1 0 i ^ M d b - c A M P + 8 0 ^ i M 1 8 p - g l y c y r r h e t i n i c a c i d 8 2 . 7 1 土 0 . 3 8 
1 0 0 i ^ M d b - c A M P + 8 0 | a M 1 S p - g l y c y r r h e t i n i c a c i d 9 4 . 8 3 ± 0 . 0 4 * * 
B U - 1 c e l l s ( 7 . 5 x 1 0 ^ c e l l s / m l ) w e r e c u l t u r e d o v e r n i g h t a n d i n c u b a t e d a l o n e w i t h 8 0 
l a M 18(3-glycyrrhetinic acid, d b - c A M P ( 1 0 and 1 0 0 ^ i M ) , o r with combinations o f 
1 8 p - g l y c y r r h e t i n i c a c i d a n d d b - c A M P a t 3 7 � C f o r 4 8 h o u r s . C u l t u r e s w e r e t h e n 
p u l s e d w i t h 0 . 5 [xCi o f ^ H - T d R f o r 6 h o u r s b e f o r e h a r v e s t . R a d i o a c t i v i t y i n c o u n t s 
per minutes (cpm) was measured by liquid scintillation counting. Results were 
expressed as % inhibition of ^H-TdR incorporation, using untreated BU-1 cells as a 
control. The data shown are the mean 土 standard error of quadruplicate wells. **p 
< 0 . 0 0 1 v s . ISP-glycyrrhetinic a c i d alone. 
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Table 5.5: Combined effect of ISP-glycyrrhetinic acid and forskolin on the 
proliferation of BU-1 cells. 
% Inhibition of ^H-TdR 
Treatment of BU-1 cells with 
Incorporation 
1 )LIM forskolin 4.05 ±1.40 
5 i^ M forskolin 9.45 土 0.78 
80 |iM 18p-glycyrrhetinic acid 67.29 土 0.72 
1 laM forskolin + 80 ^M 18p-glycyrrhetinic acid 84.64 士 0.28 ** 
5 i^ M forskolin + 80 i^M 18p-glycyrrhetinic acid 90.22 土 0.28 ** 
BU-1 cells (7.5 x cells/ml) were cultured overnight and incubated alone with 80 
{AM ISp-glycyrrhetinic acid, forskolin (1 and 5 |iM), or with combinations of 
ISp-glycyrrhetinic acid and forskolin at 37°C for 48 hours. Cultures were then 
pulsed with 0.5 |iCi of ^H-TdR for 6 hours before harvest. Radioactivity in counts 
per minutes (cpm) was measured by liquid scintillation counting. Results were 
expressed as % inhibition of ^H-TdR incorporation, using untreated BU-1 cells as a 
control. The data shown are the mean 士 standard error of quadruplicate wells. **p 
< 0.001 vs. 18p-glycyrrhetinic acid alone. 
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Figure 5.15: Combined effect of ISP-glycyrrhetinic acid and Sp-isomer on the 
differentiation of BU-1 cells. The BU-1 ceils (5,000 cells/well) grown overnight on 
coverslips in the wells of a 24-well plate were treated with (A) control solvent (0.13% 
DMSO), (B) 70 |iM 18p-glycyrrhetinic acid, (C) 80 _ 18p-glycyrrhetinic acid, (D) 
80 jiiM Sp-isomer, (E) the combination of 70 juM ISp-glycyrrhetinic acid and 80 
Sp-isomer or (F) the combination of 80 juM 1 Sp-glycyrrhetinic acid and 80 jiM 
Sp-isomer at 37°C for 4 days. The treated cells were then stained with Hemacolor 
solutions (Magnification x 200). 
“ - 1 7 0 - — 
Chapter 5 Mechanistic Studies 
I c ， f : � | | � D " : t " ^ 
p s ~ n p ^ 多 ^ 龜專 f — I 
E 先 • • 攀 # t 广‘‘ 
臂 . t ••‘ ， 攀 _ ^ 
Figure 5.16: Combined effect of 18p-glycyrrhetinic acid and db-cAMP on the 
differentiation of BU-1 cells. The BU-1 cells (5,000 cells/well) grown overnight on 
coverslips in the wells of a 24-well plate were treated with (A) control solvent (0.13% 
DMSO)，(B) 70 ^M 18p-glycyrrhetinic acid, (C) 80 ^M 18p-glycyrrhetinic acid, (D) 
100 ^M db-cAMP, (E) the combination of 70 j^ M ISP-glycyrrhetinic acid and 100 
jiiM db-cAMP or (F) the combination of 80 ]iM 18p-glycyrrhetimc acid and 100 |iM 
db-cAMP at 37°C for 4 days. The treated cells were then stained with Hemacolor 
solutions (Magnification x 200). 
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Figure 5.17: Combined effect of 18p-glycyrrhetinlc acid and forskolin on the 
differentiation of BU-1 ceils. The BU-1 cells (5,000 cells/weii) grown overnight on 
coversiips in the wells of a 24-well plate were treated with (A) control solvent (0.13% 
DMSO)，(B) 70 pM 18p-glycyrrhetinic acid, (C) 80 jiM ISp-glycyrrhetinic acid, (D) 
5 jiiM forskolin, (E) the combination of 70 jiiM ISp-glycyrrhetinic acid and 5 juM 
forskolin or (F) the combination of 80 jiiM ISP-glycyrrhetinic acid and 5 jiiM 
forskolin at 3TC for 4 days. The treated cells were then stained with Hemacolor 
solutions (Magnification x 200). 
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5.3 Discussion 
In the previous two chapters, glycyrrhizin and 18p-glycyrrhetinic acid had been 
shown to exert anti-proliferative and differentiation-inducing effects on the murine 
neuroblastoma BU-1 cells in vitro. However, the mechanisms by which they exerted 
their effects on the BU-1 cells had not been fully elucidated. In the present study, 
the effects of glycyrrhizin and ISp-glycyrrhetinic acid on the cell cycle progression of 
BU-1 cells were studied by flow cytometry. The results showed that both 
glycyrrhizin and 18p-glycyrrhetinic acid could induce cell cycle arrest of BU-1 cells 
at the G2/M phase accomplished with a decrease of cells in the GQ/GI phase and S 
phase although the cell cycle arrest of glycyrrhizin-treated cells occurred in a delayed 
fashion when compared with the ISP-glycyrrhetinic acid-treated cells. Therefore, it 
can be speculated that the anti-proliferative effect of glycyrrhizin and 
18p-glycyrrhetinic acid on BU-1 cells might be mediated through the blockade of the 
cell cycle progression. Moreover, the absence of sub-Gl peak in the DNA 
histogram is consistent with the observation in chapter three that glycyrrhizin and 
18|3-glycyrrhetinic acid are incapable of triggering apoptosis in the neuroblastoma 
BU-1 cells. 
The mammalian cell cycle consists of two major phases known as S and M 
phases, during which DNA synthesis and mitosis occurs respectively, and two 
intervening phases called Gi and G2 in which the cell is preparing to initiate DNA 
synthesis and cell division respectively. Complexes of cyclins with cyclin dependent 
kinases (CDK) play a central role in the control of the cell cycle progression by 
phosphorylating specific substrates that is thought to be critical in the regulation of an 
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ordered sequence of events leading to DNA replication and chromosomal segregation. 
Progression through the cell cycle depends on the expression of certain proteins at 
appropriate times. Cyclins are activators of CDK and their expressions are tightly 
regulated. Cyclin A is implicated in the control of the S phase as well as mitosis. 
Cdc2 forms complexes with cyclin A, allowing the progression through S into M 
phase. The cyclin B/cdc2 complexes which are also known as the 
maturation-promoting factor (MPF), accumulate in the Gi phase and induce mitosis as 
a consequence of phosphorylation of target proteins such as the nuclear membrane 
lamins and various cytoskeletal proteins (Puri et al., 1999; Denhardt, 1999). Since 
glycyrrhizin and 18P-glycyrrhetinic acid were shown to arrest the cell cycle at the 
G2/M phase and 18p-glycyrrhetinic acid was more potent than glycyrrhizin, therefore, 
the effect of 18P-glycyrrhetinic acid on the expression of G2 cyclins and cyclin 
dependent kinase was further investigated by RT-PCR and Western blot. The results 
showed that 18p-glycyrrhetinic acid down-regulated the expression of cyclin A, 
cyclin B and cdc2 dose- and time-dependently at both transcriptional and translational 
levels, suggesting that one of the mechanisms by which 18p-glycyrrhetinic acid might 
arrest the growth of BU-1 cells was via the down-regulation of these cell cycle 
regulatory proteins. 
Results in the previous two chapters showed that glycyrrhizin and 
1 sp-glycyrrhetinic acid were able to inhibit the growth and induce differentiation of 
BU-1 cells. Therefore, we aimed to determine whether combined treatment of 
glycyrrhizin with 18P-glycyrrhetinic acid would result in synergistic or additive effect 
on growth inhibition and differentiation of neuroblastoma cells. The results in this 
chapter showed that combined treatment of glycyrrhizin and 1 Sp-glycyrrhetinic acid 
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greatly enhanced the growth inhibition of BU-1 cells when compared with treatment 
with either compound alone. Synergistic effect of glycyrrhizin and 
1 Sp-glycyrrhetinic acid could also be found on the differentiation of BU-1 cells. 
Combined treatment of glycyrrhizin and 18|3-glycyrrhetinic acid at the dose that did 
not induce differentiation alone significantly induced differentiation of BU-1 cells 
with an increase in cell size and outgrowth of neurites. This finding provides a 
rational basis for the potential use of glycyrrhizin for the differentiation therapy of 
neuroblastoma since 1 Sp-glycyrrhetinic acid is the major metabolite of glycyrrhizin 
and both glycyrrhizin and ISP-glycyrrhetinic acid could be detected in the plasma 
after intravenous administration of glycyrrhizin and the presence of glycyrrhizin and 
ISP-glycyrrhetinic acid would thus greatly enhance the growth inhibition and 
differentiation of the neuroblastoma cells. However, the mechanism by which 
glycyrrhizin and ISP-glycyrrhetinic acid exert synergistic effect is still unclear and 
will require further investigations. Besides the synergistic effect between 
glycyrrhizin and ISP-glycyrrhetinic acid, ISp-glycyrrhetinic acid was also found to 
act in synergy with ATRA in both growth inhibition and differentiation of BU-1 cells, 
implying that combination of ISP-glycyrrhetinic acid and ATRA might have potential 
therapeutic value in the treatment of some forms of neuroblastoma. The actions of 
retinoic acid are thought to be mediated through two types of nuclear retinoid 
receptors: the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). 
ATRA binds with high affinity to RARs and these receptors function as transcription 
factors in a ligand-dependent manner as heterodimers with l igand- independen t RXRs 
(Allegretto et al,, 1993). Moreover, recent study showed that ATRA treatment of 
SH-SY5Y neuroblastoma cells rapidly activated the PBK/Akt signaling pathway and 
caused a decrease in the expression of differentiation-inhibiting genes and an increase 
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in the expression of differentiation-promoting genes (Lopez-Carballo et al., 2002). 
Furthermore, the PBK/Akt signaling pathway is involved in the ATRA-induced 
differentiation of SH-SY5Y cells and in the transcriptional down-regulation of 
differentiation-inhibiting genes. Lopez-Carballo et al (2002) hypothesized that 
ATRA may activate PI3K through an atypical extragenomic action of its receptor. 
Since the action mechanism of ATRA is quite complicated by itself, further 
investigation is required to elucidate the exact mechanism of the synergistic action of 
1 Sp-glycyrrhetinic acid and ATRA on the proliferation and differentiation of the 
neuroblastoma BU-1 cells. 
PKC is a family of serine-threonine kinases that have been shown to play an 
important role in the growth, survival and differentiation of cells (Goekjian & 
Jirousek, 2001). The conventional PKC isoforms were shown to be involved in 
growth and survival of neuroblastoma cells while the novel isoforms seemed to play a 
role in neurite outgrowth (Fagerstrom et al., 1996; Zeidman et al., 1999a; Zeidman et 
al., 1999b; Svensson et al., 2000). Recent studies have indicated that changes in the 
expression of PKC isoforms and/or their activities are associated with differentiation 
of neuroblastoma cells (Minana et al., 1990; Zeidman et al., 1999b; Mak et al., 2001). 
Our results showed that the mRNA expression of certain PKC isoforms remained 
fairly constant throughout the time period examined. However, due to the failure of 
proper amplification of PKC p (formation of primer dimers) by RT-PCR although 
various annealing temperature had been tried, the mRNA expression level of PKC P 
was not shown. Since PKC (3 may play a role in mediating the ISp-glycyrrhetinic 
acid induced effect, a new primer set for PKC (3 should be redesigned in order to test 
whether PKC P expression could be modulated by ISp-glycyrrhetinic acid. 
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Although, the protein levels and the enzymatic activities of the PKC isoforms had not 
been investigated, the possible involvement of PKC in the ISP-glycyrrhetinic 
acid-induced growth inhibition and differentiation of BU-1 cells was examined by 
incubation of BU-1 cells with ISp-glycyrrhetinic acid (80 |aM) in the presence or 
absence of PKC activators or inhibitors. Our results showed that for all PKC 
activators and inhibitors examined, no antagonistic effect could be found on the 
anti-proliferative effect of 18p-glycyrrhetinic acid. However, some inhibitors such 
as calphostin C and Go 6976 even slightly potentiated the growth inhibitory effect of 
18p-glycyrrhetinic acid. This potentiation effect may reflect that PKC activity is 
important for the growth and/or survival of neuroblastoma cells and inhibition of PKC 
would inhibit the growth of neuroblastoma cells (Zeidman et al., 1999b). Moreover, 
treatment of cells with PKC inhibitors alone inhibited the growth of BU-1 cells 
dose-dependently (data not shown), supporting the hypothesis that PKC activity is 
required for the growth and/or survival of BU-1 cells. Since no antagonistic effect 
was observed on the proliferation of BU-1 cells when PKC activator or inhibitor was 
combined with ISp-glycyrrhetinic acid compared with treatment of cells with 
18p-glycyrrhetinic acid alone, we cannot conclude whether the anti-proliferative 
effect of 18P-glycyrrhetinic acid is PKC dependent or not. 
On the other hand, staurosporine, a broad spectrum protein kinase inhibitor, was 
found to be capable of suppressing neurite outgrowth and decreasing the number of 
differentiated BU-1 cells, suggesting that protein kinase(s) might be involved in the 
d i f f e r e n t i a t i o n - i n d u c i n g effect of 18p-glycyrrhetinic acid. Staurosporine inhibits 
PKC with an IC50 value of approximately 0.7 nM and inhibits myosin light chain 
kinase, protein kinase A, protein kinase G and calmodulin kinase at higher 
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concentrations. Therefore, in order to confirm whether PKC was involved in the 
differentiation-inducing effect of 18p-glycyrrhetinic acid, more specific protein kinase 
C inhibitors including calphostin C and Go 6976 were used. Calphostin C is a 
highly specific inhibitor of protein kinase C that interacts with the protein's regulatory 
domain by competing at the binding site of diacylglycerol and phorbol esters with an 
IC50 value of 50 nM and inhibits myosin light chain kinase, protein kinase A and 
protein kinase G at much higher concentrations. The results showed that calphostin 
C almost completely blocked the differentiation-inducing effect of ISP-glycyrrhetinic 
acid. On the other hand, Go 6976 is a PKC inhibitor that selectively inhibits 
Ca^^-dependent PKC isoforms (PKC a and (31) at nanomolar concentrations. Our 
results showed that Go 6976 markedly inhibited the 18p-glycyrrhetinic acid-induced 
differentiation of BU-1 cells, suggesting that the conventional PKC isoforms (PKC a 
and pi) might be involved in the differentiation induced by ISp-glycyrrhetinic acid. 
This finding was in agreement with a recent report showing that conventional PKC 
isoforms play a role in euxanthone-induced neuritogenesis in the BU-1 cells (Mak et 
Recently, the role of PKC novel isoforms especially PKC s in neurite outgrowth 
has been suggested (Fagerstrom et al., 1996; Zeidman et al., 1999b; Zeidman et al., 
2002). Overexpression of the regulatory domain of PKC s has resulted in the 
induction of neurite-like processes (Zeidman et al., 1999a). Moreover, PKC s has 
been shown to play a role in the regulation of phosphorylation of 
m i c r o t u b u l e - a s s o c i a t e d protein tau (Ekinci & Shea，1997). Our present results 
indicated that calphostin C, which inhibits both the conventional and novel PKC 
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isoforms, exerted a much more pronounced effect in suppressing the 
ISP-glycyrrhetinic acid-induced differentiation of BU-1 cells. This observation 
suggests that novel PKC isoforms may also be involved in the ISP-glycyrrhetinic 
acid-induced differentiation of BU-1 cells. The finding that inhibition of PKC 
reduced the ISP-glycyrrhetinic acid-induced differentiation implies that the 
differentiation-inducing effect of ISp-glycyrrhetinic acid on the BU-1 cells may be 
PKC-dependent. However, the major problem in determining which PKC isoform 
mediates the differentiation-inducing effect is the lack of highly-specific PKC isoform 
inhibitors. Perhaps the use of antisense oligonucleotides can provide better insights 
for the involvement of certain PKC isoforms in neuronal cell differentiation. 
O,Brian et al. (1990) reported that concentrations of 18p-glycyrrhetinic acid 
2+ 
below 200 jaM slightly enhanced the PKC activity in the presence of Ca and 
phosphatidylserine. However, it had no effect on the PKC activity in the absence of 
these co-factors, suggesting that ISP-glycyrrhetinic acid may activate the 
conventional and novel PKC isoforms. In the present study, the combined treatment 
of BU-1 cells with PKC activators and 18p-glycyrrhetinic acid failed to potentiate the 
d i f f e r e n t i a t i o n - i n d u c i n g effect of ISP-glycyrrhetinic acid. In addition, incubation of 
BU-1 cells with PKC activators alone could not induce differentiation in BU-1 cells 
(data not shown), suggesting that PKC may be necessary for the differentiation 
induced by ISp-glycyrrhetinic acid but activation of PKC alone was insufficient to 
induce differentiation in the BU-1 cells. Therefore, factors other than PKC would be 
involved in the differentiation-inducing effect of 18 (3-glycyrrhetinic acid and this 
awaits further investigations. Although BU-1 is a subclone of the murine 
neuroblastoma Neuro-2a, the role of PKC in the differentiation of BU-1 and Neuro-2a 
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cells seems to be different. An earlier report showed that inhibition of protein kinase 
C by a PKC inhibitor H7 induced neuritogenesis in Neuro-2a and the neuritogenesis 
was prevented and reversed by PMA, an activator of PKC (Minana et al., 1990). 
Moreover, a recent report demonstrated that treatment of Neuro-2a cells with 
staurosporine (20 nM) resulted in marked differentiation towards the neuronal 
phenotype (Mohan et al., 1999). On the contrary, another study showed that 
calphostin C, a more specific inhibitor of PKC, inhibited the proliferation of Neuro-2a 
cells but did not induce morphological differentiation (Minana et al., 1992). The 
discrepancy of these findings remains unclear; perhaps, it may be due to the intrinsic 
differences in responses among the clonal variants or due to the differences in the 
specificity of the inhibitors employed in these studies. Since H7 and staurosporine 
are broad spectrum PKC inhibitors, perhaps the induction of differentiation promoted 
by H7 and staurosporine in Neuro-2a cells may not be directly linked to the inhibition 
of PKC and the non-specific inhibition of protein kinases other than PKC may cause 
the differentiation. 
The involvement of cyclic AMP-dependent protein kinase (PKA) on growth 
inhibition and/or neuronal differentiation has been shown on several neuronal cell 
lines (Kim et al., 2000; Kim et al., 2002). To determine whether the PKA signaling 
pathway is involved in the 18p-glycyrrhetinic acid-induced growth inhibition and 
differentiation of BU-1 cells, PKA activators or PKA inhibitors were used in 
combination with 18P-glycyrrhetinic acid in the ^H-TdR incorporation assay and 
morphological study. Interestingly, all PKA inhibitors tested (Rp-isomer, H-89, 
KT5720 and 14-22 amide) failed to modulate the growth-inhibitory and 
d i f f e r e n t i a t i o n - i n d u c i n g effects of 1 Sp-glycyrrhetinic acid (data not shown). On the 
‘ -180 -
Chapter 5 Mechanistic Studies 
Other hand, when combined with 18|3-glycyrrhetinic acid, the cAMP-elevating agent 
such as forskolin, and the cAMP analogs, Sp-isomer and dibutyryl cAMP (db-cAMP), 
markedly augmented the growth inhibition and differentiation of BU-1 cells induced 
by 18(3-glycyrrhetinic acid. These results suggest that the growth-inhibitory and 
differentiation-inducing effects of ISp-glycyrrhetinic acid on BU-1 cells were not 
mediated directly by an increase in PKA activity but the ISP-glycyrrhetinic acid 
signaling pathway might be cAMP-dependent. Similarly, it has been reported that 
induction of neurite outgrowth in PC 12 cells by the bacterial nucleoside 
N^-methyldeoxyadenosine is mediated through a cAMP-dependent/PKA-independent 
signaling pathway (Charles et al., 2003). It is possible that the promotion of neurite 
outgrowth by 18P-glycyrrhetinic acid could be mediated by a signal transduction 
pathway which involves the generation of endogenous cAMP but independent of PKA. 
However, whether ISP-glycyrrhetinic acid could directly stimulate the adenylyl 
cyclase and increase the endogenous cAMP level in BU-1 cells awaits further 
investigations. 
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Licorice {Radix Glycyrrhizae) is generally referred to as Gancao (甘草)by the 
Chinese and is one of the most widely used medicinal herbs since ancient time. It is 
also utilized extensively in foods and tobacco products as a sweetener and as a 
flavoring agent, respectively. Glycyrrhizin, a water soluble triterpenoid saponin, is 
the major active component of licorice root, and accounts for 6 - 14% by weight of 
the licorice extract. ISp-glycyrrhetinic acid, the aglycone of glycyrrhizin, is also 
present in the root of licorice (0.5 - 0.9%). After oral administration in humans, 
glycyrrhizin is primarily metabolized into ISP-glycyrrhetinic acid by the 
3-glucuronidase of intestinal bacteria. Research in the past two decades showed that 
licorice exhibits diverse biological and pharmacological activities, including 
anti-inflammatory, hepatoprotective, anti-carcinogenic, anti-tumor, anti-viral, 
immunomodulatory, and mineralocorticoid effects. Many of these activities have 
been attributed mainly, if not all, to glycyrrhizin and its aglycone, 18|3-glycyrrhetinic 
acid. Although the anti-tumor effects of glycyrrhizin and ISP-glycyrrhetinic acid on 
various cancer cells have been demonstrated by in vivo and in vitro studies, yet the 
direct anti-tumor action mechanisms of these two natural products have not been fully 
elucidated. 
In the present study, glycyrrhizin and ISP-glycyrrhetinic acid were found to 
exhibit differential anti-proliferative effect on one murine (Neuro-2a BU-1) and two 
human (SK-N-DZ and SH-SY5Y) neuroblastoma cell lines in a dose-dependent 
manner. ISP-glycyrrhetinic acid was found to be more potent than glycyrrhizin as it 
exerted its anti-proliferative activity at micromolar concentrations. The murine 
neuroblastoma BU-1 cells also responded time-dependently to the growth-inhibitory 
effect of glycyrrhizin and ISP-glycyrrhetinic acid. However, the anti-proliferative 
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effect of glycyrrhizin and ISp-glycyrrhetinic acid depended both on the duration of 
drug treatment and the drug concentration used. Exposure of the BU-1 cells to 
ISP-glycyrrhetinic acid for 24 hours had resulted in a significant decrease in the 
proliferating potential of drug-treated cells despite the drug was removed. However, 
the anti-proliferative effect of glycyrrhizin and 18p-glycyrrhetinic acid cannot be 
attributed to the direct cytotoxicity of the drugs on the neuroblastoma cells as they 
were not cytotoxic in nature and both of them also failed to induce apoptosis in the 
BU-1 cells. 
Besides the anti-proliferative effect, glycyrrhizin and ISp-glycyrrhetinic acid 
were found to be capable of inducing differentiation in the neuroblastoma cells. 
Both glycyrrhizin and ISP-glycyrrhetinic acid could induce morphological as well as 
biochemical changes in the BU-1 cells as judged by the neurite outgrowth and 
increased expression of neuronal differentiation markers MAP2 and 
neurofilament-200 in drug-treated cells. Moreover, the differentiation induced by 
18p-glycyrrhetinic acid in BU-1 cells was accompanied with a down-regulation of 
N-myc gene expression and an up-regulation of the expression of the Bcl-2, 
NF-KB/p50 and c-fos genes. It is possible that the drug-induced changes in these 
gene expressions are responsible for the ISP-glycyrrhetinic acid-induced 
differentiation of BU-1 cells. Nevertheless, the mechanisms by which 
18p-glycyrrhetinic acid could alter the expression of these genes have not been 
elucidated and await further investigations. The anti-proliferative and 
d i f f e r e n t i a t i o n - i n d u c i n g effects of glycyrrhizin and ISp-glycyrrhetinic acid suggest 
that these two drugs have potential use for the differentiation therapy of 
neuroblastoma, however, whether the pharmacologically effective concentrations of 
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glycyrrhizin and 18(3-glycyrrhetinic acid could be achieved in vivo need to be 
addressed. 
In this study, attempts had also been made to elucidate the underlying 
mechanisms for the anti-proliferative and differentiation-inducing effects of 
glycyrrhizin and 1 Sp-glycyrrhetinic acid on BU-1 cells and strategies that could lower 
the effective concentrations of these two drugs were sought. Both glycyrrhizin and 
ISP-glycyrrhetinic acid were found to be able to induce cell cycle arrest of BU-1 cells 
at the G2/M phase accompanied with a significant decrease of cells in the GQ/GI and S 
phases. Therefore, one of the underlying mechanisms by which glycyrrhizin and 
18p-glycyrrhetinic acid exert their anti-proliferative effect would be due to the arrest 
of the cell cycle progression at the G2/M phase. Further studies with the 
18p-glycyrrhetinic acid had revealed that the cell cycle arrest of BU-1 cells may be 
mediated via the down-regulation of several cell cycle regulatory proteins since 
treatment of BU-1 cells with ISP-glycyrrhetinic acid caused a down-regulation of 
cyclin A, cyclin B and cdc2 both transcriptionally and translationally. On the other 
hand, combined treatment of the BU-1 cells with glycyrrhizin and 1 Sp-glycyrrhetinic 
acid or 18p-glycyrrhetinic acid and 2L\Urans retinoic acid (ATRA) had resulted in 
synergistic action on the proliferation and differentiation of the BU-1 cells. 
Therefore, it is conceivable that the combined used of glycyrrhizin, 
18p-glycyrrhetinic acid and ATRA would be one of the effective ways to reduce the 
effective therapeutic concentrations of glycyrrhizin and 18(3-glycyrrhetinic acid, and 
thus minimizing their side effects on the cancer patients. 
Since protein kinases play important roles in many cellular events such as cell 
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growth and differentiation, the involvements of protein kinase C (PKC) and protein 
kinase A (PKA) in the anti-proliferative and differentiation-inducing effects of 
glycyrrhizin and ISp-glycyrrhetinic acid on the neuroblastoma BU-1 cells were also 
studied. Our data showed that the mRNA expression of various PKC isoforms was 
not significantly altered by ISp-glycyrrhetinic acid throughout the time periods 
examined. Interestingly, treatment of BU-1 cells with PKC inhibitors (staurosporine, 
calphostin C and Go 6976) clearly antagonized the 18|3-glycyrrhetinic acid-induced 
differentiation of BU-1 cells while treatment of BU-1 cells with PKC activators (PMA 
and PDA) failed to potentiate the neuronal cell differentiation induced by 
ISp-glycyrrhetinic acid. These results suggest that the ISP-glycyrrhetinic 
acid-induced differentiation may be dependent on the conventional and novel PKC 
isoforms but the activation of PKC alone was insufficient to induce differentiation in 
the BU-1 cells. However, the protein levels and enzyme activities of the various 
PKC isoforms in drug-treated BU-1 cells had not been examined in this study, and 
further experiments should be performed to elucidate whether ISP-glycyrrhetinic acid 
could enhance the activity of certain PKC isoforms in BU-1 cells. In addition, 
whether other factors are also involved in the ISP-glycyrrhetinic acid-induced 
differentiation of BU-1 cells is an intriguing aspect that is worthy of ftiture 
investigations. 
Surprisingly, the growth-inhibitory and differentiation-inducing effects of 
ISp-glycyrrhetinic acid on BU-1 cells were enhanced by treatment of BU-1 cells with 
PKA activators (Sp-isomer, db-cAMP and forskolin) but treatment of BU-1 cells with 
PKA inhibitors (Rp-isomer, H-89, KT5720 and 14-22 amide) was incapable of 
reducing the 18p-glycyrrhetinic acid-induced growth inhibition and neuronal cell 
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differentiation. One hypothesis is that the anti-proliferative and 
differentiation-inducing effects of ISp-glycyrrhetinic acid may be mediated by the 
cAMP signaling pathway but is independent of PKA since cAMP elevating agent 
(forskolin) or cAMP analogs (Sp-isomer and db-cAMP) clearly potentiated the 
growth-inhibitory and differentiation-inducing effects of ISP-glycyrrhetinic acid. 
However, whether 18p-glycyrrhetinic acid could stimulate the adenylyl cyclase and 
increase the endogenous cAMP level remains unclear and the downstream signaling 
pathway(s) is an intriguing area that requires further in-depth investigations. 
In conclusion, since licorice and its active constituent, glycyrrhizin, are still 
widely used not only for medicinal purposes throughout the world but also as 
important ingredients in food industry, therefore, more researches should be 
conducted in the future to gain more insights on their action mechanisms, efficacy and 
therapeutic potentials. By unraveling the cellular and molecular mechanisms by 
which glycyrrhizin and 18p-glycyrrhetinic acid might modulate the proliferation and 
differentiation of neuroblastoma cells, it is hoped that novel treatment for some forms 
of neuroblastoma, based on the inhibition of neuronal cell proliferation and induction 
of cell differentiation, can be developed with higher efficacy and minimal toxicity in 
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